| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Abstracts Index
|
|
|
2008
|
11 |
3 |
p. A322-A333
nvt p.
|
artikel
|
| 2 |
AC8 ASSOCIATION OF MEASURES OF MEDICATION ADHERENCE AND SEVERE RELAPSES WITH MULTIPLE SCLEROSIS DISEASE-MODIFYING THERAPY
|
Dickson, M
|
|
2008
|
11 |
3 |
p. A22-
1 p.
|
artikel
|
| 3 |
AC6 ASSOCIATION OF NONCOMPLIANCE WITH DIABETES CARE GUIDELINES AND DISEASE BURDEN IN A CALIFORNIA MEDICAID TYPE 2 DIABETES MELLITUS POPULATION
|
Nichol, MB
|
|
2008
|
11 |
3 |
p. A21-
1 p.
|
artikel
|
| 4 |
AC7 COMPARING ADHERENCE TO FIXED DOSE COMBINATION VERSUS MULTI-PILL COMBINATION THERAPIES AMONG PATIENTS WITH DYSLIPIDEMIA IN A MANAGED CARE POPULATION
|
Balu, S
|
|
2008
|
11 |
3 |
p. A22-
1 p.
|
artikel
|
| 5 |
AC3 DEPRESSIVE SYMPTOMATOLOGY, MEDICATION PERSISTENCE, AND ASSOCIATED HEALTH CARE COSTS IN OLDER ADULTSWITH INSOMNIA
|
Kulkarni, AS
|
|
2008
|
11 |
3 |
p. A15-
1 p.
|
artikel
|
| 6 |
AC5 ORAL ANTIDIABETIC MEDICATION ADHERENCE AND HEALTH CARE COSTSAND UTILIZATION AMONG MEDICAID-ENROLLEDTYPE 2 DIABETES PATIENTS NEWLY STARTING MONOTHERAPY
|
Shenolikar, R
|
|
2008
|
11 |
3 |
p. A21-
1 p.
|
artikel
|
| 7 |
AC2 PATTERNS OF DIABETES MEDICATION AND TEST ADHERENCE IN A MEDICAID DISEASE MANAGEMENT PROGRAM
|
Demand, M
|
|
2008
|
11 |
3 |
p. A15-
1 p.
|
artikel
|
| 8 |
AC1 THEASSOCIATION BETWEEN IMPROVEMENTS IN DRUG ADHERENCE AND SHORT-TERM SERVICE UTILIZATION AND COSTS IN A MEDICAID POPULATION
|
Thiebaud, P
|
|
2008
|
11 |
3 |
p. A14-A15
nvt p.
|
artikel
|
| 9 |
AC4 THE COST OF NON-ADHERENCETO ASTHMATREATMENT GUIDELINES AMONG A LOW-INCOME COHORT
|
Said, Q
|
|
2008
|
11 |
3 |
p. A15-A16
nvt p.
|
artikel
|
| 10 |
A Longitudinal Analysis of Outcomes Associated with Abciximab and Eptifibatide in a Consecutive Series of 3074 Percutaneous Coronary Interventions
|
Long, Kirsten H.
|
|
2008
|
11 |
3 |
p. 462-469
8 p.
|
artikel
|
| 11 |
A Modeled Economic Evaluation Comparing Atomoxetine with Stimulant Therapy in the Treatment of Children with Attention-Deficit/Hyperactivity Disorder in the United Kingdom
|
Cottrell, Suzi
|
|
2008
|
11 |
3 |
p. 376-388
13 p.
|
artikel
|
| 12 |
An Asian Regional Analysis of Cost-Effectiveness of Early Irbesartan Treatment versus Conventional Antihypertensive, Late Amlodipine, and Late Irbesartan Treatments in Patients with Type 2 Diabetes, Hypertension, and Nephropathy
|
Annemans, Lieven
|
|
2008
|
11 |
3 |
p. 354-364
11 p.
|
artikel
|
| 13 |
Assessing the Impact of Censoring of Costs and Effects on Health-Care Decision-Making: an Example Using the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Study
|
Fenwick, Elisabeth
|
|
2008
|
11 |
3 |
p. 365-375
11 p.
|
artikel
|
| 14 |
CA3 A COST-EFFECTIVENESS ANALYSIS OF HEPATITIS C SCREENING AMONG IMMIGRANTS IN CANADA
|
Chen, W
|
|
2008
|
11 |
3 |
p. A3-
1 p.
|
artikel
|
| 15 |
CA1 ECONOMIC ANALYSIS OF IMPLANTABLE CARDIOVERTER DEFIBRILLATORS INTHE PRIMARY PREVENTION OF SUDDEN CARDIAC DEATH—A CANADIAN PERSPECTIVE
|
Deniz, B
|
|
2008
|
11 |
3 |
p. A3-
1 p.
|
artikel
|
| 16 |
CASE 1 AN INTEGRATED PILOT PROJECT UTILIZING AN INTERNAL HTA PROCESSTO SET MEDICALAND PAYMENT POLICY IN A U.S. COMMERCIAL HEALTH PLAN
|
Watkins, J
|
|
2008
|
11 |
3 |
p. A1-
1 p.
|
artikel
|
| 17 |
CASE 2 DRUG ELUTING STENTS—AN EXAMPLE OFTHETRANSITION FROM EVIDENCETO POLICYTHROUGHTHE ONTARIO COMPREHENSIVE APPROACHTOTHE DIFFUSION OF HEALTHTECHNOLOGIES
|
Levin, L
|
|
2008
|
11 |
3 |
p. A1-A2
nvt p.
|
artikel
|
| 18 |
CASE 3 REVIEWING ANDADAPTINGA LOCAL HEALTH TECHNOLOGY ASSESSMENT PROGRAMTO DEPARTMENTS WITHIN A CANADIAN HEALTH REGION
|
Austen, L
|
|
2008
|
11 |
3 |
p. A2-
1 p.
|
artikel
|
| 19 |
CASE 5 THE CENTER FOR DRUG POLICY: PARTNERS HEALTHCARE
|
Reddy, P
|
|
2008
|
11 |
3 |
p. A8-A9
nvt p.
|
artikel
|
| 20 |
CASE 4 THE IMPACT OF THE PROJECT OF ENHANCING COVERAGE RATE FOR PATIENTS WITH CANCER
|
Lee, SM
|
|
2008
|
11 |
3 |
p. A8-
1 p.
|
artikel
|
| 21 |
CASE 6 THE USE OF AN EVIDENCE-BASED PRACTICE STRATEGY TO IMPROVE QUALITY INTHEACUTE CARE SETTING
|
Mutnick, AH
|
|
2008
|
11 |
3 |
p. A9-
1 p.
|
artikel
|
| 22 |
CA4 THE EARLY CLINICAL AND ECONOMIC BENEFITS OF ATORVASTATIN IN A CANADIAN SETTING
|
Merikle, E
|
|
2008
|
11 |
3 |
p. A3-A4
nvt p.
|
artikel
|
| 23 |
CA2 THE USE OF RESEARCH ABSTRACTS IN FORMULARY DECISION MAKING BYTHE ONTARIO CANCER DRUG APPROVAL COMMITTEE
|
Weizman, A
|
|
2008
|
11 |
3 |
p. A3-
1 p.
|
artikel
|
| 24 |
CN3 COMPARISON OFTHE COST-EFFECTIVENESS OF SIX CYCLES OFTAXOTERE, DOXORUBICIN, CYCLOPHOSPHAMIDE (TAC) VERSUS SIX CYCLES OF FLUOROURACIL, DOXORUBICIN, CYCLOPHOSPHAMIDE (FAC) INTHE ADJUVANT SETTING OF NODE POSITIVE BREAST CANCERWITH PRIMARY AND SECONDARY G-CSF PROPHYLAXIS
|
Mittmann, N
|
|
2008
|
11 |
3 |
p. A10-
1 p.
|
artikel
|
| 25 |
CN4 COSTS ASSOCIATED WITH NEUTROPENIA IN ELDERLY PATIENTS TREATED FIRST-LINE FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
|
Stokes, ME
|
|
2008
|
11 |
3 |
p. A10-
1 p.
|
artikel
|
| 26 |
CN2 ECONOMIC EVALUATION OF EGFR-GUIDEDTREATMENT IN ADVANCED REFRACTORY NON SMALL-CELL LUNG CANCER
|
Carlson, JJ
|
|
2008
|
11 |
3 |
p. A10-
1 p.
|
artikel
|
| 27 |
CN1 TRENDS IN TREATMENT AMONG ELDERLY COLORECTAL CANCER PATIENTS IN THE US: EVIDENCE FROM LINKED SEER-MEDICARE DATA
|
Lang, K
|
|
2008
|
11 |
3 |
p. A9-
1 p.
|
artikel
|
| 28 |
Cost-Effectiveness of Intraperitoneal Chemohyperthermia in the Treatment of Peritoneal Carcinomatosis from Colorectal Cancer
|
Bonastre, Julia
|
|
2008
|
11 |
3 |
p. 347-353
7 p.
|
artikel
|
| 29 |
Cost-Utility Analysis of Rimonabant in the Treatment of Obesity
|
Hampp, Christian
|
|
2008
|
11 |
3 |
p. 389-399
11 p.
|
artikel
|
| 30 |
CV4 CANTWO A'S RESULT IN A FAILURE?: EFFECT OF ASPIRIN ONTHE RISK OF HEART FAILURE HOSPITALIZATIONS IN CHF PATIENTS ON ACE INHIBITORS
|
Shah, DH
|
|
2008
|
11 |
3 |
p. A17-
1 p.
|
artikel
|
| 31 |
CV3 CLINICAL AND ECONOMIC OUTCOMES ASSOCIATED WITH BLEEDING DURING CORONARY ARTERY BYPASS GRAFT SURGERY AMONG ELDERLY AMERICANS
|
Ganz, ML
|
|
2008
|
11 |
3 |
p. A16-A17
nvt p.
|
artikel
|
| 32 |
CV1 EFFECTIVENESS OF COMBINED BETA-BLOCKER AND ACEI OR ARBTHERAPY IN CHRONIC HEART FAILURE
|
Sharma, M
|
|
2008
|
11 |
3 |
p. A16-
1 p.
|
artikel
|
| 33 |
CV2 THE COST-EFFECTIVENESS OF CANDESARTAN IN THE TREATMENT OF CHRONIC HEART FAILURE (HF)—AN ASSESSMENT OF THE LOW LEFT VENTRICULAR EJECTION FRACTION (LOW-LVEF) TRIALS IN THE CANDESARTAN-IN-HEART-FAILURE-ASSESSMENT-OF-REDUCTION-IN-MORTALITYAND-MORBIDITY (CHARM) TRIAL PROGRAMME
|
Levin, LÅ
|
|
2008
|
11 |
3 |
p. A16-
1 p.
|
artikel
|
| 34 |
DB2 COST-EFFECTIVENESS ANALYSIS OF PREGABALIN FOR THE MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY IN MEXICO
|
Arreola-Ornelas, H
|
|
2008
|
11 |
3 |
p. A17-A18
nvt p.
|
artikel
|
| 35 |
DB3 REAL-WORLD ANALYSIS OF PERCENT OF PATIENTS WITH TYPE 2 DIABETES ACHIEVING GLYCEMIC GOAL WITH INSULIN GLARGINE
|
Misurski, D
|
|
2008
|
11 |
3 |
p. A18-
1 p.
|
artikel
|
| 36 |
DB1 REAL-WORLD SIX MONTH OUTCOMES OF PATIENTS INITIATING EXENATIDE IN A PRIMARY CARE ELECTRONIC MEDICAL RECORD DATABASE
|
Brixner, D
|
|
2008
|
11 |
3 |
p. A17-
1 p.
|
artikel
|
| 37 |
DB4 RETROSPECTIVE STUDY OF TYPE 2 DIABETES MELLITUS (T2DM) PATIENTS NOT OPTIMALLY CONTROLLED BY METFORMIN MONOTHERAPY
|
He, J
|
|
2008
|
11 |
3 |
p. A18-
1 p.
|
artikel
|
| 38 |
DH1 FOLLOW-UPVISITS FOR PATIENTS WITH MAJOR DEPRESSIVE DISORDER DURING INITIATION OF ANTIDEPRESSANT TREATMENT
|
Chen, SY
|
|
2008
|
11 |
3 |
p. A4-
1 p.
|
artikel
|
| 39 |
DH2 IMPACT OF ADHERING TO LIPID MANAGEMENT NATIONAL GUIDELINE RECOMMENDATIONS ON CARDIOVASCULAR EVENTS AND COSTS IN A MANAGED CARE POPULATION
|
Balu, S
|
|
2008
|
11 |
3 |
p. A4-
1 p.
|
artikel
|
| 40 |
DH4 MARKET DISCONTINUATION OF PHARMACEUTICALS IN THE UNITED STATES: ANALYSIS OF NEW DRUGS APPROVED FROM 1980 TO 2007
|
Oureshi, ZP
|
|
2008
|
11 |
3 |
p. A5-
1 p.
|
artikel
|
| 41 |
DH3 THE IMPACT OF DRUG VINTAGE ON PATIENT SURVIVAL: A PATIENT-LEVEL APPROACH USING QUEBEC'S PROVINCIAL HEALTH PLAN DATA
|
Lichtenberg, F
|
|
2008
|
11 |
3 |
p. A4-A5
nvt p.
|
artikel
|
| 42 |
Diabetes-Specific or Generic Measures for Health-Related Quality of Life? Evidence from Psychometric Validation of the D-39 and SF-36
|
Huang, I-Chan
|
|
2008
|
11 |
3 |
p. 450-461
12 p.
|
artikel
|
| 43 |
DISCLOSURE INFORMATION
|
|
|
2008
|
11 |
3 |
p. A312-A321
nvt p.
|
artikel
|
| 44 |
DU6 ASSESSMENT OF DRUG UTILIZATION PATTERNS AND COSTS FOR ERYTHROPOIETIC STIMULATING AGENTS IN ELDERLY PATIENTS WITH CHRONIC KIDNEY DISEASE
|
Lafeuille, MH
|
|
2008
|
11 |
3 |
p. A23-
1 p.
|
artikel
|
| 45 |
DU3 CALIFORNIA WILDFIRES ANDTHEIR IMPACT ON MEDICATION ACQUISITION
|
Hutchins, PS
|
|
2008
|
11 |
3 |
p. A19-
1 p.
|
artikel
|
| 46 |
DU1 DEMOGRAPHIC RISK FACTORS FOR STROKE RELATED AMBULATORY CARE UTILIZATION:ANALYSIS OF UNITED STATES NATIONAL DATA 2000-2005
|
Karve, S
|
|
2008
|
11 |
3 |
p. A18-A19
nvt p.
|
artikel
|
| 47 |
DU2 DOES COMMUNITY-BASED HEALTH INSURANCE IMPROVE ACCESS TO DRUGS AND HEALTH CARE FORTHE POOREST IN AFRICA?
|
Squares, A
|
|
2008
|
11 |
3 |
p. A19-
1 p.
|
artikel
|
| 48 |
DU5 IMPACT OF FORMULARY RESTRICTIONS ON ADHERENCE TO SECOND GENERATION ANTIPSYCHOTICS
|
Zeng, F
|
|
2008
|
11 |
3 |
p. A22-
1 p.
|
artikel
|
| 49 |
DU7 NATIONAL ESTIMATES AND DETERMINANTS OF DEPRESSION AND ANTIDEPRESSANTTREATMENT IN CANCER PATIENTS IN THE UNITED STATES, 2004-2005
|
Sankaranarayanan, J
|
|
2008
|
11 |
3 |
p. A23-
1 p.
|
artikel
|
| 50 |
DU4 PRESCRIPTION DRUG UTILIZATION AMONG A NATIONALLY REPRESENTATIVE SAMPLE OF MEDICARE BENEFICIARIES WITH HEART FAILURE
|
Bain, KT
|
|
2008
|
11 |
3 |
p. A19-A20
nvt p.
|
artikel
|
| 51 |
Duration of Antipsychotic Drug Therapy in Real-World Practice: A Comparison with CATIE Trial Results
|
Chen, Lei
|
|
2008
|
11 |
3 |
p. 487-496
10 p.
|
artikel
|
| 52 |
DU8 THE EFFECT OFTHREE-TIER FORMULARY ADOPTION FOR ALPHA-BLOCKERS ON DRUG UTILIZATION INTHE DEPARTMENT OF DEFENSE
|
Devine, JW
|
|
2008
|
11 |
3 |
p. A23-
1 p.
|
artikel
|
| 53 |
HP1 A COMPARISON OFTHREETECHNOLOGY APPRAISAL SYSTEMS; NICE, SMC AND CADTH
|
Karia, R
|
|
2008
|
11 |
3 |
p. A11-
1 p.
|
artikel
|
| 54 |
HP2 NHS REIMBURSEMENT OF NEW CANCER DRUGS: IS NICE GETTING NASTIER?
|
Mason, AR
|
|
2008
|
11 |
3 |
p. A11-
1 p.
|
artikel
|
| 55 |
HP3 PRIORITY SETTING FOR NEWTECHNOLOGIES: POSSIBLE DETERMINANTS AMONGTHEWORKING POPULATION
|
Derycke, H
|
|
2008
|
11 |
3 |
p. A11-
1 p.
|
artikel
|
| 56 |
HP4 25YEARS OFTHE ORPHAN DRUG ACT:ANALYSIS OFTHE NEW ORPHAN DRUGSAPPROVED BETWEEN 1983 AND 2007
|
Rodriguez-Monguio, R
|
|
2008
|
11 |
3 |
p. A11-A12
nvt p.
|
artikel
|
| 57 |
IN3 A MICROSIMULATION OF THE COST-EFFECTIVENESS OF MARAVIROC FORANTIRETROVIRAL TREATMENT-EXPERIENCED HIV-INFECTED INDIVIDUALS
|
Chancellor, JV
|
|
2008
|
11 |
3 |
p. A24-A25
nvt p.
|
artikel
|
| 58 |
IN1 C. ALBICANS AND C. GLABRATA BLOODSTREAM INFECTIONS IN ADULTS: OUTCOMES AND ASSOCIATED COSTS
|
Grussemeyer, CA
|
|
2008
|
11 |
3 |
p. A24-
1 p.
|
artikel
|
| 59 |
IN4 COST-EFFECTIVENESS OF DORIPENEM INTHETREATMENT OF NOSOCOMIAL PNEUMONIA
|
LJ, McGarry
|
|
2008
|
11 |
3 |
p. A25-
1 p.
|
artikel
|
| 60 |
IN2 UPPER RESPIRATORY ILLNESS AND EMPLOYEE PRODUCTIVITY—RESULTS FROM THE CHILD AND HOUSEHOLD INFLUENZA-ILLNESS AND EMPLOYEE FUNCTION (CHIEF)
|
Palmer, L
|
|
2008
|
11 |
3 |
p. A24-
1 p.
|
artikel
|
| 61 |
Literature Review of Methods to Translate Health-Related Quality of Life Questionnaires for Use in Multinational Clinical Trials
|
Acquadro, Catherine
|
|
2008
|
11 |
3 |
p. 509-521
13 p.
|
artikel
|
| 62 |
MD7 DIFFERENTIALTAKE-UP OFTHE MEDICARE PART D PRESCRIPTION DRUG BENEFIT
|
Rabbani, A
|
|
2008
|
11 |
3 |
p. A12-A13
nvt p.
|
artikel
|
| 63 |
MD5 HEALTH CARE UTILIZATION BY MEDICARE ADVANTAGE BENEFICIARIES IN THE ERA OFTHE MEDICARE PART D DRUG BENEFIT COVERAGE GAP
|
Delate, T
|
|
2008
|
11 |
3 |
p. A12-
1 p.
|
artikel
|
| 64 |
MD3 IMPACT OF MEDICARE PART D DOUGHNUT HOLE ONTHE USE OF MEDICATIONS BY THERAPEUTIC CLASSES FOR STANDARD BENEFICIARIES
|
Sun, SX
|
|
2008
|
11 |
3 |
p. A6-
1 p.
|
artikel
|
| 65 |
MD4 IMPACT OF THE MEDICARE MODERNIZATION ACT OF 2003 ON PART B DRUG USE AND SPENDING: A CASE STUDY OF BIOLOGICALS FOR RHEUMATOID ARTHRITIS
|
Doshi, JA
|
|
2008
|
11 |
3 |
p. A6-
1 p.
|
artikel
|
| 66 |
MD6 INFLUENCE OF MEDICARE CLAIM-PAYING AGENTS' REIMBURSEMENT POLICY ON G-CSF CHOICE DURING FIRST CYCLE OF CHEMOTHERAPY FOR NON-HODGKIN'S LYMPHOMA PATIENTS
|
Pan, X
|
|
2008
|
11 |
3 |
p. A12-
1 p.
|
artikel
|
| 67 |
MD1 MEDICARE PART D: EARLY EVIDENCE ON PRESCRIPTION DRUGTREATMENT PATTERNS, HOSPITALIZATION OFFSETS AND MEDICARE SPENDING
|
Zhang, Y
|
|
2008
|
11 |
3 |
p. A5-
1 p.
|
artikel
|
| 68 |
MD8 THE IMPACT OF MEDICARE NEW DRUG BENEFIT (PART D) ONTHE UTILIZATION OF PSYCHOTROPIC MEDICATIONS AND CONSEQUENT OUT OF POCKET EXPENDITURE FOR ELDERLY
|
Chen, H
|
|
2008
|
11 |
3 |
p. A13-
1 p.
|
artikel
|
| 69 |
MD2 THE IMPACT OF MEDICARE PART D ONTHE PERCENT GROSS MARGIN EARNED BYTEXAS INDEPENDENT PHARMACIES FOR DUAL ELIGIBLE BENEFICIARY CLAIMS
|
Winegar, AL
|
|
2008
|
11 |
3 |
p. A5-A6
nvt p.
|
artikel
|
| 70 |
MH2 ECONOMIC AND CLINICAL CONSEQUENCES ASSOCIATED WITH POTENTIAL DRUG-DRUG INTERACTIONS BETWEEN ANTIPSYCHOTICS AND CONCOMITANT MEDICATIONS IN PATIENTS WITH SCHIZOPHRENIA
|
Guo, JJ
|
|
2008
|
11 |
3 |
p. A7-
1 p.
|
artikel
|
| 71 |
MH1 REAL WORLD ASSOCIATION BETWEEN ANTIPSYCHOTIC TREATMENT AND WEIGHT GAIN IN AN ADOLESCENT POPULATION
|
Ghate, SR
|
|
2008
|
11 |
3 |
p. A6-A7
nvt p.
|
artikel
|
| 72 |
MH4 TREATMENT COST AND COMORBIDITIES ASSOCIATEDWITH OBESITY AMONG CHILDREN ANDADOLESCENTSWITH BIPOLAR DISORDER
|
Guo, JJ
|
|
2008
|
11 |
3 |
p. A7-A8
nvt p.
|
artikel
|
| 73 |
MH3 WORK ABSENTEEISMAND BED DAYS IN CHRONIC MEDICAL DISORDER PATIENTS WITH AND WITHOUT DEPRESSION IN THE UNITED STATES, 2004-2005
|
Sankaranarayanan, J
|
|
2008
|
11 |
3 |
p. A7-
1 p.
|
artikel
|
| 74 |
OM4 LONG-TERM COST-EFFECTIVENESS OF A DIABETES RISK SCORE IN CLINICAL PRACTICE
|
Sullivan, SD
|
|
2008
|
11 |
3 |
p. A21-
1 p.
|
artikel
|
| 75 |
OM2 USINGVALUE OF INFORMATION METHODOLOGYTO DETERMINE THE SAMPLE SIZE FOR A RANDOMIZED CLINICAL TRIAL FROM AN INDUSTRY PERSPECTIVE
|
Willan, AR
|
|
2008
|
11 |
3 |
p. A20-
1 p.
|
artikel
|
| 76 |
OM1 VALIDATING A SURVEY INSTRUMENT USING NONPARAMETRIC ITEM RESPONSETHEORY— APPLICATION OF KERNEL REGRESSION
|
Lin, HW
|
|
2008
|
11 |
3 |
p. A20-
1 p.
|
artikel
|
| 77 |
OM3 WAS IT NICE FORYOU? ESTIMATING SUBGROUP QUALITY OF LIFE TARIFFS FROM CONJOINT ANALYSES: RESULTS FROM A BEST-WORST SCALING STUDY
|
Flynn, TN
|
|
2008
|
11 |
3 |
p. A20-
1 p.
|
artikel
|
| 78 |
Outcome Measurement in Clinical Genetics Services: A Systematic Review of Validated Measures
|
Payne, Katherine
|
|
2008
|
11 |
3 |
p. 497-508
12 p.
|
artikel
|
| 79 |
Patient-Reported Outcomes and Health-Care Resource Utilization in Patients with Psoriasis Treated with Etanercept: Continuous versus Interrupted Treatment
|
Gelfand, Joel M.
|
|
2008
|
11 |
3 |
p. 400-407
8 p.
|
artikel
|
| 80 |
PCASE1 GCSF: SAVING COSTS WITHOUT SAVING QUALITY OF CARE. A UNIMED VITORIA HEALTH INSURANCE EXPERIENCE
|
Figueira, CM
|
|
2008
|
11 |
3 |
p. A308-
1 p.
|
artikel
|
| 81 |
PCASE4 HEALTH PLAN AND INDUSTRY: NEW PARTNERSHIP TO ASSESS NEW TECHNOLOGY OUTCOMES AND ECONOMIC IMPACT
|
Hume, M
|
|
2008
|
11 |
3 |
p. A310-
1 p.
|
artikel
|
| 82 |
PCASE6 HOW SHOULD NEWTECHNOLOGIES AND NEW DEVICES BE ASSESSED IN A HOSPITAL SYSTEM?
|
Mutnick, AH
|
|
2008
|
11 |
3 |
p. A310-A311
nvt p.
|
artikel
|
| 83 |
PCASE5 INFORMING DECISION MAKERS IN GERMANY: THE IQWIG APPROACH
|
Caro, J
|
|
2008
|
11 |
3 |
p. A310-
1 p.
|
artikel
|
| 84 |
PCASE3 PHARMACOECONOMIC APPLICATIONS IN FORMULARY MANAGEMENTS CASE STUDY OF BORTEZOMIB AT A MAJOR CANCER CENTER
|
Miller, LA
|
|
2008
|
11 |
3 |
p. A309-A310
nvt p.
|
artikel
|
| 85 |
PCASE2 THE ROLE OF ECONOMIC EVALUATION IN CHANGING DECISION-MAKER BEHAVIOURS :A CASE STUDY FROM TRINIDAD AND TOBAGO
|
Bailey, HH
|
|
2008
|
11 |
3 |
p. A308-A309
nvt p.
|
artikel
|
| 86 |
PCN11 A BUDGET IMPACT ANALYSIS OF IXABEPILONE IN TREATING METASTATIC CANCER PATIENTS
|
Whillans, F
|
|
2008
|
11 |
3 |
p. A57-
1 p.
|
artikel
|
| 87 |
PCN19 A COST-EFFECTIVENESS ANALYSIS OF LAPATINIB AT A TERTIARY CANCER CENTER
|
Lai, LS
|
|
2008
|
11 |
3 |
p. A59-
1 p.
|
artikel
|
| 88 |
PCN58 A COST UTILITY ANALYSIS OF ERLOTINIB IN PATIENTS WITH PREVIOUSLY TREATED ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC)
|
Bradbury, PA
|
|
2008
|
11 |
3 |
p. A72-
1 p.
|
artikel
|
| 89 |
PCN55 A COST-UTILITY ANALYSIS OF FULVESTRANT IN TREATING RECURRENT METASTATIC BREAST CANCER
|
Park, SY
|
|
2008
|
11 |
3 |
p. A71-
1 p.
|
artikel
|
| 90 |
PCN54 A COST-UTILITY ANALYSIS OF PRIMARY PROPHYLAXIS VERSUS SECONDARY PROPHYLAXIS WITH COLONY-STIMULATING FACTOR IN ELDERLY PATIENTS WITH DIFFUSE AGGRESSIVE LYMPHOMA RECEIVING CURATIVE-INTENT CHEMOTHERAPY USING ONTARIO HEALTH ECONOMIC DATA
|
Chan, KKW
|
|
2008
|
11 |
3 |
p. A70-A71
nvt p.
|
artikel
|
| 91 |
PCN7 ANALYSIS OF MASTECTOMY IN BREAST CANCER TREATMENT
|
Ugiliweneza, B
|
|
2008
|
11 |
3 |
p. A56-
1 p.
|
artikel
|
| 92 |
PCN91 A PREVALENCE-BASED ECONOMIC ANALYSIS OF THE GROWTH IN CANCER TREATMENT SPENDING IN THE UNITED STATES
|
Lerner, J
|
|
2008
|
11 |
3 |
p. A82-
1 p.
|
artikel
|
| 93 |
PCN31 A PROBABILISTIC DECISION MODEL TO GUIDE OPTIMAL HEALTH POLICY DECISIONS FOR LUNG CANCER SCREENING
|
Fenwick, E
|
|
2008
|
11 |
3 |
p. A63-
1 p.
|
artikel
|
| 94 |
PCN77 A SYSTEMATIC REVIEW OF BREAST CANCER UTILITY WEIGHTS
|
Brennan, VK
|
|
2008
|
11 |
3 |
p. A77-
1 p.
|
artikel
|
| 95 |
PCN14 A SYSTEMATIC REVIEW OF ECONOMIC ANALYSES OF HER2 TESTING & TRASTUZUMAB THERAPY
|
Ferrusi, IL
|
|
2008
|
11 |
3 |
p. A58-
1 p.
|
artikel
|
| 96 |
PCN13 BUDGET IMPACT ANALYSIS OF SORAFENIB IN THE TREATMENT OF HEPATOCELLULAR CARCINOMA IN CANADA
|
Bhardwaj, T
|
|
2008
|
11 |
3 |
p. A58-
1 p.
|
artikel
|
| 97 |
PCN75 BURDEN OF IMMUNE THROMBOCYTOPENIC PURPURA ON HEALTH-RELATED QUALITY OF LIFE
|
Mathias, S
|
|
2008
|
11 |
3 |
p. A76-A77
nvt p.
|
artikel
|
| 98 |
PCN10 CANCER RISK BETWEEN ATORVASTATIN AND SIMVASTATIN IN THE LOUISIANA MEDICAID PATIENTS
|
Dubey, A
|
|
2008
|
11 |
3 |
p. A57-
1 p.
|
artikel
|
| 99 |
PCN95 CHANGE IN THE USE OF BREAST CONSERVING SURGERY BEFORE AND AFTER GUIDELINE PUBLICATION IN JAPAN
|
Fukuda, H
|
|
2008
|
11 |
3 |
p. A83-
1 p.
|
artikel
|
| 100 |
PCN64 CLINICAL AND DEMOGRAPHIC PREDICTORS OF QUALITY OF LIFE IN PROSTATE CANCER SURVIVORS
|
Bremner, KE
|
|
2008
|
11 |
3 |
p. A73-A74
nvt p.
|
artikel
|
| 101 |
PCN84 CLINICAL AND ECONOMIC OUTCOMES FOR CANCER CHEMOTHERAPY PATIENTS WHEN INITIATED ON ERYTHROPOIESIS-STIMULATING AGENTS (ESA) AT BASELINE (BL) HEMOGLOBIN (HB) <I0G/DL
|
Burton, T
|
|
2008
|
11 |
3 |
p. A79-A80
nvt p.
|
artikel
|
| 102 |
PCN80 COMPARISON OF STANDARD GAMBLE UTILITIES AND VISUAL ANALOG SCALEVALUES IN AN OVARIAN CANCER PATIENT AND ONCOLOGIST STUDY OF CANCER TREATMENT PREFERENCES
|
Hess, LM
|
|
2008
|
11 |
3 |
p. A78-
1 p.
|
artikel
|
| 103 |
PCN46 COMPARISON OF SURGICAL TREATMENT COSTS OF NONMELANOMA SKIN CANCER PATIENTS IN A UNIVERSITY-AFFILIATED PRACTICE
|
Wilson, L
|
|
2008
|
11 |
3 |
p. A68-
1 p.
|
artikel
|
| 104 |
PCN73 COMPARISON OF SURVIVAL QUALITY FROM TWO TREATMENT STRATEGIES FORACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN CHILDHOOD: DANA-FARBER CANCER INSTITUTE (DFCI) AND BERLIN-FRANKFURT-MONSTER (BFM)
|
De Pauw, S
|
|
2008
|
11 |
3 |
p. A76-
1 p.
|
artikel
|
| 105 |
PCN25 CONSIDERATIONS FOR MODELING THE COST-EFFECTIVENESS OF PREVENTATIVE PROSTATE CANCER TREATMENTS
|
Bell, CF
|
|
2008
|
11 |
3 |
p. A61-
1 p.
|
artikel
|
| 106 |
PCN40 CONTROLLING FOR POTENTIAL CENSORING BIAS ON DEPENDENT VARIABLES
|
Baser, O
|
|
2008
|
11 |
3 |
p. A66-
1 p.
|
artikel
|
| 107 |
PCN20 COST ANALYSIS OF IMMUNOGLOBULIN PROPHYLAXIS IN CHRONIC LYMPHOCYTIC LEUKEMIA
|
Conner, TM
|
|
2008
|
11 |
3 |
p. A59-A60
nvt p.
|
artikel
|
| 108 |
PCN16 COST DIVERSITY OF DRG BASED COLORECTAL CANCER THERAPIES IN HUNGARY
|
Jozsa, G
|
|
2008
|
11 |
3 |
p. A59-
1 p.
|
artikel
|
| 109 |
PCN32 COST-EFFECTIVENESS ANALYSIS OF AN HPV-16/18 PROPHYLACTIC CERVICAL CANCER VACCINE IN A SETTING OF EXISTING SCREENING IN PORTUGAL-RESULTS FROM A MATHEMATICAL MODEL
|
Pereira, JA
|
|
2008
|
11 |
3 |
p. A63-
1 p.
|
artikel
|
| 110 |
PCN35 COST-EFFECTIVENESS ANALYSIS OF DASATINIB FOR THE TREATMENT OF IMATINIB RESISTANT OR INTOLERANT CML PATIENTS IN BRAZIL
|
Ouissak, C
|
|
2008
|
11 |
3 |
p. A64-
1 p.
|
artikel
|
| 111 |
PCN23 COST-EFFECTIVENESS ANALYSIS OF LAPATINIB PLUS CAPECITABINE VERSUS CAPECITABINE ALONE IN THE SECOND LINE TREATMENT FOR BREAST CANCER TREATMENT
|
Ejzykowicz, F
|
|
2008
|
11 |
3 |
p. A60-A61
nvt p.
|
artikel
|
| 112 |
PCN28 COST-EFFECTIVENESS ANALYSIS OF RITUXIMAB-CHOP VS. CHOP ON NON-HODGKIN LYMPHOMA PATIENTS IN THE MEXICAN CONTEXT
|
Cortina, D
|
|
2008
|
11 |
3 |
p. A62-
1 p.
|
artikel
|
| 113 |
PCN27 COST-EFFECTIVENESS ANALYSIS OF SCREENING SUBJECTS WITH DIFFERENT LEVELS OF RISK FOR HEPATOCELLULAR CARCINOMA IN TAIWAN
|
Chang, Y
|
|
2008
|
11 |
3 |
p. A62-
1 p.
|
artikel
|
| 114 |
PCN26 COST-EFFECTIVENESS MODELING OF COLORECTAL CANCER I0YEARS SCREENING USING COMPUTEDTOMOGRAPHIC COLONOGRAPHYVERSUS COLONOSCOPY AND FECAL OCCULT BLOOD TESTS
|
Beresniak, A
|
|
2008
|
11 |
3 |
p. A61-A62
nvt p.
|
artikel
|
| 115 |
PCN34 COST-EFFECTIVENESS OF GEFITINIB FOR FIRST-LINE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER: A MARKOV MODEL-BASED ANALYSIS
|
Liu, PH
|
|
2008
|
11 |
3 |
p. A64-
1 p.
|
artikel
|
| 116 |
PCN36 COST-MINIMIZATION ANALYSIS OF CAPECITABINE FOR ADVANCED GASTRIC CANCER IN TAIWAN
|
Chang, CS
|
|
2008
|
11 |
3 |
p. A64-A65
nvt p.
|
artikel
|
| 117 |
PCN30 COSTS RELATED TO ADVERSE EVENTS IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH TYROSINE KINASE INHIBITORS IN CANADA
|
Newton, N
|
|
2008
|
11 |
3 |
p. A62-A63
nvt p.
|
artikel
|
| 118 |
PCN57 COST-UTILITY ANALYSIS OF ADJUVANT GOSERELIN AND ADJUVANT CHEMOTHERAPY IN PATIENTS WITH PREMENOPAUSAL BREAST CANCER
|
Cheng, TF
|
|
2008
|
11 |
3 |
p. A71-
1 p.
|
artikel
|
| 119 |
PCN33 COST UTILITY ANALYSIS OF VACCINATION AGAINST HPV IN ISRAEL
|
Ginsberg, GM
|
|
2008
|
11 |
3 |
p. A63-A64
nvt p.
|
artikel
|
| 120 |
PCN4 DATA ANALYSIS WITH GENERALIZED LINEAR MODELS ON LUNG CANCER DATA
|
Tang, G
|
|
2008
|
11 |
3 |
p. A55-
1 p.
|
artikel
|
| 121 |
PCN78 DERIVATION OF UTILITY VALUES FROM EORTC QLQC30 IN LUNG CANCER
|
Jang, RW
|
|
2008
|
11 |
3 |
p. A77-A78
nvt p.
|
artikel
|
| 122 |
PCN1 DIAGNOSIS OF HER2 PROTEIN OVEREXPRESSION IN PATIENTS WITH BREAST CANCER IN BRAZIL
|
Muranaka, AH
|
|
2008
|
11 |
3 |
p. A54-
1 p.
|
artikel
|
| 123 |
PCN39 DIFFERENCES IN COLORECTAL CANCER TREATMENT COSTS BYTREATMENT PHASE, CANCER SITE, AND STAGE AT DIAGNOSIS: EVIDENCE FROM LINKED SEER-MEDICARE DATA
|
Lang, K
|
|
2008
|
11 |
3 |
p. A65-A66
nvt p.
|
artikel
|
| 124 |
PCN51 DIRECT ECONOMIC BURDEN OF HIGH RISK AND METASTATIC MELANOMA: EVIDENCE FROM THE SEER-MEDICARE LINKED DATABASE
|
Davis, KL
|
|
2008
|
11 |
3 |
p. A69-A70
nvt p.
|
artikel
|
| 125 |
PCN52 DIRECT MEDICAL COST OF BREAST CANCER BY STAGE OF CLINICAL DISEASE. A MEXICAN COHORT
|
Cortés-Sanabria, L
|
|
2008
|
11 |
3 |
p. A70-
1 p.
|
artikel
|
| 126 |
PCN72 DISABILITY AND HEALTH-RELATED QUALITY OF LIFE IN LONG-TERM SURVIVORS OF CANCER IN CHILDHOOD IN BRAZIL: AN ASSESSMENT OF THE CONSTRUCT VALIDITY OF THE HEALTH UTILITIES INDEX (HUI3)
|
Horsman, JR
|
|
2008
|
11 |
3 |
p. A75-A76
nvt p.
|
artikel
|
| 127 |
PCN86 DRUG UTILIZATION AND COST CONSIDERATIONS OF ERYTHROPOIESIS-STIMULATING AGENTS (ESAS) IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS)
|
Laliberte, F
|
|
2008
|
11 |
3 |
p. A80-
1 p.
|
artikel
|
| 128 |
PCN89 DRUG UTILIZATION PATTERNS AND COSTS FOR ERYTHROPOIESIS-STIMULATING AGENTS (ESAS) IN A MANAGED CARE CANCER POPULATION RECEIVING CHEMOTHERAPY
|
Gosselin, A
|
|
2008
|
11 |
3 |
p. A81-
1 p.
|
artikel
|
| 129 |
PCN61 EARLY DISCONTINUATION OF ADJUVANT ENDOCRINE TREATMENT OF BREAST CANCER
|
Bowen, KL
|
|
2008
|
11 |
3 |
p. A72-A73
nvt p.
|
artikel
|
| 130 |
PCN24 ECONOMIC EVALUATION OF SORAFENIB VERSUS BEST SUPPORTIVE CARE IN ADVANCED RENAL CELL CARCINOMA: AN UPDATED COST-EFFECTIVENESS ANALYSIS
|
Gao, X
|
|
2008
|
11 |
3 |
p. A61-
1 p.
|
artikel
|
| 131 |
PCN3 EFFECTIVENESS OF BORTEZOMIB IN MULTIPLE MYELOMA: PRELIMINARY RESULTS FROM AN INTERNATIONAL ELECTRONIC OBSERVATIONAL STUDY
|
Delforge, M
|
|
2008
|
11 |
3 |
p. A55-
1 p.
|
artikel
|
| 132 |
PCN85 EFFECT OF AGE AND PLACE OF RESIDENCE ON COLORECTAL CANCER TREATMENTS IN NEBRASKA CANCER REGISTRY FROM 1998 TO 2003
|
Sankaranarayanan, J
|
|
2008
|
11 |
3 |
p. A80-
1 p.
|
artikel
|
| 133 |
PCN60 EFFECT OF DEMOGRAPHIC FACTORS AND SOCIAL ECONOMIC VARIABLES ON HEALTH CARE RESOURCE UTILIZATION AND EXPENDITURE FOR BREAST CANCER PATIENTS USING MEPS 2001
|
Zhan, L
|
|
2008
|
11 |
3 |
p. A72-
1 p.
|
artikel
|
| 134 |
PCN90 EFFECT OF THE HUNGARIAN ORGANIZED NATIONWIDE CERVICAL CANCER SCREENING PROGRAMME ON THE COVERAGE OF WOMEN UNDER THE AGE OF 25 YEARS
|
Boncz, I
|
|
2008
|
11 |
3 |
p. A81-A82
nvt p.
|
artikel
|
| 135 |
PCN6 ESTIMATION OF THE EPIDEMIOLOGICAL EFFECT OF TRASTUZUMAB OVER I0YEARS IN 5 EUROPEAN COUNTRIES
|
Weisgerber-Kriegl, U
|
|
2008
|
11 |
3 |
p. A56-
1 p.
|
artikel
|
| 136 |
PCN88 FACTORS ASSOCIATED WITH THE PRESCRIPTION OF ADJUVANT HORMONAL THERAPIES AMONG MEDICAID ENROLLEESWITH BREAST CANCER
|
McLaughlin, J
|
|
2008
|
11 |
3 |
p. A81-
1 p.
|
artikel
|
| 137 |
PCN65 HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH STAGE III OR IV FOLLICULAR LYMPHOMA RECEIVING 90Y-IBRITUMOMABTIUXETAN FOLLOWING FIRST-LINE CHEMOTHERAPY
|
Gondek, K
|
|
2008
|
11 |
3 |
p. A74-
1 p.
|
artikel
|
| 138 |
PCN68 HOUSEHOLD INCOME AS A PREDICTOR OF PSYCHOLOGICAL WELL-BEING AMONG LONG-TERM COLORECTAL CANCER SURVIVORS
|
Lundy, JJ
|
|
2008
|
11 |
3 |
p. A74-
1 p.
|
artikel
|
| 139 |
PCN47 IMPACT OF HIV INFECTION ON INVASIVE CERVICAL CANCER INCIDENCE AND TREATMENT COSTS IN SOUTH AFRICAN WOMEN
|
Vijayaraghavan, A
|
|
2008
|
11 |
3 |
p. A68-
1 p.
|
artikel
|
| 140 |
PCN76 IMPACT OF SILDENAFIL ON MARITAL AND SEXUAL ADJUSTMENT IN PATIENTS AND THEIR PARTNERS AFTER RADIOTHERAPY AND SHORT-TERM ANDROGEN SUPPRESSION FOR PROSTATE CANCER: ANALYSIS OF RTOG 0215
|
Bryan, CJ
|
|
2008
|
11 |
3 |
p. A77-
1 p.
|
artikel
|
| 141 |
PCN8 IMPROVED SURVIVAL OF PATIENTS WITH GLIOBLASTOMA MULTIFORME BYTEMOZOLOMIDE AS ADJUVANT THERAPY: A RETROSPECTIVE COHORT STUDY
|
Wang, TH
|
|
2008
|
11 |
3 |
p. A56-
1 p.
|
artikel
|
| 142 |
PCN44 INCIDENCE AND COSTS OF TREATMENT-RELATED COMPLICATIONS AMONG PATIENTS WITH ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
|
Lang, K
|
|
2008
|
11 |
3 |
p. A67-
1 p.
|
artikel
|
| 143 |
PCN81 INJECTABLE CHEMOTHERAPYVS CAPECITABINE: PREFERENCE IN BRAZILIAN PATIENTS
|
Boscatti, FHG
|
|
2008
|
11 |
3 |
p. A78-A79
nvt p.
|
artikel
|
| 144 |
PCN22 IS CAPECITABINE A COST-EFFECTIVE ADJUVANT TREATMENT OF STAGE III COLON CANCER IN ONTARIO?
|
Orchard, MC
|
|
2008
|
11 |
3 |
p. A60-
1 p.
|
artikel
|
| 145 |
PCN83 KNOWLEDGE OF THE BRAZILIAN POPULATION ABOUT COLORECTAL CANCER
|
Santos, MCCS
|
|
2008
|
11 |
3 |
p. A79-
1 p.
|
artikel
|
| 146 |
PCN62 LEUPROLIDE ACETATE PERSISTENCE VARIES BY AGE IN PATIENTS WITH PROSTATE CANCER
|
Fuldeore, MJ
|
|
2008
|
11 |
3 |
p. A73-
1 p.
|
artikel
|
| 147 |
PCN48 LONGITUDINAL COMPARISON ACROSS TREATMENTS, RISK AND AGE OF WORK LOSS COSTS IN PROSTATE CANCER PATIENTS: 10 YEAR PATTERNS
|
Wilson, L
|
|
2008
|
11 |
3 |
p. A68-A69
nvt p.
|
artikel
|
| 148 |
PCN5 META-ANALYSIS ON THE MORBIDITY AND MORTALITY OF CLODRONATE, PAMIDRONATE AND ZOLEDRONATE IN PATIENTS WITH BONE METASTASES
|
Machado, M
|
|
2008
|
11 |
3 |
p. A55-A56
nvt p.
|
artikel
|
| 149 |
PCN79 METHODS FOR ASSESSING QUALITY OF LIFE IN CANCER PATIENTS EXPERIENCING COMPLICATIONS: OSTEONECROSIS OF THE JAW PILOT STUDY
|
Miksad, R
|
|
2008
|
11 |
3 |
p. A78-
1 p.
|
artikel
|
| 150 |
PCN15 MODELING THE COST IMPACT OF POSSIBLE CROSS-PROTECTION DIFFERENCES OF TWO CERVICAL CANCERVACCINES IN CANADA USING MULTIPLE PROBABILISTIC SENSITIVITY ANALYSIS
|
Demarteau, N
|
|
2008
|
11 |
3 |
p. A58-A59
nvt p.
|
artikel
|
| 151 |
PCN56 NAB-PACLITAXEL OR DOCETAXEL; AS ALTERNATIVES TO CONVENTIONAL PACLITAXEL FOR THE TREATMENT OF METASTATIC BREAST CANCER (MBC): A COST UTILITY ANALYSIS IN FIVE EUROPEAN COUNTRIES
|
Dranitsaris, G
|
|
2008
|
11 |
3 |
p. A71-
1 p.
|
artikel
|
| 152 |
PCN82 PATIENT-REPORTED OUTCOMES IN ELDERLY VS. YOUNG PATIENTS WITH ADVANCED RENAL CELL CARCINOMA TREATED WITH SORAFENIB VS. PLACEBO
|
Shah, S
|
|
2008
|
11 |
3 |
p. A79-
1 p.
|
artikel
|
| 153 |
PCN94 PREDICTORS OF TREATMENT CHOICE IN HIGH RISK AND METASTATIC MELANOMA: EVIDENCE FROM LINKED ELECTRONIC MEDICAL RECORDS AND ADMINISTRATIVE CLAIMS DATA
|
Kotapati, S
|
|
2008
|
11 |
3 |
p. A82-A83
nvt p.
|
artikel
|
| 154 |
PCN37 PRELIMINARY COST-CONSEQUENCE ANALYSIS OF EPIRUBICIN/CISPLATIN/5FU (ECF) COMPARED TO EPIRUBICIN/CISPLATIN/CAPECITABINE (ECX) IN PATIENTS WITH ADVANCED OESOPHAGOGASTRIC CANCER
|
Horgan, AM
|
|
2008
|
11 |
3 |
p. A65-
1 p.
|
artikel
|
| 155 |
PCN69 QUALITY OF LIFE IMPACT OF HOT FLUSHES IN MEN RECEIVING TREATMENT FOR PROSTATE CANCER
|
Nixon, A
|
|
2008
|
11 |
3 |
p. A74-A75
nvt p.
|
artikel
|
| 156 |
PCN63 RACIAL DIFFERENCES IN MEDICATION ADHERENCE TO ADJUVANT HORMONAL THERAPY IN MEDICAID ENROLLED WOMEN WITH PRIMARY BREAST CANCER: A COMPARISON USING TWO ESTIMATION METHODOLOGIES
|
Bhosle, MJ
|
|
2008
|
11 |
3 |
p. A73-
1 p.
|
artikel
|
| 157 |
PCN96 REAL WORLD TREATMENT PATTERNS IN HIGH RISK OR METASTATIC MELANOMA: EVIDENCE FROM THE SEER-MEDICARE LINKED DATABASE
|
Mitra, D
|
|
2008
|
11 |
3 |
p. A83-
1 p.
|
artikel
|
| 158 |
PCN45 RESOURCE UTILIZATION AND COST ESTIMATION OF ADVERSE EVENTS OF NON-SMALL CELL LUNG CANCER TREATMENT IN MEXICAN PATIENTS. RESULTS OF A DELPHI PANEL
|
Lopez Mariscal, AR
|
|
2008
|
11 |
3 |
p. A67-A68
nvt p.
|
artikel
|
| 159 |
PCN29 SCREENING, PREVENTION, AND TREATMENT OF CERVICAL CANCER-A GLOBAL AND REGIONAL GENERALIZED COST-EFFECTIVENESS ANALYSIS
|
Ginsberg, GM
|
|
2008
|
11 |
3 |
p. A62-
1 p.
|
artikel
|
| 160 |
PCN71 SOCIETAL PREFERENCES (UTILITIES) FORADVANCED MELANOMA HEALTH STATES IN THE UNITED KINGDOM (UK) AND AUSTRALIA
|
Szabo, SM
|
|
2008
|
11 |
3 |
p. A75-
1 p.
|
artikel
|
| 161 |
PCN21 SYSTEMATIC REVIEW OF COST-EFFECTIVENESS-ANALYSIS STUDIES OF TRASTUZUMAB (HERCEPTIN™) IN TREATMENT OF HER2-POSITIVE BREAST CANCER
|
Le, OA
|
|
2008
|
11 |
3 |
p. A60-
1 p.
|
artikel
|
| 162 |
PCN2 SYSTEMATIC REVIEW OF PALONOSETRON IN CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING
|
Yeh, YC
|
|
2008
|
11 |
3 |
p. A54-A55
nvt p.
|
artikel
|
| 163 |
PCN43 THE ASSOCIATION OF TUMOR HISTOLOGY WITH FIRST-LINE TREATMENT AND LIFETIME MEDICAL-CARE COSTS AMONG ELDERLY STAGE IIIB/IV NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS TREATED WITH COMMONLY USED DOUBLET THERAPIES AMONG
|
Lang, K
|
|
2008
|
11 |
3 |
p. A67-
1 p.
|
artikel
|
| 164 |
PCN53 THE BURDEN OF MANAGING PLEURAL EFFUSIONS IN CML PATIENTS POST-IMATINIB FAILURE:A LITERATURE-BASED ECONOMIC ANALYSIS
|
Stephens, JM
|
|
2008
|
11 |
3 |
p. A70-
1 p.
|
artikel
|
| 165 |
PCN49 THE COST OF TREATING SKELETAL-RELATED EVENTS IN PATIENTS WITH BONE METASTASES SECONDARYTO BREAST, LUNG, OR PROSTATE CANCER
|
Barber, B
|
|
2008
|
11 |
3 |
p. A69-
1 p.
|
artikel
|
| 166 |
PCN50 THE COST OF TREATING SKELETAL-RELATED EVENTS IN PATIENTS WITH MULTIPLE MYELOMA
|
Oglesby, A
|
|
2008
|
11 |
3 |
p. A69-
1 p.
|
artikel
|
| 167 |
PCN42 THE ECONOMIC BURDEN OF CHRONIC LYMPHOCYTIC LEUKEMIA IN THE UNITED STATES
|
Morlock, RJ
|
|
2008
|
11 |
3 |
p. A66-
1 p.
|
artikel
|
| 168 |
PCN38 THE IMPACT OF BREAST CANCER CARE DEVELOPMENT ON MEDICAL AND ECONOMICAL OUTCOMES IN ATOTAL SOCIETAL COST CONTEXT
|
Reissell, E
|
|
2008
|
11 |
3 |
p. A65-
1 p.
|
artikel
|
| 169 |
PCN70 THE IMPACT OF HODGKIN S LYMPHOMA ON HEALTH RELATED QUALITY OF LIFE
|
Morlock, RJ
|
|
2008
|
11 |
3 |
p. A75-
1 p.
|
artikel
|
| 170 |
PCN41 THE LIFETIME COST OF CERVICAL CANCER IN TAIWAN
|
Lang, HC
|
|
2008
|
11 |
3 |
p. A66-
1 p.
|
artikel
|
| 171 |
PCN92 THE WAR ON CANCER: AN ECONOMIC EVALUATION OF RECENT GAINS IN CANCER SURVIVAL
|
Sun, E
|
|
2008
|
11 |
3 |
p. A82-
1 p.
|
artikel
|
| 172 |
PCN93 THREE SCIENTIFIC PARADIGMS IN HEALTH TECHNOLOGY ASSESSMENT: EXPERIENCES OF THE COMMITTEE TO EVALUATE DRUGS IN ONTARIO, CANADA
|
Krahn, MD
|
|
2008
|
11 |
3 |
p. A82-
1 p.
|
artikel
|
| 173 |
PCN59 TIME COSTS AND OUT-OF-POCKET COSTS OF PROSTATE CANCER SURVIVORS IN ONTARIO, CANADA
|
Carcone, SM
|
|
2008
|
11 |
3 |
p. A72-
1 p.
|
artikel
|
| 174 |
PCN12 USE OF HEALTH RESOURCES IN LUNG CANCER PATIENTS: A BRAZILIAN ANALYSIS IN THE PRIVATE PAYER PERSPECTIVE
|
Stefani, S
|
|
2008
|
11 |
3 |
p. A57-A58
nvt p.
|
artikel
|
| 175 |
PCN87 USE OF PHARMACOECONOMIC MESSAGES IN ONCOLOGY PROMOTIONAL MATERIALS
|
Kalpas, E
|
|
2008
|
11 |
3 |
p. A80-A81
nvt p.
|
artikel
|
| 176 |
PCN9 VALIDITY OF PROPORTIONAL HAZARDS (PH) WEIBULL MODELS FOR ANALYZING PROGRESSION FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) IN PATIENTS WITH TRASTUZUMAB (TZ)-REFRACTORY ERBB2+ (HER2+) METASTATIC BREAST CANCER (MBC) RECEIVING LAPATINIB PLUS CAPECITABINE (L+C) VERSUS CAPECITABINE ONLY (C-ONLY)
|
Sofrygin, O
|
|
2008
|
11 |
3 |
p. A57-
1 p.
|
artikel
|
| 177 |
PCN74 WILL KNOWLEDGE OF GENETIC RISK FOR CANCER INFLUENCE QUALITY OF LIFE AND SCREENING BEHAVIOR? FINDINGS FROM A POPULATION-BASED STUDY
|
Ramsey, SD
|
|
2008
|
11 |
3 |
p. A76-
1 p.
|
artikel
|
| 178 |
PCV29 A COST-EFFECTIVENESS ANALYSIS OF TREATMENT TO LOW-DENSITY LIPOPROTEIN (LDL) CHOLESTEROL GOAL IN HIGH-RISK PATIENTS BASED UPON THE 2004 NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) GUIDELINE UPDATE
|
Skora, JL
|
|
2008
|
11 |
3 |
p. A194-
1 p.
|
artikel
|
| 179 |
PCV51 A FLEXIBLE TOOL TO ESTIMATE MEDICAL-CARE COSTS FOR STUDY EVENTS IN CARDIOVASCULAR ENDPOINTTRIALS
|
Thompson, D
|
|
2008
|
11 |
3 |
p. A201-
1 p.
|
artikel
|
| 180 |
PCV1 A MODIFIED RXRISK-V COMORBIDITY INDEX PREDICTS ADHERENCE WITH LIPID LOWERINGTHERAPY (LLT)
|
Ghate, S
|
|
2008
|
11 |
3 |
p. A185-
1 p.
|
artikel
|
| 181 |
PCV13 ANGINA FOLLOWING REVASCULARIZATION-FREQUENCY, PATIENT CHARACTERISTICS AND TIMING
|
Kempf, J
|
|
2008
|
11 |
3 |
p. A189-
1 p.
|
artikel
|
| 182 |
PCV4 APPROPRIATE UTILIZATION AND COST-ANALYSIS OF ADD-ON EZETIMBE LIPID-LOWERING THERAPY AT THE VETERANS AFFAIRS SAN DIEGO HEALTH CARE SYSTEM (VASDHS)
|
Rubin, LM
|
|
2008
|
11 |
3 |
p. A186-
1 p.
|
artikel
|
| 183 |
PCV81 ASSESSING THE IMPACT OF INCORPORATING PATIENT KNOWLEDGE AND BELIEFS INTO ANTICOAGULATION THERAPY MANAGEMENT SERVICES
|
Lavallee, DC
|
|
2008
|
11 |
3 |
p. A210-A211
nvt p.
|
artikel
|
| 184 |
PCV11 ASSESSMENT AND QUANTIFICATION OF THE BENEFIT RISK RATIO OF ROSUVASTATIN AND ATORVASTATIN FROM A META-ANALYSIS OF HEAD TO HEAD RANDOMISED CONTROLLED TRIALS
|
Wlodarczyk, JH
|
|
2008
|
11 |
3 |
p. A188-A189
nvt p.
|
artikel
|
| 185 |
PCV77 ASSESSMENT OF CONTROL AND TREATMENT PATTERNS IN AN ELDERLY POPULATION WITH COMORBID DIABETES AND HYPERTENSION
|
Darah, GN
|
|
2008
|
11 |
3 |
p. A209-
1 p.
|
artikel
|
| 186 |
PCV24 ASSESSMENT OF SAFETY FOR BROMOCRIPTINE: COMPARISONS OF REPORTING SYSTEMS AND A RETROSPECTIVE COHORT STUDY
|
Farwell, WR
|
|
2008
|
11 |
3 |
p. A192-A193
nvt p.
|
artikel
|
| 187 |
PCV63 BARRIERS AND MOTIVATORS ASSOCIATED WITH ADHERENCE TO ANTIHYPERTENSIVE MEDICATIONS AND BLOOD PRESSURE CONTROL AMONG AFRICAN AMERICANS FROM ALABAMA
|
Salas, M
|
|
2008
|
11 |
3 |
p. A205-
1 p.
|
artikel
|
| 188 |
PCV26 BELGIAN BUDGET IMPACT ANALYSES OF ALISKIREN (TEKTURNA/RASILEZ) IN HYPERTENSION
|
Lecomte, P
|
|
2008
|
11 |
3 |
p. A193-
1 p.
|
artikel
|
| 189 |
PCV37 BIATRIAL VERSUS RIGHT ATRIAL APPENDAGE PACING IN BRADYCARDIA TACHYCARDIA SYNDROME
|
Rucinski, P
|
|
2008
|
11 |
3 |
p. A197-
1 p.
|
artikel
|
| 190 |
PCV8 BLOOD PRESSURE SUCCESS ZONE LONGITUDINAL STUDY OF SUCCESS (BPSZ-BLISS). AN OBSERVATIONAL, MULTI-CENTER STUDY OF THE IMPACT OF THE BPSZ EDUCATIONAL PROGRAM ON BLOOD PRESSURE CONTROL, PERSISTENCE, COMPLIANCE, AND TREATMENT SATISFACTION. ENROLLMENT METRICS AND BASELINE COHORT CHARACTERISTICS
|
Payne, K
|
|
2008
|
11 |
3 |
p. A187-A188
nvt p.
|
artikel
|
| 191 |
PCV38 BOSENTAN IS A COST-EFFECTIVE TREATMENT FOR UNITED KINGDOM PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION OF WHO CLASS III
|
Stevenson, MD
|
|
2008
|
11 |
3 |
p. A197-
1 p.
|
artikel
|
| 192 |
PCV28 CARDIOVASCULAR EVENT DRIVEN ECONOMIC ANALYSIS OF ROSUVASTATIN VERSUS SIMVASTATIN USING PRAGMATIC HEAD-TO-HEAD RCTSWITH SURROGATE END-POINT MEASURES
|
Farahani, P
|
|
2008
|
11 |
3 |
p. A194-
1 p.
|
artikel
|
| 193 |
PCV65 CHANGE IN HEALTH-RELATED QUALITY OF LIFE FOLLOWING NON-FATAL CARDIOVASCULAR EVENTS IN POST-MYOCARDIAL INFARCTION PATIENTS
|
Lewis, EF
|
|
2008
|
11 |
3 |
p. A205-A206
nvt p.
|
artikel
|
| 194 |
PCV68 CLINICAL DETERMINANTS OF SATISFACTION AND HEALTH RELATED QUALITY OF LIFE IN PATIENTS WITH CARDIAC DISEASE AND DYSLIPIDEMIA
|
Raju, AD
|
|
2008
|
11 |
3 |
p. A206-
1 p.
|
artikel
|
| 195 |
PCV30 CLOPIDOGREL IS COST-EFFECTIVE COMPARED WITH ASPIRIN IN UNITED KINGDOM PATIENTS WITH A MYOCARDIAL INFARCTION WHO SUBSEQUENTLY SUSTAIN AN ISCHAEMIC STROKE OR PERIPHERAL ARTERIAL DISEASE EVENT
|
Stevenson, MD
|
|
2008
|
11 |
3 |
p. A194-A195
nvt p.
|
artikel
|
| 196 |
PCV41 COMPARISON OF COST-EFFECTIVENESS OF POM (PRESCRIPTION ONLY) STATINS; OTC (OVERTHE COUNTER) STATIN AND PLANT STEROL / STANOL PRODUCTS FOR PRIMARY CVD (CARDIOVASCULAR DISEASE) PREVENTION IN THE UNITED KINGDOM FROM THE PATIENT'S PERSPECTIVE
|
Amirsadri-Naeini, M
|
|
2008
|
11 |
3 |
p. A198-
1 p.
|
artikel
|
| 197 |
PCV69 CONVENIENCE OF THE NEW LONG-ACTING ANTICOAGULANT IDRAPARINUX VERSUS VITAMIN K ANTAGONIST IN PATIENTS WITH ATRIAL FIBRILLATION
|
Prins, MH
|
|
2008
|
11 |
3 |
p. A206-A207
nvt p.
|
artikel
|
| 198 |
PCV40 COST-EFFECTIVENESS ANALYSIS OF DRUG-ELUTING STENT VS BARE METAL STENT IN PATIENTS WITH ISCHAEMIC HEART DISEASE IN SOCIAL SECURITY MEXICAN INSTITUTE.
|
González-Diaz, B
|
|
2008
|
11 |
3 |
p. A198-
1 p.
|
artikel
|
| 199 |
PCV42 COST-EFFECTIVENESS ANALYSIS OF EDUCATIONAL PREVENTIVE TECHNOLOGIES FOR PATIENTS WITH CARDIOVASCULAR DISEASES IN RUSSIA
|
Kontsevaya, A
|
|
2008
|
11 |
3 |
p. A198-A199
nvt p.
|
artikel
|
| 200 |
PCV32 COST-EFFECTIVENESS OF CLINICAL PHARMACY SERVICES ON HYPERLIPIDAEMIC MANAGEMENT IN A PUBLIC HOSPITAL OF HONG KONG
|
Lee, VWY
|
|
2008
|
11 |
3 |
p. A195-
1 p.
|
artikel
|
| 201 |
PCV31 COST-EFFECTIVENESS OF DIFFERENT STRATEGIES FOR DIAGNOSIS OF DEEP VEIN THROMBOSIS
|
Patel, VA
|
|
2008
|
11 |
3 |
p. A195-
1 p.
|
artikel
|
| 202 |
PCV27 COST EFFECTIVENESS STUDIES IN HEART FAILURE: AN UPDATE OF THE LITERATURE
|
Shah, DH
|
|
2008
|
11 |
3 |
p. A193-A194
nvt p.
|
artikel
|
| 203 |
PCV46 COSTS OF ACUTE MYOCARDIAL INFARCTION IN HUNGARY; 2003-2005
|
Karpati, K
|
|
2008
|
11 |
3 |
p. A200-
1 p.
|
artikel
|
| 204 |
PCV90 DISPARITIES IN MEDICAL EXPENDITURES AND UTILIZATION AMONG HYPERTENSIVE MEN AND WOMEN IN THE UNITED STATES
|
Basu, R
|
|
2008
|
11 |
3 |
p. A213-A214
nvt p.
|
artikel
|
| 205 |
PCV53 DRUG-ELUTING STENTS FROM A MEDICARE PAYER PERSPECTIVE: COST-UTILITY ANALYSIS WITH 4-YEAR CLINICAL META-ANALYSIS DATA
|
Bischof, M
|
|
2008
|
11 |
3 |
p. A202-
1 p.
|
artikel
|
| 206 |
PCV49 ECONOMIC BURDEN OF VENOUS THROMBOEMBOLISM IN THE GENERAL POPULATION AND AFTER MAJOR ORTHOPAEDIC SURGERY-RESULTS OF A SYSTEMATIC LITERATURE REVIEW
|
Steinle, T
|
|
2008
|
11 |
3 |
p. A201-
1 p.
|
artikel
|
| 207 |
PCV52 ECONOMIC IMPACT OF A PHYSICIAN-PHARMACIST COLLABORATIVE CARE INTERVENTION IN PRIMARY CARE FOR PATIENTS WITH DYSLIPIDEMIA A CLUSTER-RANDOMISED CONTROLLED TRIAL (TEAM STUDY)
|
Villeneuve, J
|
|
2008
|
11 |
3 |
p. A202-
1 p.
|
artikel
|
| 208 |
PCV45 ECONOMIC IMPACT OF STROKE-RELATED COMORBID CONDITIONS ON THE TREATMENT OF STROKE: AN ANALYSIS OF MEDICARE BENEFICIARIES IN THE UNITED STATES
|
Lee, WC
|
|
2008
|
11 |
3 |
p. A199-A200
nvt p.
|
artikel
|
| 209 |
PCV10 EFFECTS OF INTENSIFYING LIPID-ALTERING THERAPY ON CHD EVENTS IN A SECONDARY PREVENTION POPULATION WITH HIGH NON-HDL CHOLESTEROL
|
Menzin, J
|
|
2008
|
11 |
3 |
p. A188-
1 p.
|
artikel
|
| 210 |
PCV72 ENHANCING THE EFFECTIVENESS OF COMMUNITY STROKE RISK SCREENINGS RANDOMIZED CONTROL TRIAL
|
Anderson, RT
|
|
2008
|
11 |
3 |
p. A207-A208
nvt p.
|
artikel
|
| 211 |
PCV14 EVALUATION OF RESISTANT HYPERTENSION IN A USUAL-CARE SETTING
|
McAdam-Marx, C
|
|
2008
|
11 |
3 |
p. A189-A190
nvt p.
|
artikel
|
| 212 |
PCV82 EVALUATION OF THE EFFECT OF ACUTE DECOMPENSATED HEART FAILURE GUIDELINES IN COMMUNITY HOSPITALS
|
Perez, A
|
|
2008
|
11 |
3 |
p. A211-
1 p.
|
artikel
|
| 213 |
PCV18 FACTORS ASSOCIATED WITH RISK OF METABOLIC SYNDROME FOR US FIRST GENERATION ADOLESCENTS (AGES 12-17)
|
Sias, S
|
|
2008
|
11 |
3 |
p. A191-
1 p.
|
artikel
|
| 214 |
PCV35 GADOFOSVESET IN THE MANAGEMENT OF PERIPHERAL ARTERIAL OCCLUSIVE DISEASE IN CANADA-A MODEL APPROACH FOCUSING ON DIAGNOSTIC CONFIDENCE
|
Hass, B
|
|
2008
|
11 |
3 |
p. A196-
1 p.
|
artikel
|
| 215 |
PCV83 GENDER DISPARITIES IN THE UTILIZATION OF MYOCARDIAL PERFUSION IMAGING
|
Gao, X
|
|
2008
|
11 |
3 |
p. A211-
1 p.
|
artikel
|
| 216 |
PCV84 HEALTH CARE UTILIZATION ASSOCIATED WITH DEPRESSION FOLLOWING THROMBOTIC CARDIOVASCULAR EVENTS IN ELDERLY MEDICARE BENEFICIARIES
|
Blanchette, CM
|
|
2008
|
11 |
3 |
p. A211-A212
nvt p.
|
artikel
|
| 217 |
PCV95 IMPACT OF ADOPTION OF NEWANTIHYPERTENSIVE DRUGS ON THE HEALTH CARE UTILIZATION IN HYPERTENSIVE PATIENTS
|
Ganguli, A
|
|
2008
|
11 |
3 |
p. A215-
1 p.
|
artikel
|
| 218 |
PCV105 IMPACT OF GUIDELINES FORTREATMENT AND PROPHYLAXIS OF VENOUS THROMBOEMBOLISM IN COMMUNITY HOSPITALS
|
Vats, V
|
|
2008
|
11 |
3 |
p. A218-
1 p.
|
artikel
|
| 219 |
PCV85 IMPACT OF MEDICARE PART D IMPLEMENTATION ON STATIN UTILIZATION AND MARKET SHARE IN STATE MEDICAID PROGRAMS
|
Nag, A
|
|
2008
|
11 |
3 |
p. A212-
1 p.
|
artikel
|
| 220 |
PCV61 IMPACT OF PRESCRIPTION COPAY ON ADHERENCE WITH RENIN-ANGIOTENSIN SYSTEM AGENTS IN HEART FAILURE PATIENTS
|
Ye, X
|
|
2008
|
11 |
3 |
p. A204-A205
nvt p.
|
artikel
|
| 221 |
PCV64 IMPACT OF STATIN STEP CARE PROGRAM ON PATIENT COMPLIANCE
|
Ying, X
|
|
2008
|
11 |
3 |
p. A205-
1 p.
|
artikel
|
| 222 |
PCV25 IMPROVEMENTS IN CARDIOVASCULAR DISEASE OUTCOMES IN MANAGED CARE PATIENTS MANAGED ACCORDING TO NATIONAL LIPID TREATMENT GUIDELINES
|
Simko, RJ
|
|
2008
|
11 |
3 |
p. A193-
1 p.
|
artikel
|
| 223 |
PCV39 INDIRECT COMPARISONS OF RIVAROXABAN VS ALTERNATIVE PROPHYLAXES FORTHE PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS UNDERGOING TOTAL HIP ORTOTAL KNEE REPLACEMENT
|
Diamantopoulos, A
|
|
2008
|
11 |
3 |
p. A197-A198
nvt p.
|
artikel
|
| 224 |
PCV78 INTERNATIONAL COMPARISON OF HEALTH CARE RESOURCES AND QUALITY OF LIFE IN ACUTE CORONARY SYNDROME PATIENTS IN 2007: RESULTS FROM THE ANTIPLATELETTREATMENT OBSERVATIONAL STUDY (APTOR)
|
Bakhai, A
|
|
2008
|
11 |
3 |
p. A209-A210
nvt p.
|
artikel
|
| 225 |
PCV97 IS THERE A LEARNING CURVE ASSOCIATED WITH EXERCISE TRAINING IN PATIENTS WITH HEART FAILURE?
|
Li, Y
|
|
2008
|
11 |
3 |
p. A215-A216
nvt p.
|
artikel
|
| 226 |
PCV93 LIFETIME MEDICAL EXPENDITURES AMONG HYPERTENSIVE MEN AND WOMEN IN THE UNITED STATES
|
Basu, R
|
|
2008
|
11 |
3 |
p. A214-
1 p.
|
artikel
|
| 227 |
PCV48 LIKELIHOOD AND COST OF ADVERSE EVENTS IN ATRIAL FIBRILLATION ARE ASSOCIATED WITH CHOICE OF ACUTE CONVERSION THERAPY
|
Belz, M
|
|
2008
|
11 |
3 |
p. A200-
1 p.
|
artikel
|
| 228 |
PCV76 LONGITUDINAL ASSESSMENT OF THE CLINICAL UTILITY OF POINT-OF-CARE MEASUREMENT DEVICES FOR DETERMINING THE INTERNATIONAL NORMALIZED RATIO
|
Shermock, KM
|
|
2008
|
11 |
3 |
p. A209-
1 p.
|
artikel
|
| 229 |
PCV33 LONG-TERM REDUCTION OF CARDIOVASCULAR EVENTS AND COST-EFFECTIVENESS OF DIFFERENT STATINS AND DOSES IN MEXICO
|
Mino, D
|
|
2008
|
11 |
3 |
p. A195-A196
nvt p.
|
artikel
|
| 230 |
PCV75 LOW-DENSITY LIPOPROTEIN APHERESIS FORTHE TREATMENT OF FAMILIAL HYPERCHOLESTEROLEMIA
|
Khan, T
|
|
2008
|
11 |
3 |
p. A208-A209
nvt p.
|
artikel
|
| 231 |
PCV23 MEDICAL CLAIMS FOR GASTROINTESTINAL ADVERSE EVENTS ARE COMMON IN PATIENTS PRESCRIBED CLOPIDOGREL
|
Lapuerta, P
|
|
2008
|
11 |
3 |
p. A192-
1 p.
|
artikel
|
| 232 |
PCV47 MEDICARE OUTLIER PAYMENTS FOR CORONARY ARTERY BYPASS GRAFTING
|
Baser, O
|
|
2008
|
11 |
3 |
p. A200-
1 p.
|
artikel
|
| 233 |
PCV12 METHODS FOR INDIVIDUALIZING THE BENEFIT AND HARM OF WARFARIN
|
Pereira, JA
|
|
2008
|
11 |
3 |
p. A189-
1 p.
|
artikel
|
| 234 |
PCV58 MODELING CARDIOVASCULAR HEALTH OUTCOMES IN MEDICAID HYPERTENSIVE PATIENTS-EFFECT OF PATIENT ADHERENCE
|
Gu, A
|
|
2008
|
11 |
3 |
p. A204-
1 p.
|
artikel
|
| 235 |
PCV80 NATIONAL ESTIMATES OF ENROLLMENT IN DISEASE STATE MANAGEMENT PROGRAMS IN THE UNITED STATES
|
Kalsekar, ID
|
|
2008
|
11 |
3 |
p. A210-
1 p.
|
artikel
|
| 236 |
PCV88 OLD HABITS DIE HARD: A NATIONWIDE UTILIZATION STUDY OF CALCIUM CHANNEL BLOCKERS IN TAIWAN
|
Chen, TJ
|
|
2008
|
11 |
3 |
p. A213-
1 p.
|
artikel
|
| 237 |
PCV43 OPTIMIZATION OF DIAGNOSIS AND TREATMENT OF CORONARY ARTERY DISEASE IN CHINA WITH USE OF CORONARY CT ANGIOGRAPHY
|
Cheng, M
|
|
2008
|
11 |
3 |
p. A199-
1 p.
|
artikel
|
| 238 |
PCV70 PATIENT ADHERENCE TO CHOLESTEROL TREATMENT (PACT): CANADIAN PHYSICIAN AND PATIENT PERSPECTIVES
|
Beamer, B
|
|
2008
|
11 |
3 |
p. A207-
1 p.
|
artikel
|
| 239 |
PCV91 PATIENT INSURANCE AND MEDICATION CHOICE FOR HYPERCHOLESTEROLEMIA
|
Epstein, AJ
|
|
2008
|
11 |
3 |
p. A214-
1 p.
|
artikel
|
| 240 |
PCV86 PATTERNS OF DIURETIC USE IN MULTI-DRUG ANTI-HYPERTENSIVE REGIMENS IN THE POSTALLHAT ERA
|
Parikh, NM
|
|
2008
|
11 |
3 |
p. A212-
1 p.
|
artikel
|
| 241 |
PCV16 PERMANENT STRESS MAY BE THE TRIGGER OF A HEART ATTACK ON THE FIRST WORK-DAY OF THE WEEK
|
Kriszbacher, I
|
|
2008
|
11 |
3 |
p. A190-
1 p.
|
artikel
|
| 242 |
PCV87 PHYSICIAN AND PATIENT FACTORS PREDICTING THE PRESCRIBING OF STATINS IN HYPERTENSION AND DIABETES
|
Bodhani, A
|
|
2008
|
11 |
3 |
p. A212-A213
nvt p.
|
artikel
|
| 243 |
PCV79 PHYSICIAN CHARACTERISTICS ASSOCIATED WITH STROKE RELATED OUTPATIENT CARE UTILIZATION: ANALYSIS OF THE NATIONAL AMBULATORY MEDICAL CARE SURVEY DATA 2000-2005
|
Karve, S
|
|
2008
|
11 |
3 |
p. A210-
1 p.
|
artikel
|
| 244 |
PCV89 PRE AND POST STROKE STATIN USE AND ASSOCIATED HEALTH CARE COSTS AMONG ELDERLY STROKE SURVIVORS
|
Karve, S
|
|
2008
|
11 |
3 |
p. A213-
1 p.
|
artikel
|
| 245 |
PCV17 PREDICTING CLINICAL OUTCOMES IN MIXED DYSLIPIDEMIA PATIENTS USING THE FRAMINGHAM RISK AND A NEW RISK EQUATION BASED ON A MANAGED CARE DATABASE: A VALIDATION APPROACH
|
Burge, RT
|
|
2008
|
11 |
3 |
p. A190-
1 p.
|
artikel
|
| 246 |
PCV94 PREDICTING HIGH COSTS IN MEDICARE BENEFICIARIES WITH HEART FAILURE
|
Curtis, LH
|
|
2008
|
11 |
3 |
p. A215-
1 p.
|
artikel
|
| 247 |
PCV21 PREVALENCE, AWARENESS AND MANAGEMENT OF HYPERTENSION, DYSLIPIDEMIA, AND DIABETES AMONG UNITED STATES ADULTS AGED 65 AND OLDER
|
McDonald, M
|
|
2008
|
11 |
3 |
p. A192-
1 p.
|
artikel
|
| 248 |
PCV57 PREVALENCE OF UNDERUTILIZATION OF INITIATED STATIN THERAPY AND RENIN-ANGIOTENSIN SYSTEM BLOCKADE
|
Bowen, KL
|
|
2008
|
11 |
3 |
p. A203-
1 p.
|
artikel
|
| 249 |
PCV71 PSYCHOLOGICAL FACTORS AS PREDICTORS OF CARDIOVASCULAR RISK IN A PROSPECTIVE STUDY COHORT IN THE UNITED KINGDOM
|
Timmaraju, V
|
|
2008
|
11 |
3 |
p. A207-
1 p.
|
artikel
|
| 250 |
PCV104 RELATIONSHIP BETWEEN QUALITY OF CARE AND EXCESSIVE COST FOR MEDICARE PATIENTS UNDERGOING LOWER EXTREMITY BYPASS SURGERY
|
Baser, O
|
|
2008
|
11 |
3 |
p. A217-A218
nvt p.
|
artikel
|
| 251 |
PCV44 RELATIONSHIP BETWEEN THE OBESITY PARADOX AND HEALTH CARE EXPENDITURES IN SUBJECTS WITH CARDIOVASCULAR DISEASE USING THE MEDICAL EXPENDITURE PANEL SURVEY
|
Suh, HS
|
|
2008
|
11 |
3 |
p. A199-
1 p.
|
artikel
|
| 252 |
PCV19 RESIDUAL DYSLIPIDEMIA ON SIMVASTATIN: POPULATION MODELING OF OPTIMAL LIPID VALUE ACHIEVEMENT WITH ADDED EXTENDED-RELEASE NIACIN VERSUS EZETIMIBE
|
Stanek, E
|
|
2008
|
11 |
3 |
p. A191-
1 p.
|
artikel
|
| 253 |
PCV67 RESPONSIVENESS OF PROXY-RATED PREFERENCE-BASED MEASURES OF HEALTH-RELATED QUALITY OF LIFE
|
Wilke, CT
|
|
2008
|
11 |
3 |
p. A206-
1 p.
|
artikel
|
| 254 |
PCV7 RISK OF HOSPITALIZATION ASSOCIATED WITH BETA-BLOCKERTHERAPY IN PATIENTS OF CHRONIC HEART FAILURE AND DIABETES: A MEDIC AID STUDY
|
Sudharshan, L
|
|
2008
|
11 |
3 |
p. A187-
1 p.
|
artikel
|
| 255 |
PCV6 ROLE OF OSTEOPROTEGERIN AND RANKL IN BONE AND VASCULAR CALCIFICATION
|
Bakhireva, LN
|
|
2008
|
11 |
3 |
p. A187-
1 p.
|
artikel
|
| 256 |
PCV15 SEASONAL VARIATION OF HEART ATTACKS IN WOMEN
|
Kriszbacher, I
|
|
2008
|
11 |
3 |
p. A190-
1 p.
|
artikel
|
| 257 |
PCV22 SIGMOID MAXIMUM EFFECT MODELING OF CORONARY HEART DISEASE DEATH AND MYOCARDIAL INFARCTION RATE VERSUS LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN STATIN SECONDARY PREVENTION TRIALS
|
Charland, S
|
|
2008
|
11 |
3 |
p. A192-
1 p.
|
artikel
|
| 258 |
PCV2 STROKE EVENTS IN MANAGED CARE PATIENTS MANAGED ACCORDINGTO NATIONAL LIPID TREATMENT GUIDELINES
|
Balu, S
|
|
2008
|
11 |
3 |
p. A185-A186
nvt p.
|
artikel
|
| 259 |
PCV36 SYSTEMATIC REVIEW OF COST-EFFECTIVENESS STUDIES ON DIABETES MEDICATION
|
Zhang, YJ
|
|
2008
|
11 |
3 |
p. A196-A197
nvt p.
|
artikel
|
| 260 |
PCV3 SYSTEMATIC REVIEW OF NICARDIPINE IN NEUROVASCULAR CONDITIONS
|
Reddy, P
|
|
2008
|
11 |
3 |
p. A186-
1 p.
|
artikel
|
| 261 |
PCV102 THE ASSESSING CARDIOVASCULAR TARGETS (ACT '07) PROGRAM: PRELIMINARY RESULTS FROM A PRACTICE REFLECTIVE ASSESSMENT ACROSS CANADA
|
Beamer, B
|
|
2008
|
11 |
3 |
p. A217-
1 p.
|
artikel
|
| 262 |
PCV59 THE COST AND EFFECTIVENESS OF ADHERENCE-IMPROVING INTERVENTIONS FOR LIPID-LOWERING AND ANTIHYPERTENSIVE DRUGS
|
Chapman, RH
|
|
2008
|
11 |
3 |
p. A204-
1 p.
|
artikel
|
| 263 |
PCV34 THE COST-EFFECTIVENESS OF ALISKIREN AS ADD ON TO LOSARTAN AND OPTIMAL ANTIHYPERTENSIVE THERAPY IN PATIENTS WITH TYPE 2 DIABETES, HYPERTENSION AND NEPHROPATHY IN THE UNITED KINGDOM SETTING
|
Palmer, JL
|
|
2008
|
11 |
3 |
p. A196-
1 p.
|
artikel
|
| 264 |
PCV54 THE COST-UTILITY OF ALISKIREN IN THE TREATMENT OF MILD TO MODERATE HYPERTENSION. A CANADIAN HEALTH CARE SYSTEM PERSPECTIVE
|
Lee, A
|
|
2008
|
11 |
3 |
p. A202-A203
nvt p.
|
artikel
|
| 265 |
PCV100 THE EFFECTIVENESS OF A PATIENT AND PHYSICIAN EDUCATIONAL PROGRAM IN INITIATING STATIN THERAPY AMONG DIABETICS
|
Patel, BV
|
|
2008
|
11 |
3 |
p. A216-A217
nvt p.
|
artikel
|
| 266 |
PCV96 THE EFFECT OF MEASUREMENT ERROR FROM POINT-OF-CARE INR DEVICES ON WARFARIN DOSING DECISIONS
|
Shermock, KM
|
|
2008
|
11 |
3 |
p. A215-
1 p.
|
artikel
|
| 267 |
PCV98 THE EFFECTS OF STEP THERAPY: LOOKING BEYOND IMPACTS ON PRESCRIBING RATES AND COSTS
|
Mark, TL
|
|
2008
|
11 |
3 |
p. A216-
1 p.
|
artikel
|
| 268 |
PCV99 THE FIRST MOVER STRIKES AGAIN. COST-EFFECTIVENESS OF STATINS AND PRESCRIBING BEHAVIOR IN PORTUGAL
|
Pinto, CG
|
|
2008
|
11 |
3 |
p. A216-
1 p.
|
artikel
|
| 269 |
PCV92 THE HEALTH AND ECONOMIC IMPACT OF SWITCHING FROM ATORVASTATIN TO SIMVASTATIN IN THE US
|
Liew, D
|
|
2008
|
11 |
3 |
p. A214-
1 p.
|
artikel
|
| 270 |
PCV5 THE IMPACT OF PHARMACISTS' INTERVENTIONS: SENSITIVITY ON PATIENT OUTCOMES IN HYPERLIPIDEMIA MANAGEMENT
|
Machado, M
|
|
2008
|
11 |
3 |
p. A186-A187
nvt p.
|
artikel
|
| 271 |
PCV74 THE IMPACT OF TARGETED MEMBER EDUCATION ON CHOICE OF PREFERRED STATIN THERAPY AFTER A FORMULARY CHANGE
|
Cox, E
|
|
2008
|
11 |
3 |
p. A208-
1 p.
|
artikel
|
| 272 |
PCV103 THE PATIENT SAFETY STANDARDS OF ACUTE STROKE MANAGEMENT IN HUNGARY
|
Betlehem, J
|
|
2008
|
11 |
3 |
p. A217-
1 p.
|
artikel
|
| 273 |
PCV55 THIRY-DAY RESOURCE USE DIARY DATA FROM THE BURST STUDY
|
Seung, SJ
|
|
2008
|
11 |
3 |
p. A203-
1 p.
|
artikel
|
| 274 |
PCV9 TRENDS IN MORTALITY, LENGTH OF STAY AND READMISSIONS AMONG PATIENTS WITH ACUTE STROKE AT THE NATIONAL HEALTHCARE GROUP, SINGAPORE, 2000-2006
|
Sun, Y
|
|
2008
|
11 |
3 |
p. A188-
1 p.
|
artikel
|
| 275 |
PCV20 UPDATING THE RXRISK-V: CREATING A CROSSWALK BETWEEN VA AND FIRSTDATABANK THERAPEUTIC CATEGORIES
|
LaFleur, J
|
|
2008
|
11 |
3 |
p. A191-
1 p.
|
artikel
|
| 276 |
PCV50 UP-TITRATION OF STATIN THERAPY TO MEET CANADIAN TARGET LIPID GOALS: ECONOMIC IMPACT OFTITRATION ASSOCIATED WITH COMPARATIVE EFFICACY OF ROSUVASTATIN, ATORVASTATIN, SIMVASTATIN AND PRAVASTATIN
|
Frial, T
|
|
2008
|
11 |
3 |
p. A201-
1 p.
|
artikel
|
| 277 |
PCV60 USING A LONGITUDINAL MODEL TO ANALYZE DRUG COMPLIANCE
|
Gause, D
|
|
2008
|
11 |
3 |
p. A204-
1 p.
|
artikel
|
| 278 |
PCV73 VALIDATION OF AN ABBREVIATED TREATMENT SATISFACTION QUESTIONNAIRE FOR MEDICATION (TSQM-9) AMONG PATIENTS ON ANTIHYPERTENSIVE MEDICATIONS
|
Bharmal, M
|
|
2008
|
11 |
3 |
p. A208-
1 p.
|
artikel
|
| 279 |
PCV56 VOLUME AND MIX OF CARDIAC X-RAY PROCEDURES ACROSS U.S. HOSPITALS: UTILIZATION DATA TO SUPPORT FINANCIAL DECISIONS
|
Jassak, S
|
|
2008
|
11 |
3 |
p. A203-
1 p.
|
artikel
|
| 280 |
PDB30 A MODELLED COST-EFFECTIVENESS ANALYSIS OF SWITCHING PATIENTS WITH POORLY CONTROLLED TYPE 2 DIABETES TO INSULIN DETEMIR FROM ORAL ANTIDIABETICS OR NPH IN THE AUSTRIAN SETTING; DATA FROM THE PREDICTIVE STUDY
|
Stechemesser, L
|
|
2008
|
11 |
3 |
p. A227-
1 p.
|
artikel
|
| 281 |
PDB68 AN ASSESSMENT OF THE IMPACT OF THE COVERAGE GAP UPON MEDICARE PART D BENEFICIARIES UTILIZING INSULIN
|
Skrepnek, GH
|
|
2008
|
11 |
3 |
p. A237-
1 p.
|
artikel
|
| 282 |
PDB63 AN ECONOMIC EVALUATION OF A DIABETES DISEASE MANAGEMENT PROGRAM FORADULT MEDICAID CLIENTS IN THE STATE OF COLORADO, UNITED STATES
|
Skrepnek, GH
|
|
2008
|
11 |
3 |
p. A235-A236
nvt p.
|
artikel
|
| 283 |
PDB17 AN EVALUATION OF EXPECTED WASTE OF GROWTH HORMONE PEN DEVICES AND AN ELECTRONIC GROWTH HORMONE DELIVERY DEVICE
|
Edwards, NC
|
|
2008
|
11 |
3 |
p. A222-A223
nvt p.
|
artikel
|
| 284 |
PDB51 A RESTROSPECTIVE ANALYSIS OF MEDICATIONS ADHERENCE AND ASSOCIATED HEALTH CARE COST FOR THE DIABETIC PATIENTS
|
Jing, Y
|
|
2008
|
11 |
3 |
p. A232-
1 p.
|
artikel
|
| 285 |
PDB34 ASSESSING DIFFERENCES IN UTILIZATION AND COSTS BETWEEN INSULIN DETEMIR (LEVEMIR) AND INSULIN GLARGINE (LANTUS) USERS
|
Borah, B
|
|
2008
|
11 |
3 |
p. A228-
1 p.
|
artikel
|
| 286 |
PDB58 ASSOCIATION BETWEEN THE DIABETES-39 (DM-39)ASA PATIENT REPORTED OUTCOME (PRO) AND HBAIC IN A CLINICAL TRIAL INVOLVING INSULIN THERAPY
|
Lee, LJ
|
|
2008
|
11 |
3 |
p. A234-
1 p.
|
artikel
|
| 287 |
PDB14 BUDGET IMPACT OF ADDING FIXED-DOSE COMBINATION OF PIOGLITAZONE PLUS GLIMEPIRIDETO A FORMULARY PLAN OVERATHREE-YEARTIME FRAME
|
Lobo, F
|
|
2008
|
11 |
3 |
p. A221-A222
nvt p.
|
artikel
|
| 288 |
PDB45 CANADIAN COST UTILITY ANALYSIS COMPARING EXENATIDE VERSUS INSULIN GLARGINE IN PATIENTS WITH TYPE TWO DIABETES
|
Coyle, D
|
|
2008
|
11 |
3 |
p. A231-
1 p.
|
artikel
|
| 289 |
PDB35 CLINICAL AND ECONOMIC CHARACTERISTICS OF PATIENTS WITH DIABETIC NEUROPATHY
|
Zhao, Y
|
|
2008
|
11 |
3 |
p. A228-
1 p.
|
artikel
|
| 290 |
PDB12 CLINICAL AND ECONOMIC OUTCOMES RELATED TO A PAY-FOR-PERFORMANCE PROGRAM
|
Marehbian, J
|
|
2008
|
11 |
3 |
p. A221-
1 p.
|
artikel
|
| 291 |
PDB5 COMPARISON OF CLINICAL EFFECTIVENESS AND SAFETY OF GLULISINE VERSUS INSULIN LISPRO, ASPART AND REGULAR HUMAN INSULIN IN PATIENTS WITH TYPE I AND 2 DIABETES
|
Walczak, J
|
|
2008
|
11 |
3 |
p. A219-
1 p.
|
artikel
|
| 292 |
PDB65 COMPARISON OF FOUR HEALTH STATE PREFERENCE MEASURES AMONG PATIENTS ENROLLED IN THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES TRIAL
|
Raisch, DW
|
|
2008
|
11 |
3 |
p. A236-
1 p.
|
artikel
|
| 293 |
PDB69 COMPARISON OF HEALTH CARE UTILIZATION AND COSTS IN TYPE 2 DIABETES PATIENTS INITIATING ANALOG AND HUMAN INSULINS
|
Margolis, J
|
|
2008
|
11 |
3 |
p. A237-A238
nvt p.
|
artikel
|
| 294 |
PDB18 COMPARISON OF RESOURCES UTILIZATION (RU)AND COST IN DRUG NAÏVE TYPE 2 DIABETES (T2D) PATIENTS TREATED WITH ROSIGLITAZONE (RSG)VS. SULFONYLUREA (SU) MONOTHERAPY
|
Duh, MS
|
|
2008
|
11 |
3 |
p. A223-
1 p.
|
artikel
|
| 295 |
PDB57 CONTENT DEVELOPMENT FORA NEW INSTRUMENT TO ASSESS PATIENT AND PARENT PREFERENCE FOR GROWTH HORMONE REPLACEMENT THERAPY DELIVERY DEVICES
|
Stephens, JM
|
|
2008
|
11 |
3 |
p. A233-A234
nvt p.
|
artikel
|
| 296 |
PDB23 COST-EFFECTIVENESS ANALYSIS OF CONTINUOUS SUBCUTANEOUS INSULIN INJECTION VS. MULTIPLE DAILY INJECTIONS IN TYPE I DIABETES PATIENTS: A CANADIAN PERSPECTIVE
|
St. Charles, M
|
|
2008
|
11 |
3 |
p. A224-
1 p.
|
artikel
|
| 297 |
PDB22 COST-EFFECTIVENESS ANALYSIS OF CONTINUOUS SUBCUTANEOUS INSULIN INJECTION VS. MULTIPLE DAILY INJECTIONS IN TYPE I DIABETES PATIENTS:AN INTERNATIONAL COMPARISON
|
Graham, C
|
|
2008
|
11 |
3 |
p. A224-
1 p.
|
artikel
|
| 298 |
PDB28 COST-EFFECTIVENESS ANALYSIS OF DOPAMINE AGONISTS FOR THE TREATMENT OF INFERTILITY ASOCIATED TO HYPERPROLACTINEMIA IN MEXICO
|
Guillen-Gonzalez, S
|
|
2008
|
11 |
3 |
p. A226-
1 p.
|
artikel
|
| 299 |
PDB31 COST-EFFECTIVENESS OF DETEMIRVERSUS NPH FORTYPE I DIABETES PATIENTS TREATED WITH BASAL-BOLUS THERAPY IN PORTUGAL
|
Silva, C
|
|
2008
|
11 |
3 |
p. A227-
1 p.
|
artikel
|
| 300 |
PDB21 COST-EFFECTIVENESS OF INSULIN DETEMIR COMPARED TO NPH INSULIN FOR TYPE 2 DIABETES MELLITUS (T2DM) IN THE CANADIAN PAYER SETTING: MODELING ANALYSIS USING AN OBSERVATIONAL STUDY
|
Minshall, ME
|
|
2008
|
11 |
3 |
p. A224-
1 p.
|
artikel
|
| 301 |
PDB20 COST-EFFECTIVENESS OF INSULIN DETEMIR COMPARED TO NPH INSULIN FOR TYPE I DIABETES MELLITUS (TIDM) IN THE CANADIAN PAYER SETTING: MODELING ANALYSIS USING A RANDOMIZED CONTROLLED TRIAL
|
Minshall, ME
|
|
2008
|
11 |
3 |
p. A223-A224
nvt p.
|
artikel
|
| 302 |
PDB44 COST-EFFECTIVENESS OF THE USE OF ANGIOTENSIN-II-RECEPTER BLOCKERS IN PATIENTS WITH TYPE 2 DIABETES AND NEPHROPATHY IN JAPAN
|
Ikeda, S
|
|
2008
|
11 |
3 |
p. A231-
1 p.
|
artikel
|
| 303 |
PDB33 COST MINIMIZATION ANALYSIS OF DIFFERENT GROWTH HORMONE DEVICES BASED ON TIME-AND-MOTION SIMULATIONS
|
Nickman, NA
|
|
2008
|
11 |
3 |
p. A227-A228
nvt p.
|
artikel
|
| 304 |
PDB42 COST OF ILLNESS STUDY OF TYPE 2 DIABETES MELLITUS IN LATIN AMERICA
|
Gonzalez, JC
|
|
2008
|
11 |
3 |
p. A230-
1 p.
|
artikel
|
| 305 |
PDB25 COSTS AND EFFECTIVENESS OF INSULIN VS. ROSIGLITAZONE IN TYPE 2 DIABETES AFTER METFORMIN MONOTHERAPY FAILURE
|
Skoupá, J
|
|
2008
|
11 |
3 |
p. A225-
1 p.
|
artikel
|
| 306 |
PDB15 COSTS OF PEN (NOVOPEN(r) 3)VERSUS SYRINGE IN THE TREATMENT OF DIABETES MELLITUSTYPE 2- A PHARMACOECONOMIC STUDY FROM THE SLOVAK REPUBLIC
|
Bielik, J
|
|
2008
|
11 |
3 |
p. A222-
1 p.
|
artikel
|
| 307 |
PDB8 DEFINING HYPOGLYCEMIA AND ASSESSING ITS AFFECT ON OUTCOMES IN THE HOSPITAL SETTING
|
Curkendall, SM
|
|
2008
|
11 |
3 |
p. A219-A220
nvt p.
|
artikel
|
| 308 |
PDB67 DESCRIPTIVE ANALYSIS OF BODY WEIGHT AND CLINICAL EFFECTIVENESS MEASURES ASSOCIATED WITH TYPE 2 DIABETES THERAPIES IN A PRIMARY CARE ELECTRONIC MEDICAL RECORD DATABASE
|
Nelson, RE
|
|
2008
|
11 |
3 |
p. A237-
1 p.
|
artikel
|
| 309 |
PDB62 DETERMINANTS OF INSULIN INITIATION FOR PATIENTS WITH TYPE 2 DIABETES
|
Gibson, TB
|
|
2008
|
11 |
3 |
p. A235-
1 p.
|
artikel
|
| 310 |
PDB43 DETERMINANTS OF THE ECONOMIC BURDEN OF DIABETES HOSPITALIZATIONS IN TENNESSEE
|
White-Means, S
|
|
2008
|
11 |
3 |
p. A230-
1 p.
|
artikel
|
| 311 |
PDB54 DEVELOPMENT OF A CLASSIFICATION SYSTEM FOR A DIABETES-SPECIFIC PREFERENCE-BASED MEASURE OF HEALTH
|
Sundaram, M
|
|
2008
|
11 |
3 |
p. A233-
1 p.
|
artikel
|
| 312 |
PDB60 DISCREPANCIES BETWEEN IMPORTANCE AND EVALUATION OF INSULIN DELIVERY SYSTEM (IDS) FEATURES CONTRIBUTE TO IDS SATISFACTION IN PATIENTS WITH TYPE 2 DIABETES
|
Yang, HK
|
|
2008
|
11 |
3 |
p. A234-A235
nvt p.
|
artikel
|
| 313 |
PDB32 ECONOMIC EVALUATION OF LONG TERM SOMATOSTATIN ANALOGS IN THE TREATMENT OFACROMEGALY IN MEXICO
|
Salinas Escudero, G
|
|
2008
|
11 |
3 |
p. A227-
1 p.
|
artikel
|
| 314 |
PDB19 ECONOMIC EVALUATION OF SOMATROPIN (NORDITROPIN) FOR THE TREATMENT OF SHORT CHILDREN BORN SMALL FOR GESTATIONAL AGE (SGA)
|
Christensen, T
|
|
2008
|
11 |
3 |
p. A223-
1 p.
|
artikel
|
| 315 |
PDB26 ECONOMIC EVALUATION OF THE TREATMENT WITH QUINAGOLIDE IN PATIENTS WITH HYPERPROLACTINAEMIA, TUMOUR REDUCTION
|
Mendez, MT
|
|
2008
|
11 |
3 |
p. A225-
1 p.
|
artikel
|
| 316 |
PDB4 ESTIMATION OF STUDY POPULATION SIZE FOR EFFECTIVENESS OUTCOMES AT 6 AND 12 MONTHS VIA ELECTRONIC MEDICAL RECORDS
|
McAdam-Marx, C
|
|
2008
|
11 |
3 |
p. A219-
1 p.
|
artikel
|
| 317 |
PDB71 EVALUATION OF ECONOMIC OUTCOMES. ADHERENCE, AND GLYCEMIC CONTROL FOR DIABETIC PATIENTS IN A PHARMACIST-RUN MEDICATION MANAGEMENT PROGRAM
|
Hanson, KA
|
|
2008
|
11 |
3 |
p. A238-
1 p.
|
artikel
|
| 318 |
PDB7 EVALUATION OF INSULIN CONTAINING ANTI-DIABETIC REGIMENS IN HIGH-RISK CARDIOVASCULAR PATIENTS WITH A PRE-TREATMENT AIC MEASUREMENT GREATER THAN 9%
|
Livengood, K
|
|
2008
|
11 |
3 |
p. A219-
1 p.
|
artikel
|
| 319 |
PDB1 EXENATIDE UTILIZATION AND EFFECTIVENESS IN A HEALTH PLAN POPULATION
|
Schroeder, B
|
|
2008
|
11 |
3 |
p. A218-
1 p.
|
artikel
|
| 320 |
PDB37 FACTORS ASSOCIATED WITH HEALTH CARE COSTS AMONG ELDERLY PATIENTS WITH DIABETIC NEUROPATHY
|
Boulanger, L
|
|
2008
|
11 |
3 |
p. A229-
1 p.
|
artikel
|
| 321 |
PDB39 FACTORS ASSOCIATED WITH HIGH TREATMENT CHARGES IN PATIENTS WITH DIABETIC NEUROPATHY
|
Ye, W
|
|
2008
|
11 |
3 |
p. A229-A230
nvt p.
|
artikel
|
| 322 |
PDB2 HBAIC GOAL ATTAINMENT IN RELATION TO DOSE AMONG DIABETES PATIENTS USING METFORMIN
|
Penning-van Beest, FJ
|
|
2008
|
11 |
3 |
p. A218-
1 p.
|
artikel
|
| 323 |
PDB66 HEALTH CARE UTILISATION AND EXPENDITURES ASSOCIATED WITH TREATMENTS OF DIABETES MELLITUS WITHIN THE SLOVAK REPUBLIC
|
Tesar, T
|
|
2008
|
11 |
3 |
p. A236-A237
nvt p.
|
artikel
|
| 324 |
PDB36 HEALTH SERVICE COSTS AND RESOURCE UTILIZATION AMONG MANAGED CARE ENROLLEES WITH GOUT AND RENAL DISEASE
|
Riedel, AA
|
|
2008
|
11 |
3 |
p. A228-A229
nvt p.
|
artikel
|
| 325 |
PDB70 IMPACT OF ANEMIA ON HOSPITALIZATION COSTS IN PATIENTS WITH DIABETES AND CHRONIC KIDNEY DISEASE
|
Laliberte, F
|
|
2008
|
11 |
3 |
p. A238-
1 p.
|
artikel
|
| 326 |
PDB59 IMPACT OF DOCTORS' INSTRUCTIONS ON LIFESTYLE BEHAVIORS AMONG DIABETES POPULATION IN USA
|
Guo, JD
|
|
2008
|
11 |
3 |
p. A234-
1 p.
|
artikel
|
| 327 |
PDB50 INCREASED HOSPITALIZATIONS BY CHILDREN WITH TYPE 2 DIABETES
|
Kim, SH
|
|
2008
|
11 |
3 |
p. A232-
1 p.
|
artikel
|
| 328 |
PDB49 INFLUENCE OF FAMILY STRUCTURE ON EMERGENCY ROOM UTILIZATION OF DIABETIC MOTHERS
|
Wingate, L
|
|
2008
|
11 |
3 |
p. A232-
1 p.
|
artikel
|
| 329 |
PDB77 INVOLVEMENT OF LAYVOLUNTEERS IN TRAINING ON SELF-MANAGEMENT OF PATIENTS WITH DIABETES IN THE UNITED KINGDOM-COST IMPLICATIONS
|
Wex, J
|
|
2008
|
11 |
3 |
p. A240-
1 p.
|
artikel
|
| 330 |
PDB24 LONG-TERM CLINICAL AND COST OUTCOMES OF TREATMENT WITH INSULIN DETEMIR PLUS INSULIN ASPART IN TYPE I DIABETES PATIENTS IN THE CZECH SETTING; DATA FROM THE PREDICTIVE STUDY
|
Clegg, JP
|
|
2008
|
11 |
3 |
p. A225-
1 p.
|
artikel
|
| 331 |
PDB48 LOST PRODUCTIVITY ASSOCIATED WITH TYPE I AND TYPE 2 DIABETES IN A COMMERCIALLY-INSURED POPULATION
|
Durden, ED
|
|
2008
|
11 |
3 |
p. A231-
1 p.
|
artikel
|
| 332 |
PDB78 MEASURING THE IMPACT OF AN EDUCATIONAL PROGRAM ON PHYSICIAN PRACTICE PATTERNS: EXPERTMD(tm) CV DIABETES
|
Nemis-White, J
|
|
2008
|
11 |
3 |
p. A240-
1 p.
|
artikel
|
| 333 |
PDB41 MEDICAL CARE OF PATIENTS WITH DIABETIC NEUROPATHY: IMPACT OF TYPE I DIABETES AND PRESENCE OF OTHER DIABETES-RELATED COMPLICATIONS
|
Zhao, Y
|
|
2008
|
11 |
3 |
p. A230-
1 p.
|
artikel
|
| 334 |
PDB73 NON-INJECTABLE INSULIN-TO PAY OR NOT TO PAY?
|
Piwko, C
|
|
2008
|
11 |
3 |
p. A239-
1 p.
|
artikel
|
| 335 |
PDB10 OBESITY IS MORE PREVALENT AMONG ABORIGINALS WITH DIABETES AS COMPARED TO ALL CANADIANS WITH DIABETES
|
Beard, K
|
|
2008
|
11 |
3 |
p. A220-
1 p.
|
artikel
|
| 336 |
PDB29 PHARMACOECONOMIC EVALUATION OF CABERGOLINE FOR THE MANAGEMENT OF HYPERPROLACTINEMIA CAUSED BY HYPOPHYSEAL MICROADENOMA IN MEXICO
|
Guillen-González, M
|
|
2008
|
11 |
3 |
p. A226-
1 p.
|
artikel
|
| 337 |
PDB64 PHYSICIAN PRACTICE SPECIALTY AND TYPES OF ANTI-DIABETIC TREATMENTS FOR PATIENTS WITH TYPE 2 DIABETES: ARE THEY ASSOCIATED?-A LARGE NATIONAL OBSERVATIONAL STUDY IN A MANAGED CARE SETTING
|
Sun, P
|
|
2008
|
11 |
3 |
p. A236-
1 p.
|
artikel
|
| 338 |
PDB13 PREDICTING INPATIENT HOSPITALIZATION RISKS FOR MEDICAID DIABETES PATIENTS
|
Zeng, F
|
|
2008
|
11 |
3 |
p. A221-
1 p.
|
artikel
|
| 339 |
PDB61 PREDICTORS OF INSULIN DELIVERY SYSTEM USE IN PATIENTS WITH TYPE 2 DIABETES
|
Molife, C
|
|
2008
|
11 |
3 |
p. A235-
1 p.
|
artikel
|
| 340 |
PDB56 PREFERENCES FOR ORAL ANTIDIABETIC AGENTS AMONG PEOPLE WITH TYPE 2 DIABETES
|
Hauber, AB
|
|
2008
|
11 |
3 |
p. A233-
1 p.
|
artikel
|
| 341 |
PDB75 PRESCRIBING PATTERN AND PREDICTORS ASSOCIATED WITH THE USE OF HYPOGLYCAEMIC DRUGS: A CROSS-SECTIONAL STUDY IN ITALIAN GENERAL PRACTICE
|
Alacqua, M
|
|
2008
|
11 |
3 |
p. A239-
1 p.
|
artikel
|
| 342 |
PDB11 PREVALENCE OF AND RISK FACTORS FOR HOSPITALIZATIONS IN PATIENTS WITH TYPE 2 DIABETES IN SOUTH KOREA
|
Kim, CM
|
|
2008
|
11 |
3 |
p. A220-A221
nvt p.
|
artikel
|
| 343 |
PDB38 PREVALENCE OF OTHER DIABETES-ASSOCIATED COMPLICATIONS AND ITS IMPACT ON HEALTH CARE CHARGES AMONG PATIENTS WITH DIABETIC NEUROPATHY
|
Zhao, Y
|
|
2008
|
11 |
3 |
p. A229-
1 p.
|
artikel
|
| 344 |
PDB76 PROFILING PHYSICIAN PRESCRIPTION BEHAVIORWITH CANONICAL CORRESPONDENCE ANALYSIS
|
Sun, P
|
|
2008
|
11 |
3 |
p. A239-A240
nvt p.
|
artikel
|
| 345 |
PDB80 REDUCING COSTS AND IMPROVING OUTCOMES BY REDUCING MEDICAL ERRORS: A COMPARISON OF EXPERTS WITH PROBABLISTIC LABORATORY ERROR DETECTION IN A POPULATION OF PRE-DIABETICS
|
Doctor, JN
|
|
2008
|
11 |
3 |
p. A241-
1 p.
|
artikel
|
| 346 |
PDB52 SYSTEMATIC REVIEW OF ADHERENCE, COMPLIANCE AND QUALITY OF LIFE IN TYPE 2 DIABETES PATIENTS
|
Kumar, J
|
|
2008
|
11 |
3 |
p. A232-A233
nvt p.
|
artikel
|
| 347 |
PDB16 THE BUDGET IMPACT OFAPIDRA(r) (INSULIN GLULISINE) REIMBURSEMENT IN POLAND
|
Walczak, J
|
|
2008
|
11 |
3 |
p. A222-
1 p.
|
artikel
|
| 348 |
PDB27 THE COST-EFFECTIVENESS OF INSULIN GLULISINE IN TYPE 2 DIABETES IN POLAND
|
Walczak, J
|
|
2008
|
11 |
3 |
p. A226-
1 p.
|
artikel
|
| 349 |
PDB72 THE NEED FOR EARLIER INSULIN INITIATION AND INTENSIFICATION AMONG PATIENTS WITH TYPE 2 DIABETES: EVIDENCE FROM HEALTH CLAIMS AND LABORATORY DATABASE
|
Sarpong, EM
|
|
2008
|
11 |
3 |
p. A238-A239
nvt p.
|
artikel
|
| 350 |
PDB9 TYPE 2 DIABETES IN YOUTH: 2002 AND 2006 PREVALENCE AND OBESITY IN A PRIMARY CARE SETTING
|
McAdam-Marx, C
|
|
2008
|
11 |
3 |
p. A220-
1 p.
|
artikel
|
| 351 |
PDB79 USING DECISION ANALYTIC METHODS TO REDUCE COSTLY LABORATORY ERRORS: ATEST OF A PROBABILISTIC AUTOVERIFICATION SYSTEM
|
Doctor, JN
|
|
2008
|
11 |
3 |
p. A240-A241
nvt p.
|
artikel
|
| 352 |
PGI4 A BRAZILIAN CROSS SECTIONAL STUDY TO EVALUATE HOSPITALIZATION AMONG MODERATE AND SEVERE CROHN'S DISEASE PATIENTS
|
Araujo, G
|
|
2008
|
11 |
3 |
p. A84-A85
nvt p.
|
artikel
|
| 353 |
PGI21 A COMPARISON OF TEST-RETEST RELIABILITY OF SELF-REPORTED SF-36, WHOQOL, AND EQ-5D QUESTIONNAIRES BASED ON DIFFERENT ADMINISTRATION APPROACHES
|
Lin, YJ
|
|
2008
|
11 |
3 |
p. A90-
1 p.
|
artikel
|
| 354 |
PGI17 ADHERENCE TO INFLIXIMAB MAINTENANCE THERAPY AND ITS IMPACT ON HOSPITALIZATION OF PATIENTS WITH CROHN'S DISEASE
|
Kane, SV
|
|
2008
|
11 |
3 |
p. A88-A89
nvt p.
|
artikel
|
| 355 |
PGI7 COST EFFECTIVENESS ANALYSIS OF HELICOBACTER PYLORI SCREENING IN PREVENTION OF GASTRIC CANCER IN CHINESE
|
Xie, F
|
|
2008
|
11 |
3 |
p. A85-A86
nvt p.
|
artikel
|
| 356 |
PGI5 COST-EFFECTIVENESS OF NATALIZUMAB IN CROHN'S DISEASE PATIENTS WHO HAVE FAILED ANTI-TNF ALPHA THERAPY
|
Panjabi, S
|
|
2008
|
11 |
3 |
p. A85-
1 p.
|
artikel
|
| 357 |
PGI14 COST-EFFECTIVENESS OF PROTON PUMP INHIBITORS FOR PATIENTS WITH GASTROESOPHAGEAL REFLUX DISEASE: SHOULD EMERGING SAFETY CONCERNS AFFECT THERAPEUTIC DECISION-MAKING?
|
Ryan, PB
|
|
2008
|
11 |
3 |
p. A87-A88
nvt p.
|
artikel
|
| 358 |
PGI6 COST-EFFECTIVENESS RECOMBINANT FACTORVIIA USE IN ORTHOTOPIC LIVER TRANSPLANT
|
Schoenhaus, R
|
|
2008
|
11 |
3 |
p. A85-
1 p.
|
artikel
|
| 359 |
PGI3 COST OF PATIENT CARE IN PATIENTS WITH ULCERATIVE COLITIS IN BRAZIL: PUBLIC HEALTH PERSPECTIVE
|
Araujo, G
|
|
2008
|
11 |
3 |
p. A84-
1 p.
|
artikel
|
| 360 |
PGI25 COSTS OF A PRIOR AUTHORIZATION ON LUBIPROSTONE FOR ELDERLY (AGE > 65) PATIENTS WITH CHRONIC CONSTIPATION IN A MEDICARE PART D POPULATION
|
Lobo, F
|
|
2008
|
11 |
3 |
p. A91-
1 p.
|
artikel
|
| 361 |
PGI9 DEVELOPMENT OF A CLAIMS-BASED MARKOV MODEL FOR CROHN'S DISEASE
|
Malone, DC
|
|
2008
|
11 |
3 |
p. A86-
1 p.
|
artikel
|
| 362 |
PGI19 DEVELOPMENT OF AN HIV-RELATED, DIARRHEA IMPACT, PATIENT REPORTED OUTCOME (PRO) QUESTIONNAIRE
|
Ernst, J
|
|
2008
|
11 |
3 |
p. A89-
1 p.
|
artikel
|
| 363 |
PGI11 DIRECT COST SIMILARITIES BY POINT OF SERVICE FOR PERSONS WITH CONSTIPATION OR IRRITABLE BOWEL SYNDROME PLUS CONSTIPATION IN THE SIX MONTHS BEFORE AND AFTER DIAGNOSIS: AN EMPLOYER PERSPECTIVE
|
Kleinman, NL
|
|
2008
|
11 |
3 |
p. A86-A87
nvt p.
|
artikel
|
| 364 |
PGI13 DIRECT ECONOMIC BURDEN OF CHRONIC HEPATITIS C VIRUS IN A LARGE MANAGED CARE POPULATION
|
Davis, KL
|
|
2008
|
11 |
3 |
p. A87-
1 p.
|
artikel
|
| 365 |
PGI16 DISPARITIES IN MEDICATION UTILIZATION AND COMPLIANCE FOR GASTRO-ESOPHAGEAL REFLUX DISEASE: A POPULATION-BASED STUDY
|
Yuen, EJ
|
|
2008
|
11 |
3 |
p. A88-
1 p.
|
artikel
|
| 366 |
PGI10 DOES THE DOSING FREQUENCY OF PROTON PUMP INHIBITORS (PPIS) AFFECT SUBSEQUENT RESOURCE UTILIZATION AND COSTS AMONG PATIENTS DIAGNOSED WITH GASTROESOPHAGEAL REFLUX DISEASE (GERD)?
|
Boulanger, L
|
|
2008
|
11 |
3 |
p. A86-
1 p.
|
artikel
|
| 367 |
PGI15 ECONOMIC EVALUATION OF PROTON PUMP INHIBITORS, RELATIVE TO ALTERNATIVE GASTROINTESTINAL PROPHYLAXIS AGENTS, FOR PREVENTION OF Gl COMPLICATIONS IN ELDERLY PATIENTS TAKING NON-SELECTIVE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSNSAIDS)
|
Cameron, C
|
|
2008
|
11 |
3 |
p. A88-
1 p.
|
artikel
|
| 368 |
PGI26 FINANCIAL IMPACT OF LIFTING A PRIOR AUTHORIZATION ON LUBIPROSTONE FOR CHRONIC CONSTIPATION PATIENTS IN A COMMERCIAL MANAGED CARE POPULATION (AGE < 65 YEARS)
|
Lobo, F
|
|
2008
|
11 |
3 |
p. A91-A92
nvt p.
|
artikel
|
| 369 |
PGI12 HEALTH CARE COSTS RELATED TO THE TREATMENT OF CROHN'S DISEASE
|
Tian, H
|
|
2008
|
11 |
3 |
p. A87-
1 p.
|
artikel
|
| 370 |
PGI1 HETEROGENEITY ACROSS RANDOMIZED CONTROLLED TRIALS OF PROTON-PUMP INHIBITORS IN NIGHTTIME GERD: A SYSTEMATIC REVIEW
|
Kothawala, P
|
|
2008
|
11 |
3 |
p. A83-A84
nvt p.
|
artikel
|
| 371 |
PGI2 HOSPITALIZATIONS FOR GASTROINTESTINAL EVENTS AMONG USERS OF COX 2 INHIBITORS COMPARED WITH TRADITIONAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS WITH PROTON-PUMP INHIBITORS
|
Van der Linden, MW
|
|
2008
|
11 |
3 |
p. A84-
1 p.
|
artikel
|
| 372 |
PGI28 IMPORTANT FACTORS WHEN CONSIDERING TREATMENT FOR ULCERATIVE COLITIS
|
Waters, H
|
|
2008
|
11 |
3 |
p. A92-
1 p.
|
artikel
|
| 373 |
PGI27 INFLAMMATORY BOWEL DISEASES (IBD) PATIENTS PROFILE: FACTS EXTRACTED FROM A MULTICENTER RETROSPECTIVE STUDY
|
Araujo, G
|
|
2008
|
11 |
3 |
p. A92-
1 p.
|
artikel
|
| 374 |
PGI18 LINGUISTIC VALIDATION OF THE INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE (IBDQ) IN 35 LANGUAGES
|
Muller, S
|
|
2008
|
11 |
3 |
p. A89-
1 p.
|
artikel
|
| 375 |
PGI20 PARTIAL RESPONDERS TO PPI TREATMENT; HOW DO THEY DIFFER FROM OTHER GERD PATIENTS IN TERMS OF HEALTH-RELATED QUALITY OF LIFE AND HEALTH CARE RESOURCE UTILISATION?-A DATABASE ANALYSIS
|
Toghanian, S
|
|
2008
|
11 |
3 |
p. A89-A90
nvt p.
|
artikel
|
| 376 |
PGI23 PATIENT REPORTED PREVALENCE AND SEVERITY OF CONSTIPATION IN HOSPICE PATIENTS
|
Strassels, SA
|
|
2008
|
11 |
3 |
p. A90-A91
nvt p.
|
artikel
|
| 377 |
PGI24 RACIAL, SOCIAL, AND ECONOMIC DISPARITIES IN KNOWLEDGE AND CARE SEEKING BEHAVIORS FOR GASTRO-ESOPHAGEAL REFLUX DISEASE (GERD)
|
Yuen, EJ
|
|
2008
|
11 |
3 |
p. A91-
1 p.
|
artikel
|
| 378 |
PGI22 VALIDATION OF A NOCTURNAL GASTROESOPHAGEAL REFLUX DISEASE (GERD) SYMPTOM SEVERITY AND IMPACT INSTRUMENT
|
Harding, G
|
|
2008
|
11 |
3 |
p. A90-
1 p.
|
artikel
|
| 379 |
PHC2 A COMPARISON OF COSTS ASSOCIATED WITH SPINAL SURGERIES BY CHOICE OF FIBRIN SEALANT
|
Narayan, S
|
|
2008
|
11 |
3 |
p. A241-A242
nvt p.
|
artikel
|
| 380 |
PHC1 A COST COMPARISON OF CARDIAC SURGERIES BY CHOICE OF FIBRIN SEALANT
|
Narayan, S
|
|
2008
|
11 |
3 |
p. A241-
1 p.
|
artikel
|
| 381 |
PHC10 AN ASSESSMENT OF HOSPITAL COSTS AND REIMBURSEMENT AMONG TOTAL HIP OR KNEE ARTHROPLASTY PATIENTS IN THE UNITED STATES THAT EXPERIENCE VENOUS THROMBOEMBOLISM
|
Song, X
|
|
2008
|
11 |
3 |
p. A244-
1 p.
|
artikel
|
| 382 |
PHC11 A SYSTEMATIC REVIEW OF STUDIES ON QUALITY OF LIFE IN ANIMALS
|
Poulsen Nautrup, B
|
|
2008
|
11 |
3 |
p. A244-A245
nvt p.
|
artikel
|
| 383 |
PHC4 COST-EFFECTIVENESS ANALYSIS OF THROMBOPROPHYLACTIC STRATEGIES OVER I YEARAFTER TOTAL HIP REPLACEMENT IN VETERAN PATIENTS
|
Raisch, DW
|
|
2008
|
11 |
3 |
p. A242-
1 p.
|
artikel
|
| 384 |
PHC5 COST-EFFECTIVENESS ANALYSIS OF THROMBOPROPHYLACTIC STRATEGIES OVER ONEYEAR AFTERTOTAL KNEE REPLACEMENT IN VETERAN PATIENTS
|
Campbell, HM
|
|
2008
|
11 |
3 |
p. A242-A243
nvt p.
|
artikel
|
| 385 |
PHC6 COST-EFFECTIVENESS COMPARISON OF TENSION-FREE MESH REPAIR VS. TENSION SUTURE REPAIR METHODS OF INGUINAL HERNIA IN HUNGARY
|
Plisko, R
|
|
2008
|
11 |
3 |
p. A243-
1 p.
|
artikel
|
| 386 |
PHC7 COST-EFFECTIVENESS COMPARISON OF TENSION-FREE MESH REPAIR VS. TENSION SUTURE REPAIR METHODS OF INGUINAL HERNIA IN POLAND
|
Plisko, R
|
|
2008
|
11 |
3 |
p. A243-
1 p.
|
artikel
|
| 387 |
PHC8 COST-EFFECTIVENESS COMPARISON OF TENSION-FREE MESH REPAIR VS. TENSION SUTURE REPAIR METHODS OF INGUINAL HERNIA IN SLOVAKIA
|
Plisko, R
|
|
2008
|
11 |
3 |
p. A243-A244
nvt p.
|
artikel
|
| 388 |
PHC3 COST-EFFECTIVENESS MODELING OF DENTAL IMPLANT 1ST LINE STRATEGY VERSUS BRIDGE
|
Beresniak, A
|
|
2008
|
11 |
3 |
p. A242-
1 p.
|
artikel
|
| 389 |
PHC12 STARR PROCEDURE FOR OBSTRUCTED DEFAECATION SYNDROME (ODS): 12-MONTH FOLLOW-UP
|
Ribaric, G
|
|
2008
|
11 |
3 |
p. A245-
1 p.
|
artikel
|
| 390 |
PHC9 THE POTENTIAL SAVINGS IN OPERATING ROOM TIME ASSOCIATED WITH THE USE OF SUGAMMADEXTO REVERSE SELECTED NEUROMUSCULAR BLOCKING AGENTS: FINDINGS FROM A HOSPITAL EFFICIENCY MODEL
|
Zhang, B
|
|
2008
|
11 |
3 |
p. A244-
1 p.
|
artikel
|
| 391 |
PHP5 ADHERENCE AND SWITCHING WITH DRUGS USED FOR THE PROPHYLAXIS OF ORGAN REJECTION
|
Varasteh, LT
|
|
2008
|
11 |
3 |
p. A30-
1 p.
|
artikel
|
| 392 |
PHP2 ADHERENCE TO EVIDENCE-BASED GUIDELINES AND MEDICATION COMPLIANCE FOR MULTIPLE CHRONIC DISEASES IN A MANAGED CARE DATABASE
|
Burch, SP
|
|
2008
|
11 |
3 |
p. A29-
1 p.
|
artikel
|
| 393 |
PHP76 ALBERTA'S HEALTH SYSTEM PERFORMANCES BALANCED SCORECARD STUDY
|
Thanh, NX
|
|
2008
|
11 |
3 |
p. A52-
1 p.
|
artikel
|
| 394 |
PHP80 ANALYSIS OF FDA WARNING LETTERS AND NOTICES TO MANUFACTURERS OF PHARMACEUTICALS CONCERNING HEALTH OUTCOMES-RELATED PROMOTIONAL CLAIMS VIOLATIONS
|
Kamal, KM
|
|
2008
|
11 |
3 |
p. A53-
1 p.
|
artikel
|
| 395 |
PHP40 ANALYZING INEQUITY IN HEALTH CARE UTILIZATION BY THE US POPULATION
|
Kawatkar, AA
|
|
2008
|
11 |
3 |
p. A40-A41
nvt p.
|
artikel
|
| 396 |
PHP38 A QUALITATIVE REVIEW OF OFF-LABEL USES OF INTRAVENOUS IMMUNGLOBULIN
|
Leong, H
|
|
2008
|
11 |
3 |
p. A40-
1 p.
|
artikel
|
| 397 |
PHP47 ASSESSMENT OF NATIONAL MEDICARE PART D ESTIMATED ANNUAL COSTS FOR 2007 AND 2008 USING A PATIENT COHORT
|
Walberg, MR
|
|
2008
|
11 |
3 |
p. A42-A43
nvt p.
|
artikel
|
| 398 |
PHP12 ASSOCIATION BETWEEN DIRECT-TO-CONSUMER ADVERTISING (DTCA) AND DRUG UTILIZATION INTHE U.S. MEDICAID MARKET FOR SELECTED DRUG CLASSES
|
Sheridan, J
|
|
2008
|
11 |
3 |
p. A32-
1 p.
|
artikel
|
| 399 |
PHP50 A TYPOLOGY OF AFRICAN AMERICAN COMPLEMENTARY AND ALTERNATIVE MEDICINE (CAM) USE AND ITS CORRELATES FROM THE ANDERSEN HEALTH CARE UTILIZATION MODEL
|
Bohman, TM
|
|
2008
|
11 |
3 |
p. A43-A44
nvt p.
|
artikel
|
| 400 |
PHP52 CHANGES IN PHARMACIST-PROVIDED MEDICATION THERAPY MANAGEMENT SERVICES: ANALYSIS OF ONE INNOVATIVE COMPANYS MTM SERVICE CLAIMS OVERTIME
|
Barnett, MJ
|
|
2008
|
11 |
3 |
p. A44-
1 p.
|
artikel
|
| 401 |
PHP68 CHARACTERISTICS OF RISK-SHARING SCHEMES IN EUROPE
|
Muston, D
|
|
2008
|
11 |
3 |
p. A49-
1 p.
|
artikel
|
| 402 |
PHP35 CHARACTERIZING PHARMACY AND MEDICAL CLAIMS FOR A PRIVATE INSURANCE POLYPHARMACY POPULATION
|
Bresnahan, BW
|
|
2008
|
11 |
3 |
p. A39-
1 p.
|
artikel
|
| 403 |
PHP21 CLINICALLY SIGNIFICANT DRUG-DRUG INTERACTION PROFILES IN THE ELDERLY—A CALIFORNIA QUALITY IMPROVEMENT ORGANIZATION (QIO) COLLABORATIVE EXPERIENCE
|
Kwok, P
|
|
2008
|
11 |
3 |
p. A35-
1 p.
|
artikel
|
| 404 |
PHP45 COMMON DRUG REVIEW (CDR) RECOMMENDATIONS: DOES COST-EFFECTIVENESS MATTER?
|
Rocchi, A
|
|
2008
|
11 |
3 |
p. A42-
1 p.
|
artikel
|
| 405 |
PHP56 COMPARATIVE ANALYSIS OF THE ACCESS TO PHARMACEUTICALS IN SELECTED EAST EUROPEAN COUNTRIES
|
Lakic, D
|
|
2008
|
11 |
3 |
p. A45-A46
nvt p.
|
artikel
|
| 406 |
PHP51 COMPARISONS OF RELATIVE RISKS OF SERIOUS COMORBIDITIES AMONG EMPLOYEES WITH AND WITHOUT INSOMNIA, GERD, HEPATITIS C, MULTIPLE SCLEROSIS, AND CHRONIC CONSTIPATION
|
Brook, RA
|
|
2008
|
11 |
3 |
p. A44-
1 p.
|
artikel
|
| 407 |
PHP73 CONSUMPTION PATTERNS AND ECONOMIC BURDEN OF DRUGS IN FORTALEZA, BRAZIL
|
Barroso, M
|
|
2008
|
11 |
3 |
p. A51-
1 p.
|
artikel
|
| 408 |
PHP13 CONTROLLED SUBSTANCEWASTE IN HOME HOSPICE SETTINGS
|
Maxwell, T
|
|
2008
|
11 |
3 |
p. A32-A33
nvt p.
|
artikel
|
| 409 |
PHP30 COST-EFFECTIVENESS ANALYSIS AND RETURN ON INVESTMENT OF HIGH COST PATIENTS MANAGEMENT PROGRAMWITHIN A PRIVATE HEALTH CARE PLAN IN BRAZIL
|
Abicalaffe, CL
|
|
2008
|
11 |
3 |
p. A37-A38
nvt p.
|
artikel
|
| 410 |
PHP10 CREATION OF A RISK RATING SYSTEMTO COMMUNICATE DRUG SAFETY INFORMATIONTO CONSUMERS
|
Cascade, EF
|
|
2008
|
11 |
3 |
p. A31-A32
nvt p.
|
artikel
|
| 411 |
PHP55 DEVELOPING A PRACTICE -BASED RESEARCH NETWORK (PBRN)TO EVALUATE MULTI-CENTER PHARMACIST-CONDUCTED MEDICATION THERAPY MANAGEMENT PROGRAMS (MTMPS) USING THE ECHO MODEL
|
Coletto, M
|
|
2008
|
11 |
3 |
p. A45-
1 p.
|
artikel
|
| 412 |
PHP60 DEVELOPMENT OF A DRUG INVENTORY MANAGEMENT MODEL FOR THE STATE HOUSE MEDICAL CENTRE, ABUJA, NIGERIA
|
Eti-ukwu, A
|
|
2008
|
11 |
3 |
p. A47-
1 p.
|
artikel
|
| 413 |
PHP31 DRUG PROXIES FOR IDENTIFYING SPECIFIC DIAGNOSES IN MEDICARE PART D
|
Livengood, KB
|
|
2008
|
11 |
3 |
p. A38-
1 p.
|
artikel
|
| 414 |
PHP59 DRUG THERAPY PROBLEMS: DOES PHARMACIST'S INTERVENTION SAVE COST?
|
Udezi, WA
|
|
2008
|
11 |
3 |
p. A46-A47
nvt p.
|
artikel
|
| 415 |
PHP58 ECONOMIC-BASED OUTCOMES ASSESSMENT OF PHARMACEUTICAL CARE IN A UNIVERSITY HOSPITAL MEDICAL INTENSIVE CARE UNIT IN TAIWAN
|
Huang, CY
|
|
2008
|
11 |
3 |
p. A46-
1 p.
|
artikel
|
| 416 |
PHP1 EFFECT OF PRESCRIPTION COPAY ON MEDICATION UTILIZATION
|
Gause, D
|
|
2008
|
11 |
3 |
p. A29-
1 p.
|
artikel
|
| 417 |
PHP19 EFFECT OF PRESCRIPTION DRUG COVERAGE ON HEALTH AMONG CHRONICALLY ILL ELDERLY POPULATION
|
Khan, N
|
|
2008
|
11 |
3 |
p. A34-
1 p.
|
artikel
|
| 418 |
PHP27 ESTIMATION AND COMPARISON OF ORTHOTIC BRACE COSTS WITH REIMBURSEMENT TARIFFS AND RETAIL PRICES IN BELGIUM
|
Simoens, S
|
|
2008
|
11 |
3 |
p. A36-A37
nvt p.
|
artikel
|
| 419 |
PHP14 ESTIMATION OF USAGE OF NEW DRUG AFTER REIMBURSEMENT FOR BUDGET IMPACT ANALYSIS
|
Park, SE
|
|
2008
|
11 |
3 |
p. A33-
1 p.
|
artikel
|
| 420 |
PHP11 ETHNIC DISPARITIES IN HOSPITAL DISCHARGES AGAINST MEDICAL ADVICE AMONG CARDIOVASCULAR DISEASE PATIENTS:THE ROLE OF HOSPITAL QUALITY
|
Onukwugha, E
|
|
2008
|
11 |
3 |
p. A32-
1 p.
|
artikel
|
| 421 |
PHP15 EVALUATING THE USE OF PROVISIONAL PATENTS BYTHE PHARMACEUTICAL INDUSTRY:THE EXPERIENCE OF THE UNITED STATES
|
Beyer, AP
|
|
2008
|
11 |
3 |
p. A33-
1 p.
|
artikel
|
| 422 |
PHP66 EVALUATION OF INDIRECT COMPARISONS USED FOR REIMBURSEMENT DECISIONS: LESSONS FROM THE COMMON DRUG REVIEW
|
Vicente, C
|
|
2008
|
11 |
3 |
p. A49-
1 p.
|
artikel
|
| 423 |
PHP77 EVALUATION OF THE IMPACT OF PATIENT SAFETY ACTIVITIES ON THE NUMBER OF VOLUNTARY INCIDENT REPORTS AT TEACHING HOSPITALS IN JAPAN
|
Fukuda, H
|
|
2008
|
11 |
3 |
p. A52-
1 p.
|
artikel
|
| 424 |
PHP57 FACTOR ANALYSIS OF PHARMACISTS' PERCEIVED BARRIERS TO PROVISION OF MEDICATION THERAPY MANAGEMENT SERVICES (MTMS) IN WEST VIRGINIA
|
Blake, KB
|
|
2008
|
11 |
3 |
p. A46-
1 p.
|
artikel
|
| 425 |
PHP49 FRAMEWORK AND METHODOLOGYTO IDENTIFY AND ASSESS PHARMACIST-SENSITIVE OUTCOMES IN COLLABORATIVE MEDICATION MANAGEMENT
|
Bajcar, J
|
|
2008
|
11 |
3 |
p. A43-
1 p.
|
artikel
|
| 426 |
PHP72 GENETIC TESTING FOR WARFARIN INITIATION: A COST-EFFECTIVENESS ANALYSIS BASED ON CURRENT EVIDENCE
|
Meckley, LM
|
|
2008
|
11 |
3 |
p. A51-
1 p.
|
artikel
|
| 427 |
PHP33 HERB/DIETARY SUPPLEMENT AND PRESCRIPTION DRUG USE TRENDS AMONG US ADULTS, 1999-2004
|
Lin, HW
|
|
2008
|
11 |
3 |
p. A38-
1 p.
|
artikel
|
| 428 |
PHP62 HOW EVIDENCE-BASED AND TIMELY ARE MEDICARE COVERAGE DECISIONS FOR NEWTECHNOLOGIES: AN EMPIRICAL ANALYSIS, 1999-2007
|
Kamae, M
|
|
2008
|
11 |
3 |
p. A47-A48
nvt p.
|
artikel
|
| 429 |
PHP17 HOW MANDATORY PRICE REDUCTION OF REIMBURSED PHARMACEUTICALS COULD RESULT IN INCREASED PHARMACEUTICAL EXPENDITURE?
|
Bacskai, M
|
|
2008
|
11 |
3 |
p. A34-
1 p.
|
artikel
|
| 430 |
PHP46 IMPACT OF A DRUG POLICY ON AVAILABILITY AND DRUG COST CONTAINMENT IN A TERTIARY CARE HOSPITAL: I0YEARS OF EXPERIENCE
|
Sharma, S
|
|
2008
|
11 |
3 |
p. A42-
1 p.
|
artikel
|
| 431 |
PHP16 IMPROVING HEALTH TECHNOLOGY APPRAISAL AND DECISION-MAKING: WHAT HAS THE BRITISH PARLIAMENT'S INQUIRY OF NICE TAUGHT US?
|
Cross, JT
|
|
2008
|
11 |
3 |
p. A33-A34
nvt p.
|
artikel
|
| 432 |
PHP3 IS THERE AN ACCEPTABLE LEVEL OF MEDICATION ADHERENCE? A REVIEW OF RETROSPECTIVE ADHERENCE EVALUATION STUDIES
|
Visaria, J
|
|
2008
|
11 |
3 |
p. A29-A30
nvt p.
|
artikel
|
| 433 |
PHP22 MEDICARE SPENDING GROWTH FOR DIAGNOSTIC IMAGING AND ACCESS TO CARE
|
Lee, DW
|
|
2008
|
11 |
3 |
p. A35-
1 p.
|
artikel
|
| 434 |
PHP41 PATIENT RACE AND MEDICATION CHOICE FOR HYPERCHOLESTEROLEMIA, HYPERTENSION, AND DIABETES
|
Rathore, SS
|
|
2008
|
11 |
3 |
p. A41-
1 p.
|
artikel
|
| 435 |
PHP61 PAY-FOR-PERFORMANCE PROGRAMME FOR BRAZILIAN PRIVATE HEALTH PLAN: HOWTO IMPLEMENT AND MEASURE
|
Abicalaffe, CL
|
|
2008
|
11 |
3 |
p. A47-
1 p.
|
artikel
|
| 436 |
PHP71 PHARMACY STUDENTS' ABILITYTO RECOGNIZE DRUG-DRUG INTERACTIONS (DDIS)
|
Saverno, K
|
|
2008
|
11 |
3 |
p. A50-
1 p.
|
artikel
|
| 437 |
PHP79 PHYSICIAN QUALITY MEASUREMENT IN THE HEALTH PLAN PPO SETTING:THE IMPORTANCE OF SCORING ALGORITHMS
|
Kang, N
|
|
2008
|
11 |
3 |
p. A53-
1 p.
|
artikel
|
| 438 |
PHP70 PHYSICIANS' KNOWLEDGE OF LABELED DRUG INDICATIONS AND ATTITUDES REGARDING OFF-LABEL USE: RESULTS OF A NATIONAL SURVEY OF GENERAL INTERNISTS AND PSYCHIATRISTS
|
Alexander, GC
|
|
2008
|
11 |
3 |
p. A50-
1 p.
|
artikel
|
| 439 |
PHP42 PHYSICIANS' VIEWS REGARDING PRESCRIPTION DRUG ACCESS UNDER MEDICARE PART D
|
Epstein, AJ
|
|
2008
|
11 |
3 |
p. A41-
1 p.
|
artikel
|
| 440 |
PHP43 PHYSICIANS' VIEWS REGARDING THE IMPACT OF MEDICARE PART D DRUG COVERAGE FOR DUAL-ELIGIBLE PATIENTS
|
Epstein, AJ
|
|
2008
|
11 |
3 |
p. A41-A42
nvt p.
|
artikel
|
| 441 |
PHP20 PREDICTORS OF ENROLLMENT IN MEDICARE PART D:THE EXPERIENCE OF MEDICARE DRUG DEMONSTRATION PARTICIPANTS WITH RHEUMATOID ARTHRITIS AND MULTIPLE SCLEROSIS
|
Polinski, JM
|
|
2008
|
11 |
3 |
p. A34-A35
nvt p.
|
artikel
|
| 442 |
PHP6 PREDICTORS OF NONCOMPLIANT COST-CUTTING BEHAVIORS AMONG ADULTS IN THE UNITED STATES
|
Kannan, H
|
|
2008
|
11 |
3 |
p. A30-A31
nvt p.
|
artikel
|
| 443 |
PHP54 PREVALENCE OF CONDITIONS IN THE US EMPLOYER-INSURED POPULATION
|
Hansen, LG
|
|
2008
|
11 |
3 |
p. A45-
1 p.
|
artikel
|
| 444 |
PHP34 PRINCIPAL COMPONENTS ANALYSIS OF DRUG UTILIZATION AND EXPENDITURETRENDS FOR MAJORTHERAPEUTIC CLASSES IN U.S. MEDICAID PROGRAMS
|
Jing, Y
|
|
2008
|
11 |
3 |
p. A38-A39
nvt p.
|
artikel
|
| 445 |
PHP81 PROGRESSIVE LICENSING AND VALUE FOR MONEY: USE OF RESPONDERANALYSIS IN ECONOMIC EVALUATION
|
McDonald, HP
|
|
2008
|
11 |
3 |
p. A53-A54
nvt p.
|
artikel
|
| 446 |
PHP82 RECENT TRENDS IN THE INCLUSION OF PATIENT-REPORTED OUTCOME (PRO) DATA IN APPROVED DRUGS LABELING BY FDA AND EMEA
|
Caron, M
|
|
2008
|
11 |
3 |
p. A54-
1 p.
|
artikel
|
| 447 |
PHP36 RELATIONSHIP OF DOCTOR SHOPPING AND POLYPHARMACY:A NATIONWIDE STUDY IN TAIWAN
|
Chou, LF
|
|
2008
|
11 |
3 |
p. A39-
1 p.
|
artikel
|
| 448 |
PHP26 RESEARCH AND MARKETING COMPLEMENTARITY IN PHARMACEUTICAL FIRMS: EMPIRICAL EVIDENCE
|
Snyder, S
|
|
2008
|
11 |
3 |
p. A36-
1 p.
|
artikel
|
| 449 |
PHP75 SATISFACTION WITH MEDICATION: PRELIMINARY RESULTS FROM A NOVEL PATIENT REGISTRYTRACKING SATISFACTION WITH DIFFERENT CHRONIC MEDICATIONS
|
Bharmal, M
|
|
2008
|
11 |
3 |
p. A52-
1 p.
|
artikel
|
| 450 |
PHP63 SEGMENTED REGRESSION ANALYSIS OF INTERRUPTED TIME SERIES PRESCRIPTION GROSS MARGIN TRENDS FOR INDEPENDENT PHARMACIES BEFORE AND AFTER MEDICARE PART D
|
Richards, KM
|
|
2008
|
11 |
3 |
p. A48-
1 p.
|
artikel
|
| 451 |
PHP44 SOURCES OF MEDICAL INFORMATION AND DEGREE OF TRUST PLACED IN THEM BY RUSSIAN DOCTORS
|
Zaytsev, A
|
|
2008
|
11 |
3 |
p. A42-
1 p.
|
artikel
|
| 452 |
PHP23 SPECIALTY BIOLOGIC DRUG COVERAGE UNDER MEDICARE PART D:THE EXPERIENCE OFVULNERABLE BENEFICIARIES WITH RHEUMATOID ARTHRITIS (RA) AND MULTIPLE SCLEROSIS (MS)
|
Polinski, JM
|
|
2008
|
11 |
3 |
p. A35-
1 p.
|
artikel
|
| 453 |
PHP78 STABILITY OF PHYSICIAN PERFORMANCE ON PAY-FOR-PERFORMANCE PROCESS MEASURES OVERTIME: EFFECT OF PATIENT DENOMINATOR THRESHOLDS
|
Marehbian, J
|
|
2008
|
11 |
3 |
p. A53-
1 p.
|
artikel
|
| 454 |
PHP29 STAKEHOLDER PERSPECTIVES ON ECONOMIC EVALUATION: THE CASE OF NICE
|
Sorenson, C
|
|
2008
|
11 |
3 |
p. A37-
1 p.
|
artikel
|
| 455 |
PHP74 THE CADTH GUIDELINES FORTHE ECONOMIC EVALUATION OF HEALTH TECHNOLOGIES: DO CURRENT CANADIAN ECONOMIC EVALUATIONS PASS THE TEST?
|
Lim, ME
|
|
2008
|
11 |
3 |
p. A51-
1 p.
|
artikel
|
| 456 |
PHP64 THE EFFECT OF THE PERFORMANCE VOLUME LIMIT (PVL) ON THE DRG FINANCING OF THE HUNGARIAN HOSPITALS
|
Boncz, I
|
|
2008
|
11 |
3 |
p. A48-
1 p.
|
artikel
|
| 457 |
PHP8 THE EFFECTS OF NONCOMPLIANT COST-CUTTING BEHAVIORS ON INDIRECT COSTS AMONG ADULTS IN THE UNITED STATES
|
Bolge, SC
|
|
2008
|
11 |
3 |
p. A31-
1 p.
|
artikel
|
| 458 |
PHP7 THE EFFECTS OF NONCOMPLIANT COST-CUTTING BEHAVIORS ON OUTCOMES AMONG ADULTS INTHE UNITED STATES
|
Bolge, SC
|
|
2008
|
11 |
3 |
p. A31-
1 p.
|
artikel
|
| 459 |
PHP37 THE EPIDEMIOLOGY AND OUTCOMES OF PATIENTS BY SERUM DIGOXIN LEVELS DURING HOSPITALIZATION
|
Gupta, V
|
|
2008
|
11 |
3 |
p. A39-A40
nvt p.
|
artikel
|
| 460 |
PHP39 THE EPIDEMIOLOGY AND OUTCOMES OF PATIENTS TREATED WITH HEPARIN DURING HOSPITALIZATION
|
Gupta, V
|
|
2008
|
11 |
3 |
p. A40-
1 p.
|
artikel
|
| 461 |
PHP24 THE IMPACT OF BENEFIT PLAN DESIGN ON COST AND HEALTH OUTCOMES
|
Chin, W
|
|
2008
|
11 |
3 |
p. A35-A36
nvt p.
|
artikel
|
| 462 |
PHP4 THE IMPACT OF COPAYMENTS OR BRAND NAMED DRUG ON MEDICATION PERSISTENCE
|
Wu, J
|
|
2008
|
11 |
3 |
p. A30-
1 p.
|
artikel
|
| 463 |
PHP69 THE PRESCRIBING OF CHINESE HERBAL PRODUCTS IN TAIWAN:A CROSS-SECTIONAL ANALYSIS OFTHE NATIONAL HEALTH INSURANCE REIMBURSEMENT DATABASE
|
Hsieh, SC
|
|
2008
|
11 |
3 |
p. A50-
1 p.
|
artikel
|
| 464 |
PHP28 THE PROCESS OF UPDATINGTHE NATIONAL LIST OF HEALTH SERVICES IN ISRAEL: IS IT LEGITIMATE? IS IT FAIR?
|
Greenberg, D
|
|
2008
|
11 |
3 |
p. A37-
1 p.
|
artikel
|
| 465 |
PHP65 THE ROLE OF THE ACADEMY OF MANAGED CARE PHARMACY (AMCP) FORMAT IN MANAGED CARE FORMULARY AND COVERAGE DECISIONMAKING
|
Schaefer, C
|
|
2008
|
11 |
3 |
p. A48-
1 p.
|
artikel
|
| 466 |
PHP48 THE STATE OF HEALTH ECONOMICS AND PHARMACOECONOMICS EVALUATION RESEARCH IN ZIMBABWE
|
Gavaza, P
|
|
2008
|
11 |
3 |
p. A43-
1 p.
|
artikel
|
| 467 |
PHP67 THRESHOLD VALUE FOR A QALY-CORRELATION WITH DISEASE SEVERITY AND DECISION UNCERTAINTY
|
Hugosson, K
|
|
2008
|
11 |
3 |
p. A49-
1 p.
|
artikel
|
| 468 |
PHP25 TOWARD HIGH PERFORMANCE ‘PHARMACARE’ SYSTEMS: A REVIEW OF EXPERIENCES IN SEVEN COUNTRIES
|
Morgan, S
|
|
2008
|
11 |
3 |
p. A36-
1 p.
|
artikel
|
| 469 |
PHP53 TRENDS IN COMMUNITY BASED ADVERSE DRUG EVENTS IN THE UNITED STATES: 1996-2005
|
Bhanegaonkar, AJ
|
|
2008
|
11 |
3 |
p. A45-
1 p.
|
artikel
|
| 470 |
PHP9 UNITED STATES PHYSICIANS AND IN-OFFICE DRUG ADMINISTRATION:THE CONCEPT OF “INCIDENT-TO” SERVICES
|
Pierce, CA
|
|
2008
|
11 |
3 |
p. A31-
1 p.
|
artikel
|
| 471 |
PHP32 WHAT'S DRIVING PRESCRIPTION COPAYMENTS?
|
Cox, E
|
|
2008
|
11 |
3 |
p. A38-
1 p.
|
artikel
|
| 472 |
PIH13 A CONCEPTUAL FRAMEWORK TOWARD A MODIFIED REFERENCE CASE FOR DEVELOPING COUNTRIES: INCORPORATING DONOR FUNDING FLOWS IN COST-EFFECTIVENESS ANALYSIS
|
Gauvreau, CL
|
|
2008
|
11 |
3 |
p. A249-
1 p.
|
artikel
|
| 473 |
PIH24 AN ANALYSIS OF POTENTIALLY INAPPROPRIATE MEDICATION USE IN THE DUALLY ELIGIBILE MEDICARE AND MEDICAID POPULATION USING THE NEW 2003 BEERS DRUG UPDATE
|
Blackwell, SA
|
|
2008
|
11 |
3 |
p. A252-A253
nvt p.
|
artikel
|
| 474 |
PIH28 AN EXAMINATION OF LOW AVERAGE DOSE AS A QUALITY MEASURE OF THE NEED FOR ANTICOAGULATION MANAGEMENT AMONG THE ELDERLY
|
Banahan III, BF
|
|
2008
|
11 |
3 |
p. A253-
1 p.
|
artikel
|
| 475 |
PIH18 ASSESSING THE ASSOCIATION BETWEEN SCORE DIFFERENCES ON THE PREMENSTRUAL SYMPTOMS IMPACT SURVEY (PMSIS) AND HEALTH-RELATED QUALITY OF LIFE
|
Yang, M
|
|
2008
|
11 |
3 |
p. A250-A251
nvt p.
|
artikel
|
| 476 |
PIH7 BURDEN OF ILLNESS OF HYPERTENSION AMONG WOMEN USING MENOPAUSAL HORMONE THERAPY
|
Pelletier, E
|
|
2008
|
11 |
3 |
p. A247-
1 p.
|
artikel
|
| 477 |
PIH22 CARESS: THE CANADIAN REGISTRY OF SYNAGIS(®)
|
Lanctot, KL
|
|
2008
|
11 |
3 |
p. A252-
1 p.
|
artikel
|
| 478 |
PIH4 COMPARISON OF MEN AGE 21 YEARS AND OLDER WITH AND WITHOUT ERECTILE DYSFUNCTION ON CONCOMITANT PRESCRIPTION DRUG, COMORBID CONDITIONS, SMOKING STATUS AND BMI
|
Roper, MA
|
|
2008
|
11 |
3 |
p. A246-
1 p.
|
artikel
|
| 479 |
PIH2 CONTRACEPTIVE FAILURE RATES AMONG MEDICAID AND NON-MEDICAID ENROLLEES
|
Bradford, WD
|
|
2008
|
11 |
3 |
p. A245-A246
nvt p.
|
artikel
|
| 480 |
PIH9 COST-EFFECTIVENESS ANALYSIS OF CONTRACEPTIVES AVAILABLE IN UNITED STATES
|
Trussell, J
|
|
2008
|
11 |
3 |
p. A248-
1 p.
|
artikel
|
| 481 |
PIH17 COST-EFFECTIVENESS OF MAGNETIC RESONANCE-GUIDED FOCUSED ULTRASOUND SURGERY FOR TREATMENT OF UTERINE FIBROIDS
|
Zowall, H
|
|
2008
|
11 |
3 |
p. A250-
1 p.
|
artikel
|
| 482 |
PIH8 COST-EFFECTIVENESS OF ORAL AND TRANSDERMAL CONTRACEPTIVES
|
Zaliska, O
|
|
2008
|
11 |
3 |
p. A247-A248
nvt p.
|
artikel
|
| 483 |
PIH6 ECONOMIC ASSESSMENT OF SILDAFENIL FOR THE MANAGEMENT OF PATIENTS WITH ERECTILE DYSFUNCTION (ED) SECONDARYTO DIABETES MELLITUSTYPE 2 (DM2) AND HYPERTENSION IN MEXICO
|
Arreola-Ornelas, H
|
|
2008
|
11 |
3 |
p. A247-
1 p.
|
artikel
|
| 484 |
PIH14 ECONOMIC EVALUATION OF ATOSIBAN VERSUS BETA-MIMETICS IN THE TREATMENT OF PRETERM LABOUR IN GERMANY
|
Wex, J
|
|
2008
|
11 |
3 |
p. A249-
1 p.
|
artikel
|
| 485 |
PIH29 ESTIMATION OF TYPE AND NUMBER OF MEDICATION ERRORS IN LONG-TERM CARE
|
Kohaupt, I
|
|
2008
|
11 |
3 |
p. A253-A254
nvt p.
|
artikel
|
| 486 |
PIH27 GENERIC SUBSTITUTION OF WARFARIN AMONG THE ELDERLY: AN EXAMINATION OF HOSPITAL AND EMERGENCY ROOM USE
|
Banahan III, BF
|
|
2008
|
11 |
3 |
p. A253-
1 p.
|
artikel
|
| 487 |
PIH3 HOSPITALIZATIONS AND MORTALITY ASSOCIATED WITH INCIDENT POTENTIALLY INAPPROPRIATE MEDICATIONS USE AMONG ELDERLY INDIANA MEDICAID BENEFICIARIES RESIDING IN NURSING HOMES
|
Dedhiya, S
|
|
2008
|
11 |
3 |
p. A246-
1 p.
|
artikel
|
| 488 |
PIH11 IMPACT OF THE RISK SCORING MODEL ON THE COST-EFFECTIVENESS OF PALIVIZUMAB FOR RESPIRATORY SYNCYTIALVIRUS PROPHYLAXIS IN PREMATURE INFANTS WITH A GESTATIONAL AGE OF 32-35 WEEKS IN CANADA
|
Lanctot, KL
|
|
2008
|
11 |
3 |
p. A248-A249
nvt p.
|
artikel
|
| 489 |
PIH21 LITERATURE REVIEW OF DISCRETE CHOICE EXPERIMENTS TO ASSESS WOMEN'S PREFERENCES AND WILLINGNESS TO PAY FOR MATERNAL HEALTH SERVICES
|
Hancock, RL
|
|
2008
|
11 |
3 |
p. A251-A252
nvt p.
|
artikel
|
| 490 |
PIH23 PATIENT SATISFACTION WITH ERECTILE DYSFUNCTION TREATMENT: SILDENAFIL VS. FOOD SUPPLEMENTS
|
Skoupá, J
|
|
2008
|
11 |
3 |
p. A252-
1 p.
|
artikel
|
| 491 |
PIH20 PREDICTING RISK OF WORK LOSS ASSOCIATED WITH PREMENSTRUAL SYNDROME AND PREMENSTRUAL DYSPHORIC DISORDER USING MENTAL COMPONENT SUMMARY (MCS) SCORE
|
Yang, M
|
|
2008
|
11 |
3 |
p. A251-
1 p.
|
artikel
|
| 492 |
PIH19 PREDICTING RISK OF WORK LOSS ASSOCIATED WITH PREMENSTRUAL SYNDROME (PMS) AND PREMENSTRUAL DYSPHORIC DISORDER (PMDD) USING PHYSICAL COMPONENT SUMMARY (PCS) SCORE
|
Yang, M
|
|
2008
|
11 |
3 |
p. A251-
1 p.
|
artikel
|
| 493 |
PIH1 PREVENTION OF FALLS AND FALL-RELATED INJURIES IN THE COMMUNITY-DWELLING ELDERLYA REVIEW
|
Gomes, T
|
|
2008
|
11 |
3 |
p. A245-
1 p.
|
artikel
|
| 494 |
PIH30 PRIVATE HEALTH INSURANCE VS. MEDICAID COVERAGE: DISPARITIES IN PROCESS OF CARE MEASURES
|
Marehbian, J
|
|
2008
|
11 |
3 |
p. A254-
1 p.
|
artikel
|
| 495 |
PIH15 STUDENT PHARMACIST INTERVENTIONS LEAD TO COST MINIMIZATION OF MEDICARE PART D PRESCRIPTION DRUG PLAN COSTS
|
Lipton, HL
|
|
2008
|
11 |
3 |
p. A249-A250
nvt p.
|
artikel
|
| 496 |
PIH10 THE COST-EFFECTIVENESS OF ROUTINE SCREENING FOR VASA PREVIA AT 18-20 WEEKS GESTATION IN ONTARIO
|
Cipriano, LE
|
|
2008
|
11 |
3 |
p. A248-
1 p.
|
artikel
|
| 497 |
PIH16 THE DIRECT COSTS OF INJURIOUS FALLS IN SENIORS
|
Woolcottj, C
|
|
2008
|
11 |
3 |
p. A250-
1 p.
|
artikel
|
| 498 |
PIH5 THE EFFECT OF INJURY SEVERITY ON THE INCIDENCE AND RESOURCE UTILIZATION-RELATED OUTCOMES OF DEEP VEIN THROMBOSIS AMONG PEDIATRIC TRAUMA ADMISSIONS IN THE UNITED STATES
|
Candrilli, SD
|
|
2008
|
11 |
3 |
p. A246-A247
nvt p.
|
artikel
|
| 499 |
PIH25 VARIATIONS IN ANTIPSYCHOTIC THERAPY AND SHORT-TERM MORTALITY ACROSS LONG-TERM CARE HOMES
|
Bronskill, SE
|
|
2008
|
11 |
3 |
p. A253-
1 p.
|
artikel
|
| 500 |
PIN33 A DYNAMIC MODEL FOR ASSESSING THE IMPACT OF EMERGING VACCINE TECHNOLOGIES ON MEASLES DISEASE BURDEN IN DEVELOPING COUNTRIES
|
Bauch, CT
|
|
2008
|
11 |
3 |
p. A102-
1 p.
|
artikel
|
| 501 |
PIN37 AN EXAMINATION OF THE CORRELATION BETWEEN QUALITY OF PATIENT CARE AND PATIENT RACE OR SOCIAL CLASS IN INPATIENT APPENDICITIS CASES
|
Cerrito, PB
|
|
2008
|
11 |
3 |
p. A104-
1 p.
|
artikel
|
| 502 |
PIN44 ANTIBIOTIC PRESCRIBING IN THE HOSPITAL EMERGENCY DEPARTMENT
|
Cerrito, PB
|
|
2008
|
11 |
3 |
p. A106-
1 p.
|
artikel
|
| 503 |
PIN4 ANTIMICROBIAL RESISTANCE PREVALENCE OF ENTEROCOCCI FROM BOGOTA, COLOMBIA HOSPITALS 2001-2006
|
Lemos, EV
|
|
2008
|
11 |
3 |
p. A93-
1 p.
|
artikel
|
| 504 |
PIN51 A PICTURE OF DEMOGRAPHIC DISPARITIES IN THE RECEIPT OF ANTIRETROVIRAL THERAPY AMONG HIV PATIENTS IN THE 2000-2005 NATIONAL AMBULATORY MEDICAL CARE SURVEYS (NAMCS)
|
Oramasionwu, CU
|
|
2008
|
11 |
3 |
p. A108-
1 p.
|
artikel
|
| 505 |
PIN28 A REALISTIC-AGE-STRUCTURED, DETERMINISTIC, COMPARTMENTAL. TRANSMISSION MODEL TO ESTIMATE THE COST-EFFECTIVENESS OF VACCINATION AGAINST SEASONAL INFLUENZA
|
Thompson, WA
|
|
2008
|
11 |
3 |
p. A101-
1 p.
|
artikel
|
| 506 |
PIN40 ASSESSMENT OF THE CROSS-CULTURAL VALIDITY OF AN HIV SYMPTOM DISTRESS MODULE IN AN INTERNATIONAL HIV CLINICAL TRIAL
|
Regnault, A
|
|
2008
|
11 |
3 |
p. A104-A105
nvt p.
|
artikel
|
| 507 |
PIN2 A SYSTEMATIC REVIEW OF THE EFFECTIVENESS OF PEGYLATED INTERFERON, LAMIVUDINE, ADEFOVIR AND ENTECAVIR FORTHETREATMENT OF HEPATITIS B
|
Woo, GW
|
|
2008
|
11 |
3 |
p. A92-A93
nvt p.
|
artikel
|
| 508 |
PIN36 BASELINE CHARACTERISTICS ASSOCIATED WITH HOSPITAL LENGTH OF STAY (LOS) FOR PATIENTS WITH STAPHYLOCOCCUSAUREUS SKIN INFECTIONS IN THE 1996-2005 NATIONAL HOSPITAL DISCHARGE SURVEY (NHDS)
|
Miller, ML
|
|
2008
|
11 |
3 |
p. A103-
1 p.
|
artikel
|
| 509 |
PIN8 BUDGET IMPACT OF ADDING DORIPENEMTO A HOSPITAL FORMULARY
|
Kongnakorn, T
|
|
2008
|
11 |
3 |
p. A94-
1 p.
|
artikel
|
| 510 |
PIN10 COMPARATIVE (POSACONAZOLE VS. OTHER SYSTEMIC ANTIFUNGALS) ALL-CAUSE MORTALITY AND COST ANALYSIS IN PATIENTS WITH REFRACTORY INVASIVE ASPERGILLOSIS
|
Tahami Monfared, AA
|
|
2008
|
11 |
3 |
p. A95-
1 p.
|
artikel
|
| 511 |
PIN41 COMPLEMENTARY AND ALTERNATIVE MEDICATION USE AND ADVERSE EVENTS IN HIV-INFECTED PATIENTS
|
Ajugo, E
|
|
2008
|
11 |
3 |
p. A105-
1 p.
|
artikel
|
| 512 |
PIN45 COMPREHENSIVE EDUCATIONAL APPROACH HOWTO INFLUENCE PRESCRIPTION HABITS AND ANTIBIOTIC RESISTANCE IN AMBULATORY PRACTICE
|
Hupkova, H
|
|
2008
|
11 |
3 |
p. A106-
1 p.
|
artikel
|
| 513 |
PIN24 COST-EFFECTIVENESS ANALYSIS OF ANIDULAFUNGIN FOR THE MANAGEMENT OF INVASIVE CANDIDIASIS IN NON-NEUTROPENIC PATIENTS IN MEXICO
|
Mould-Quevedo, J
|
|
2008
|
11 |
3 |
p. A99-
1 p.
|
artikel
|
| 514 |
PIN29 COST-EFFECTIVENESS EVALUATION OF THREE HEALTH CARE DELIVERY MODELS FOR HIV POSITIVE PATIENTS IN COLOMBIA
|
Burbano-Levy, X
|
|
2008
|
11 |
3 |
p. A101-
1 p.
|
artikel
|
| 515 |
PIN21 COST-EFFECTIVENESS OF ANIDULAFUNGIN THERAPY IN CONFIRMED CANDIDEMIA AND OTHER FORMS OF INVASIVE CANDIDIASIS IN CANADA
|
Graham, CN
|
|
2008
|
11 |
3 |
p. A98-
1 p.
|
artikel
|
| 516 |
PIN14 COST-EFFECTIVENESS OF PEGINTERFERON-ALFA-2A (40 KD) ASSOCIATED WITH RIBAVIRIN IN THE TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C IN BRAZIL UNDER THE PRIVATE HEALTH CARE SYSTEM
|
Parana, R
|
|
2008
|
11 |
3 |
p. A96-
1 p.
|
artikel
|
| 517 |
PIN16 COST-EFFECTIVENESS OF POSACONAZOLE VS. FLUCONAZOLE IN THE PROPHYLAXIS AGAINST INVASIVE FUNGAL INFECTIONS IN PATIENTS WITH GRAFT-VERSUS-HOST DISEASE IN CANADA
|
Tahami Monfared, AA
|
|
2008
|
11 |
3 |
p. A97-
1 p.
|
artikel
|
| 518 |
PIN30 COST-MINIMIZATION ANALYSIS OF ORALVALGANCICLOVIR VERSUS INTRAVENOUS GANCICLOVIR FORTHE PROPHYLAXIS OF CYTOMEGALOVIRUS INFECTION IN SOLID ORGAN TRANSPLANT RECIPIENTS IN BRAZIL
|
David-Neto, E
|
|
2008
|
11 |
3 |
p. A101-
1 p.
|
artikel
|
| 519 |
PIN11 COST SAVINGS FROM REDUCED HIV INCIDENCE ESTIMATES
|
Flavin, JK
|
|
2008
|
11 |
3 |
p. A95-
1 p.
|
artikel
|
| 520 |
PIN46 COUNTRY ASSESSMENT TO DETERMINE FACTORS INFLUENCING THE COST, AVAILABILITY AND DISTRIBUTION OF ACYCLOVIR IN EIGHT SUB-SAHARAN AFRICAN COUNTRIES
|
Waweru, CW
|
|
2008
|
11 |
3 |
p. A106-A107
nvt p.
|
artikel
|
| 521 |
PIN3 DATA MINING PHYSICIAN DECISION AND INVESTIGATING TREATMENT OPTIONS OF OSTEOMYELITIS
|
Zahedi, H
|
|
2008
|
11 |
3 |
p. A93-
1 p.
|
artikel
|
| 522 |
PIN17 DECISION ANALYTIC MODEL EVALUATING THE COST-EFFECTIVENESS OF LINEZOLID VERSUS VANCOMYCIN IN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS COMPLICATED SKIN AND SOFT TISSUE INFECTION
|
Bounthavong, M
|
|
2008
|
11 |
3 |
p. A97-
1 p.
|
artikel
|
| 523 |
PIN42 DESIGNING AND TESTING A HIV-PATIENT SATISFACTION SURVEY FOR A COMPARITIVE ANALYSIS OF MAIL-ORDER PHARMACYVS. COMMUNITY PHARMACY SERVICES
|
Ramasamy, A
|
|
2008
|
11 |
3 |
p. A105-
1 p.
|
artikel
|
| 524 |
PIN19 ECONOMICAL EVALUATION OF DARUNAVIR + LOW DOSE RITONAVIR IN TREATMENT-EXPERIENCED HIV-I-INFECTED PATIENTS
|
Vorobiev, P
|
|
2008
|
11 |
3 |
p. A98-
1 p.
|
artikel
|
| 525 |
PIN27 ECONOMIC ANALYSIS OF MICAFUNGIN VERSUS LIPOSOMAL AMPHOTERICIN B FORTREATMENT OF CANDIDAEMIA AND INVASIVE CANDIDIASIS IN THE UNITED KINGDOM
|
Park, G
|
|
2008
|
11 |
3 |
p. A100-A101
nvt p.
|
artikel
|
| 526 |
PIN13 ECONOMIC EVALUATION OF POSACONAZOLE VS. STANDARD AZOLE THERAPY IN THE PROPHYLAXIS AGAINST INVASIVE FUNGAL INFECTIONS IN PATIENTS WITH PROLONGED NEUTROPENIA IN CANADA
|
Tahami Monfared, AA
|
|
2008
|
11 |
3 |
p. A96-
1 p.
|
artikel
|
| 527 |
PIN26 ECONOMIC EVALUATION OF SUNITINIBVS. INTERFERON-ALFA (IFN-ALFA) IN FIRST-LINE TREATMENT OF METASTATIC RENAL CELL CARCINOMA (MRCC) IN COLOMBIA
|
Godoy, JI
|
|
2008
|
11 |
3 |
p. A100-
1 p.
|
artikel
|
| 528 |
PIN15 ECONOMIC EVALUATION OFTIPRANAVIR IN THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS
|
Risebrough, N
|
|
2008
|
11 |
3 |
p. A96-A97
nvt p.
|
artikel
|
| 529 |
PIN34 HEALTH CARE UTILIZATION AND COSTS ASSOCIATED WITH CHRONIC HEPATITIS C IN A MANAGED CARE POPULATION
|
Mitra, D
|
|
2008
|
11 |
3 |
p. A103-
1 p.
|
artikel
|
| 530 |
PIN50 INITIAL THERAPIES FOR ACUTE OTITIS EXTERNA IN THE LOUISIANA MEDICAID POPULATION
|
Parmar, J
|
|
2008
|
11 |
3 |
p. A108-
1 p.
|
artikel
|
| 531 |
PIN47 INPATIENT COSTS AND OUTCOMES ASSOCIATED WITH CHRONIC HEPATITIS C RELATED COMPLICATIONS IN THE UNITED STATES
|
Mitra, D
|
|
2008
|
11 |
3 |
p. A107-
1 p.
|
artikel
|
| 532 |
PIN5 INTEREST OF MULTI-CRITERIA MODELING APPROACH IN ASSESSMENT OF YELLOW FEVER EPIDEMIC RISK
|
Beresniak, A
|
|
2008
|
11 |
3 |
p. A93-A94
nvt p.
|
artikel
|
| 533 |
PIN7 MRSA: INVESTIGATING THE DANGEROUS HOSPITAL INFECTION
|
Glassford, RJ
|
|
2008
|
11 |
3 |
p. A94-
1 p.
|
artikel
|
| 534 |
PIN43 NATURAL HISTORY OF CHRONIC HCV INFECTION OBTAINED THROUGH INJECTION DRUG USE: A BAYESIAN META-ANALYSIS
|
John-Baptiste, A
|
|
2008
|
11 |
3 |
p. A105-A106
nvt p.
|
artikel
|
| 535 |
PIN22 PHARMACOECONOMIC ANALYSIS BASED ON GUIDELINES FOR TREATING MILD DIABETIC FOOT INFECTIONS: A DECISION TREE MODEL FOR CANADA
|
Chow, I
|
|
2008
|
11 |
3 |
p. A98-A99
nvt p.
|
artikel
|
| 536 |
PIN12 PHARMACOECONOMIC ANALYSIS BASED ON GUIDELINES FOR TREATING MILD DIABETIC FOOT INFECTIONS: A DECISION TREE MODEL FOR COLOMBIA
|
Lemos, EV
|
|
2008
|
11 |
3 |
p. A95-A96
nvt p.
|
artikel
|
| 537 |
PIN23 PHARMACOECONOMIC ANALYSIS OF ANTIFUNGAL AGENTS FOR THE MANAGEMENT OF NON NEUTROPENIC PATIENTS WITH INVASIVE CANDIDIASIS ATTHE SOCIAL SECURITY MEXICAN INSTITUTE (IMSS)
|
Contreras-Hernandez, I
|
|
2008
|
11 |
3 |
p. A99-
1 p.
|
artikel
|
| 538 |
PIN20 PHARMACOECONOMICS OF CHRONIC HEPATITIS BAND HEPATITIS C
|
Freiberga, M
|
|
2008
|
11 |
3 |
p. A98-
1 p.
|
artikel
|
| 539 |
PIN52 PRESCRIBING TRENDS IN ANTIVIRAL PRESCRIPTIONS AMONG PATIENTS WITH INFLUENZA IN THE UNTED STATES FROM 1999-2005
|
Bonthapally, V
|
|
2008
|
11 |
3 |
p. A108-A109
nvt p.
|
artikel
|
| 540 |
PIN38 RANDOMIZED CONTROLLED TRIAL OF TELEPHONE, EMAIL AND TEXT MESSAGING REMINDERS ON PATIENT COMPLIANCE WITH ANTIBIOTIC REGIMEN
|
Yang, Y
|
|
2008
|
11 |
3 |
p. A104-
1 p.
|
artikel
|
| 541 |
PIN35 RESOURCE UTILIZATION IN UNITED KINGDOM DIAGNOSED HCV PATIENTS
|
Zhang, H
|
|
2008
|
11 |
3 |
p. A103-
1 p.
|
artikel
|
| 542 |
PIN39 ROLE OF DRUG DISTRIBUTION STRATEGIES TO IMPROVE HEALTH OUTCOME IN HIGH RISK PATIENTS
|
Wattal, R
|
|
2008
|
11 |
3 |
p. A104-
1 p.
|
artikel
|
| 543 |
PIN49 SPREAD PATTERN FORMATION OF H5NI-AVIAN INFLUENZA AND ITS IMPLICATIONS FOR CONTROL STRATEGIES
|
Duwuri, VRSK
|
|
2008
|
11 |
3 |
p. A107-A108
nvt p.
|
artikel
|
| 544 |
PIN32 THE CHILD AND HOUSEHOLD INFLUENZA-ILLNESS AND EMPLOYEE FUNCTION (CHIEF) STUDY-LINKING SURVEY AND CLAIMS DATA TO UNDERSTAND DISEASE IMPACT ON INDIRECT COSTS
|
Rousculp, MD
|
|
2008
|
11 |
3 |
p. A102-
1 p.
|
artikel
|
| 545 |
PIN25 THE ECONOMIC IMPACT OF SINGLE-DOSE AZITHROMYCIN MICROSPHERES FORMULATION FORTHE MANAGEMENT OF ACUTE STREPTOCOCCAL PHARYNGITIS (ASP) IN MEXICO
|
Arreola-Ornelas, H
|
|
2008
|
11 |
3 |
p. A100-
1 p.
|
artikel
|
| 546 |
PIN18 THE IMPACT OF PEDIATRIC ADVERSE EVENTS ON THE COST-EFFECTIVENESS OF OSELTAMIVIR
|
Lavelle, TA
|
|
2008
|
11 |
3 |
p. A97-
1 p.
|
artikel
|
| 547 |
PIN9 THE WORKFORCE AND COST IMPLICATIONS OF SUBSTITUTING NURSES AND PHARMACISTS FOR DOCTORS IN THE FOLLOW-UP OF PATIENTS WITH AIDS ON ANTIRETROVIRALTHERAPY IN UGANDA
|
Babigumira, JB
|
|
2008
|
11 |
3 |
p. A94-A95
nvt p.
|
artikel
|
| 548 |
PIN31 TOTAL TREATMENT COST OF LINEZOLID COMPARED TO VANCOMYCIN IN MRSA INFECTIONS
|
Borgman, B
|
|
2008
|
11 |
3 |
p. A102-
1 p.
|
artikel
|
| 549 |
PIN1 TREATMENT OF HEPATITIS C INFECTION FOR CURRENT OR FORMER SUBSTANCE ABUSERS IN A COMMUNITY SETTING
|
John-Baptiste, A
|
|
2008
|
11 |
3 |
p. A92-
1 p.
|
artikel
|
| 550 |
PIN48 TRENDS FOR NOSOCOMIAL SOFT TISSUE INFECTIONS, STAPHLOCOCCOUS AUREUS INFECTIONS, AND MRSA IN US HOSPITALS: 1998-2004
|
Dickson, M
|
|
2008
|
11 |
3 |
p. A107-
1 p.
|
artikel
|
| 551 |
PMC37 ACCESS TO PATIENT-REPORTED OUTCOME (PRO) INSTRUMENTS ANDTHEIR TRANSLATIONS IN THE LIGHT OF FDA RECOMMENDATIONS
|
Anfray, C
|
|
2008
|
11 |
3 |
p. A180-
1 p.
|
artikel
|
| 552 |
PMC11 ACCOUNTING FOR THE PLACEBO RESPONSE IN COST-EFFECTIVENESS ANALYSIS
|
McDonald, HP
|
|
2008
|
11 |
3 |
p. A172-
1 p.
|
artikel
|
| 553 |
PMC39 A COMPREHENSIVE PARADIGM TO ESTIMATE MINIMAL CLINICALLY IMPORTANT DIFFERENCES (MCID)
|
Treglia, M
|
|
2008
|
11 |
3 |
p. A180-
1 p.
|
artikel
|
| 554 |
PMC8 A CONCEPTUAL FRAMEWORKTO ANALYZE A DISEASE'S WORKPLACE IMPACT ON AN EMPLOYER
|
Sun, P
|
|
2008
|
11 |
3 |
p. A171-
1 p.
|
artikel
|
| 555 |
PMC17 A METHOD FOR CONVERTING NATIONAL DRUG CODES (NDCS) TO GENERIC ANDTHERAPEUTIC CATEGORY CODES FOR USE IN LARGE DATABASE STUDIES OF PRESCRIPTION DRUG CLAIMS
|
Dickson, M
|
|
2008
|
11 |
3 |
p. A174-
1 p.
|
artikel
|
| 556 |
PMC22 A MODELTO EXAMINE THE EFFECT OF GUIDELINES ON OUTCOMES RESEARCH
|
Baser, O
|
|
2008
|
11 |
3 |
p. A175-A176
nvt p.
|
artikel
|
| 557 |
PMC5 AN ANATOMY OF PHARMACEUTICAL COST-UTILITY ANALYSES, 1976–2005
|
Fang, C
|
|
2008
|
11 |
3 |
p. A170-A171
nvt p.
|
artikel
|
| 558 |
PMC26 APPLICATION OFTHE FRAMEWORK FOR EVALUATING COMPLEX INTERVENTIONS TO CLUSTER RANDOMIZED TRIALS FOR THE EVALUATION OF DISEASE MANAGEMENT PROGRAMS
|
Marchisio, S
|
|
2008
|
11 |
3 |
p. A177-
1 p.
|
artikel
|
| 559 |
PMC30 A REVIEW AND CRITIQUE OF METHODS FOR MEASURING TEMPORARY HEALTH STATES IN COST-UTILITY ANALYSES
|
Wright, DR
|
|
2008
|
11 |
3 |
p. A177-A178
nvt p.
|
artikel
|
| 560 |
PMC35 A SYSTEMATIC REVIEW OF APPLICATIONS OF CONJOINT ANALYSIS IN MEDICINE
|
Kinter, ET
|
|
2008
|
11 |
3 |
p. A179-
1 p.
|
artikel
|
| 561 |
PMC18 COMPARISONS OF DATA MINING ALGORITHMS FOR ADVERSE DRUG REACTIONS: AN EMPIRICAL STUDY BASED ONTHE ADVERSE EVENT REPORTING SYSTEM OFTHE FOOD AND DRUG ADMINISTRATION
|
Chen, Y
|
|
2008
|
11 |
3 |
p. A174-
1 p.
|
artikel
|
| 562 |
PMC31 CONTROLLING MEASUREMENT ERROR OF PATIENT-REPORTED-OUTCOMES DURING THE IMPLEMENTATION STAGE OF CLINICAL TRIALS
|
Gnanasakthy, A
|
|
2008
|
11 |
3 |
p. A178-
1 p.
|
artikel
|
| 563 |
PMC21 COST-EFFECTIVENESS SENSITIVITY TO COST-EFFECTIVENESS CORRELATION: A SIMULATION STUDY
|
Muston, D
|
|
2008
|
11 |
3 |
p. A175-
1 p.
|
artikel
|
| 564 |
PMC16 CREATING NATIONAL WEIGHTS FOR A LARGE-SCALE, PATIENT LONGITUDINAL DATABASE
|
Baser, O
|
|
2008
|
11 |
3 |
p. A174-
1 p.
|
artikel
|
| 565 |
PMC15 DETERMINING THE MECHANISM OF MISSING DATA IN INCOMPLETE DATASETS
|
Whillans, F
|
|
2008
|
11 |
3 |
p. A173-A174
nvt p.
|
artikel
|
| 566 |
PMC46 DEVELOPMENT OF A STANDARDIZED CLASSIFICATION SYSTEM FOR THE TRANSLATIONS OF PRO INSTRUMENTS
|
Conway, K
|
|
2008
|
11 |
3 |
p. A182-
1 p.
|
artikel
|
| 567 |
PMC47 EFFICIENCY OF HYBRID APPLICATIONS OF EXACT COVARIATE MATCHING AND PROPENSITY SCORE
|
Yang, G
|
|
2008
|
11 |
3 |
p. A182-A183
nvt p.
|
artikel
|
| 568 |
PMC45 EQ-5D + VAS = PRO
|
Kind, P
|
|
2008
|
11 |
3 |
p. A182-
1 p.
|
artikel
|
| 569 |
PMC19 ESTIMATING SOCIODEMOGRAPHIC VARIABLES IN A PHARMACY DATASET: APPLYING DATA FROM US CENSUS 2000
|
LaFleur, J
|
|
2008
|
11 |
3 |
p. A175-
1 p.
|
artikel
|
| 570 |
PMC50 EVIDENCE ANDVALUE: IMPACT ON DECISION MAKING—THE EVIDEM FRAMEWORK AND POTENTIAL APPLICATIONS
|
Goetghebeur, MM
|
|
2008
|
11 |
3 |
p. A183-A184
nvt p.
|
artikel
|
| 571 |
PMC14 EXPLORING CANDIDATE DIFFERENCES BETWEEN DRUG COHORTS PRIOR TO EXPOSURE: A SYSTEMATIC APPROACH USING MULTIPLE OBSERVATIONAL DATABASES
|
Ryan, PB
|
|
2008
|
11 |
3 |
p. A173-
1 p.
|
artikel
|
| 572 |
PMC34 INTERNATIONAL SURVEY ONWTP FOR ONE ADDITIONAL QALY GAIN—HOW MUCH IS THE THRESHOLD OF COST-EFFECTIVENESS ANALYSIS
|
Shiroiwa, T
|
|
2008
|
11 |
3 |
p. A179-
1 p.
|
artikel
|
| 573 |
PMC29 INTERNATIONAL VALUATION SET FOR EQ-5D HEALTH STATES
|
Craig, BM
|
|
2008
|
11 |
3 |
p. A177-
1 p.
|
artikel
|
| 574 |
PMC24 INVERSE PROBABILITY WEIGHTED RANDOM EFFECT MODELS FOR ESTIMATION OF CENSORED OUTCOMES VARIABLES
|
Baser, O
|
|
2008
|
11 |
3 |
p. A176-
1 p.
|
artikel
|
| 575 |
PMC44 IS A LITERAL BACKTRANSLATION IN PRO DOCUMENTS ALWAYS THE BEST OPTION?
|
Houchin, C
|
|
2008
|
11 |
3 |
p. A182-
1 p.
|
artikel
|
| 576 |
PMC41 MAPPING SF-12 TO EUROQOL EQ-5D PREFERENCE SCORES IN THE SPANISH-SPEAKING HISPANIC COMMUNITY IN THE UNITED STATES
|
Zarate, V
|
|
2008
|
11 |
3 |
p. A181-
1 p.
|
artikel
|
| 577 |
PMC55 MATRIX MODEL FOR DETERMINING A DRUG'S HEALTH ECONOMIC FOCUSTO OPTIMIZE ITS ECONOMICVIABILITY
|
Hemels, M
|
|
2008
|
11 |
3 |
p. A185-
1 p.
|
artikel
|
| 578 |
PMC12 MEASURING ECONOMIC AND CLINICAL OUTCOMES ASSOCIATED WITHTELE-ICU MONITORING
|
Franzini, L
|
|
2008
|
11 |
3 |
p. A172-A173
nvt p.
|
artikel
|
| 579 |
PMC51 MEDICATION ADHERENCE: A CONCEPTUAL REVIEW
|
Nadkarni, A
|
|
2008
|
11 |
3 |
p. A184-
1 p.
|
artikel
|
| 580 |
PMC42 METHODOLOGICAL ISSUES WITHTHE ANALYSIS OF PREFERENCE-BASED EQ-5D INDEX SCORE
|
Li, L
|
|
2008
|
11 |
3 |
p. A181-
1 p.
|
artikel
|
| 581 |
PMC3 METHODS FOR ESTIMATING CONFIDENCE INTERVALS OF PER MEMBER PER MONTH (PMPM) UTILIZATION RATES
|
Saverno, K
|
|
2008
|
11 |
3 |
p. A170-
1 p.
|
artikel
|
| 582 |
PMC20 METHODSTO SUMMARIZE COMPLICATED DATASETS CONTAINING STRUCTURED, NOMINAL DATA USING SAS
|
Zahedi, H
|
|
2008
|
11 |
3 |
p. A175-
1 p.
|
artikel
|
| 583 |
PMC40 PHARMACY STUDENTS' PERCEPTIONS OF HEALTH-RELATED QUALITY OF LIFE FOR MULTIPLE CHRONIC HEALTH STATES MEASURED VIA ALTERNATIVE METHODS FOR UTILITY ASSESSMENT
|
Patel, RA
|
|
2008
|
11 |
3 |
p. A180-A181
nvt p.
|
artikel
|
| 584 |
PMC33 PREDICTING A MEAN EQ-5D PREFERENCE-BASED SCORE FROMTHE 8 MEAN SF-36 DIMENSION SCORESWHEN INDIVIDUAL DATA IS NOT AVAILABLE
|
Ara, R
|
|
2008
|
11 |
3 |
p. A178-A179
nvt p.
|
artikel
|
| 585 |
PMC32 PREDICTING SF-6D PREFERENCE-BASED UTILITIES USING MEAN SF-36 HEALTH DIMENSION SCORESWHEN PATIENT LEVEL DATA ARE NOT AVAILABLE
|
Ara, R
|
|
2008
|
11 |
3 |
p. A178-
1 p.
|
artikel
|
| 586 |
PMC23 PREDICTION MODELS FOR TRANSITIONS IN THE ELDERLY USING ADMINISTRATIVE CLAIMS
|
Rapp, T
|
|
2008
|
11 |
3 |
p. A176-
1 p.
|
artikel
|
| 587 |
PMC53 PREVALENCE OF RESEARCH FOCUSED ON GENETICALLY-LINKED DISORDERS: WHERE HAVEWE BEEN AND WHERE AREWE GOING?
|
Samuels, E
|
|
2008
|
11 |
3 |
p. A184-A185
nvt p.
|
artikel
|
| 588 |
PMC28 RASCH PARTIAL CREDIT ANALYSIS OFTHE SF-12V2 USING THE 2003 MEDICAL EXPENDITURE PANEL SURVEY (MEPS)
|
Gu, NY
|
|
2008
|
11 |
3 |
p. A177-
1 p.
|
artikel
|
| 589 |
PMC1 SEARCH STRATEGIES AND RESULTS OF SYSTEMATIC REVIEWS
|
Proudfoot, C
|
|
2008
|
11 |
3 |
p. A169-
1 p.
|
artikel
|
| 590 |
PMC25 SENSITIVITY ANALYSIS FOR PROPENSITY SCORE MATCHING
|
Baser, O
|
|
2008
|
11 |
3 |
p. A176-
1 p.
|
artikel
|
| 591 |
PMC48 SETTING THE OPTIMAL SCREENING TOOLTHRESHOLD FOR A CHRONIC UNDERDIAGNOSED ILLNESS: WHOSE BURDEN MATTERS MOST?
|
Yu, HT
|
|
2008
|
11 |
3 |
p. A183-
1 p.
|
artikel
|
| 592 |
PMC4 THE ADOPTION AND DIFFUSION OF COST-EFFECTIVENESS ACCEPTABILITY CURVES IN PUBLISHED ECONOMIC EVALUATIONS
|
Greenberg, D
|
|
2008
|
11 |
3 |
p. A170-
1 p.
|
artikel
|
| 593 |
PMC10 THE DEVELOPMENT OF COST-EFFECTIVENESS INDICES WITH EQUITY IMPLICATIONS FOR THE ECONOMIC EVALUATION OF HEALTH CARE
|
Hu, FC
|
|
2008
|
11 |
3 |
p. A172-
1 p.
|
artikel
|
| 594 |
PMC52 THE DEVELOPMENT OFTHE PROGNOSTIC PROPENSITY SCORE: UTILIZED TO PROVIDE PHYSICIANS WITH DETAILED EVIDENCE TO ALLOW FOR OPTIMAL PRESCRIBING
|
Stafkey-Mailey, DR
|
|
2008
|
11 |
3 |
p. A184-
1 p.
|
artikel
|
| 595 |
PMC6 THE $50,000/QALY THRESHOLD RECONSIDERED: A RETROSPECTIVE ON KLARMAN'S ORIGINAL PAPER WITH AN EYE TOTHE FUTURE
|
Nauenberg, E
|
|
2008
|
11 |
3 |
p. A171-
1 p.
|
artikel
|
| 596 |
PMC36 THE USE OF A MOBILE PHONE FOR ASSESSING MOOD AND PERFORMANCE IN EVERYDAY LIFE
|
Tiplady, B
|
|
2008
|
11 |
3 |
p. A179-A180
nvt p.
|
artikel
|
| 597 |
PMC7 TOTAL DIRECT MEDICAL EXPENDITURE OF CHRONIC DISEASES UNDER DIFFERENT ECONOMETRIC MODELS
|
Kawatkar, AA
|
|
2008
|
11 |
3 |
p. A171-
1 p.
|
artikel
|
| 598 |
PMC49 TRANSLATING HETEROGENEITY BIAS FROM HEALTH STATUS IN OUTCOMES STUDIES—USING LATENT CLASS CLUSTER ANALYSIS AND LONGITUDINAL DATA
|
Ahn, J
|
|
2008
|
11 |
3 |
p. A183-
1 p.
|
artikel
|
| 599 |
PMC38 USE OF A MOBILE PHONETO ADMINISTER VISUAL ANALOGUE SCALES (VAS)
|
Tiplady, B
|
|
2008
|
11 |
3 |
p. A180-
1 p.
|
artikel
|
| 600 |
PMC43 USE OF BACKTRANSLATION REVIEW IN THE TRANSLATION OF PRO INSTRUMENTS—SOME EXAMPLES
|
Gordon-Stables, R
|
|
2008
|
11 |
3 |
p. A181-
1 p.
|
artikel
|
| 601 |
PMC13 USE OF POTENTIALLY INAPPROPRIATE PSYCHOACTIVE MEDICATIONS AND FALLS IN U.S. NURSING HOME RESIDENTS
|
Agashivala, N
|
|
2008
|
11 |
3 |
p. A173-
1 p.
|
artikel
|
| 602 |
PMC2 WHEN ARE INDIRECT AND MIXED TREATMENT COMPARISONS BIASED? A GRAPHICAL EXPLANATION WITH DAGS
|
Jansen, JP
|
|
2008
|
11 |
3 |
p. A169-A170
nvt p.
|
artikel
|
| 603 |
PMC9 30 YEARS OF COST-EFFECTIVENESS ANALYSES:A BIBLIOMETRIC REVIEW OF ARTICLES PUBLISHED IN THE ECONOMIC AND MEDICAL LITERATURE: 1976–2005
|
Greenberg, D
|
|
2008
|
11 |
3 |
p. A172-
1 p.
|
artikel
|
| 604 |
PM4 EVALUATION OF ATHEORY OF GLOBAL HEALTH PREFERENCE FORMATION
|
Shaw, JW
|
|
2008
|
11 |
3 |
p. A14-
1 p.
|
artikel
|
| 605 |
PMH32 ACAMPROSATE IN TREATMENT OF ALCOHOL DEPENDENCE-ECONOMIC BENEFITS REVISITED
|
Erder, MH
|
|
2008
|
11 |
3 |
p. A118-
1 p.
|
artikel
|
| 606 |
PMH23 A COMPARISION OF HEALTH CARE UTILIZATION AND COST OF CHILDREN AND ADOLESCENTS WITH BIPOLAR DISORDER TREATED WITH ATYPICAL ANTIPSYCHOTIC MONOTHERAPYVERSUS MOOD STABILIZER MONOTHERAPY
|
Jing, Y
|
|
2008
|
11 |
3 |
p. A116-
1 p.
|
artikel
|
| 607 |
PMH20 A COST-BENEFIT ANALYSIS OF HIGHER MEDICATION COPAYMENTS IN VETERANS WITH SCHIZOPHRENIA
|
Zeber, JE
|
|
2008
|
11 |
3 |
p. A115-
1 p.
|
artikel
|
| 608 |
PMH15 ANALYSIS OF POTENTIAL DRUG-DRUG INTERACTION PAIRS ASSOCIATED WITH ANTIPSYCHOTICS AMONG MEDICAID PATIENTS WITH SCHIZOPHRENIA OR BIPOLAR DISORDER
|
Jing, Y
|
|
2008
|
11 |
3 |
p. A113-
1 p.
|
artikel
|
| 609 |
PMH51 A NEW MEASURE OF ADHERENCE—THE DAILY POSSESSION RATIO (DPR): COMPARISONS WITHTHE MEDICATION POSSESSION RATIO (MPR) IN THE PRESENCE OF MEDICATION SWITCHING ANDTHERAPEUTIC DUPLICATION
|
Martin, BC
|
|
2008
|
11 |
3 |
p. A124-A125
nvt p.
|
artikel
|
| 610 |
PMH70 AN INVESTIGATION OF EVIDENCE-BASED USE OF ATYPICAL ANTIPSYCHOTICS IN ARKANSAS MEDICAID PEDIATRIC
|
Pathak, P
|
|
2008
|
11 |
3 |
p. A130-A131
nvt p.
|
artikel
|
| 611 |
PMH77 ANTIPSYCHOTIC METABOLIC PROPENSITY AND POLYTHERAPY: INFLUENCE ON HOSPITALIZATION
|
Simoni-Wastila, L
|
|
2008
|
11 |
3 |
p. A133-
1 p.
|
artikel
|
| 612 |
PMH31 A PHARMACOECONOMIC ANALYSIS OF SCHIZOPHRENIC PATIENTS SWITCHING FROM BRANDED TO GENERIC RISPERIDONE INVOLVING A POSSIBLE COMPLIANCE LOSS
|
Treur, MJ
|
|
2008
|
11 |
3 |
p. A118-
1 p.
|
artikel
|
| 613 |
PMH11 ASSESSING THE REPORTING AND SCIENTIFIC QUALITY OF META-ANALYTIC RESEARCH SYNTHESISING RANDOMIZED CONTROLLED TRIALS FOR ANXIETY DISORDER TREATMENTS
|
Bereza, BG
|
|
2008
|
11 |
3 |
p. A112-
1 p.
|
artikel
|
| 614 |
PMH62 ASSESSING THE VALIDITY OF DERIVING CLINICAL DEMENTIA RATING (CDR) GLOBAL SCORES FROM INDEPENDENTLY OBTAINED FUNCTIONAL RATING SCALE (FRS) SCORES IN VASCULAR DEMENTIA AND MIXED VASCULAR DEMENTIA PATIENTS
|
Lanctôt, KL
|
|
2008
|
11 |
3 |
p. A128-
1 p.
|
artikel
|
| 615 |
PMH4 ATYPICAL ANTIPSYCHOTIC MEDICATIONS IN THE TREATMENT OF SCHIZOPHRENIAS BAYESIAN META-ANALYSIS OF DIRECT AND INDIRECT COMPARISONS
|
Mahmood, MH
|
|
2008
|
11 |
3 |
p. A110-
1 p.
|
artikel
|
| 616 |
PMH2 BENCHMARKING SCHIZOPHRENIA WITH A FOCUS ON PHARMACOTHERAPYAND METABOLIC SYNDROME
|
Prescott, J
|
|
2008
|
11 |
3 |
p. A109-
1 p.
|
artikel
|
| 617 |
PMH48 BETTER PERSISTENCE ONTREATMENT WITH ESCITALOPRAM COMPARED WITH CITALOPRAM
|
Ereshefsky, L
|
|
2008
|
11 |
3 |
p. A123-A124
nvt p.
|
artikel
|
| 618 |
PMH68 CHANGES OVER TIME IN PATIENT CHARACTERISTICS FOLLOWINGTHE INTRODUCTION OF DULOXETINE: A 24 MONTHS STUDY
|
Able, S
|
|
2008
|
11 |
3 |
p. A130-
1 p.
|
artikel
|
| 619 |
PMH7 CLINICAL AND FUNCTIONAL IMPROVEMENTS IN PATIENTS WITH SCHIZOPHRENIA TREATED WITH RISPERIDONE LONG ACTING INJECTION: INTERIM RESULTS FROM OBSERVATIONAL STUDIES CONDUCTED IN AUSTRALIA, BELGIUM AND THE UNITED STATES
|
Emmerson, B
|
|
2008
|
11 |
3 |
p. A111-
1 p.
|
artikel
|
| 620 |
PMH67 CLINICAL CHARACTERISTICS AMONG ANTIDEPRESSANT INITIATORS
|
Able, S
|
|
2008
|
11 |
3 |
p. A130-
1 p.
|
artikel
|
| 621 |
PMH27 COST-EFFECTIVENESS OF A MINIMAL INTERVENTION STRATEGY FOR STRESS-RELATED SICK LEAVE IN GENERAL PRACTICE: RESULTS OF AN ECONOMIC EVALUATION ALONGSIDE A PRAGMATIC RANDOMIZED CONTROLLED TRIAL
|
Uegaki, K
|
|
2008
|
11 |
3 |
p. A117-
1 p.
|
artikel
|
| 622 |
PMH33 COST-EFFECTIVENESS OF ARIPIPRAZOLE FOR THE MANAGEMENT OF SCHIZOPHRENIA IN THE UNITED KINGDOM
|
Davies, A
|
|
2008
|
11 |
3 |
p. A119-
1 p.
|
artikel
|
| 623 |
PMH28 COST-EFFECTIVENESS OF ONCE-DAILY STIMULANT, NON-STIMULANT & COMBINED STIMULANT/BEHAVIORAL THERAPY INTERVENTIONS IN THE TREATMENT OF ADHD IN CHILDREN
|
Ganapathy, V
|
|
2008
|
11 |
3 |
p. A117-
1 p.
|
artikel
|
| 624 |
PMH35 COST-EFFECTIVENESS OF ORALLY DISSOLVING OLANZAPINE TABLETS IN THE TREATMENT OF SCHIZOPHRENIA IN THE USA
|
Ascher-Svanum, H
|
|
2008
|
11 |
3 |
p. A119-
1 p.
|
artikel
|
| 625 |
PMH30 COST-EFFECTIVENESS OF QUETIAPINE IN COMBINATION WITH LITHIUM OR DIVALPROEX: IN THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER
|
Woodward, TC
|
|
2008
|
11 |
3 |
p. A118-
1 p.
|
artikel
|
| 626 |
PMH76 COST ESTIMATION OF PSYCHIATRIC CARE IN THE JAPANESE HOSPITAL USING SYSTEM DYNAMICS SIMULATION
|
Nakahara, N
|
|
2008
|
11 |
3 |
p. A132-
1 p.
|
artikel
|
| 627 |
PMH45 COST OF PSYCHIATRIC HOSPITALIZATIONS IN THE UNITED SSTATES IN 2006
|
Stensland, M
|
|
2008
|
11 |
3 |
p. A122-A123
nvt p.
|
artikel
|
| 628 |
PMH52 COSTS OF NON-COMPLIANCE WITH ANTIPSYCHOTIC MEDICATIONS AMONG PATIENTS WITH SCHIZOPHRENIA
|
Salas, M
|
|
2008
|
11 |
3 |
p. A125-
1 p.
|
artikel
|
| 629 |
PMH41 COST UTILITY OF EEG BIOMARKERS FOR PERSONALIZED TREATMENT OF MAJOR DEPRESSION
|
Simpson, KN
|
|
2008
|
11 |
3 |
p. A121-
1 p.
|
artikel
|
| 630 |
PMH14 DIFFERENTIAL EFFECTS OF OLANZAPINE AND CLOZAPINE ON TYPE II DIABETES: FINDINGS FROM A CLAIMS DATABASE
|
Donga, PZ
|
|
2008
|
11 |
3 |
p. A113-
1 p.
|
artikel
|
| 631 |
PMH49 EARLY DISCONTINUATION ONTREATMENT AND ITS CONSEQUENCES IN PATIENTS TREATED WITH VENLAFAXINE OR ESCITALOPRAM
|
Ereshefsky, L
|
|
2008
|
11 |
3 |
p. A124-
1 p.
|
artikel
|
| 632 |
PMH22 ECONOMIC ASSESSMENT OF THREE COMMONLY USED ANTIPSYCHOTIC AGENTS IN THE PUBLIC SECTOR OF HONG KONG USING A DECISION ANALYTIC MODEL
|
Lee, KK
|
|
2008
|
11 |
3 |
p. A115-
1 p.
|
artikel
|
| 633 |
PMH65 EFFECT OF PRIOR AUTHORIZATION ON ANTIPSYCHOTIC DRUG USE IN LONG-TERM CARE: POPULATION-BASED NATURAL EXPERIMENT
|
Paterson, JM
|
|
2008
|
11 |
3 |
p. A129-
1 p.
|
artikel
|
| 634 |
PMH78 EFFECTS OF DIRECT-TO-CONSUMER ADVERTISING AND DETAILING SPENDING ON ANTIDEPRESSANT SWITCH AND TREATMENT COMPLETION
|
Chen, SY
|
|
2008
|
11 |
3 |
p. A133-
1 p.
|
artikel
|
| 635 |
PMH1 ESTIMATING THE MAGNITUDE OF ORAL ANTIPSYCHOTIC DRUG-DRUG INTERACTIONS
|
Howe, A
|
|
2008
|
11 |
3 |
p. A109-
1 p.
|
artikel
|
| 636 |
PMH66 ETHNICITY ANDTHE IMPACT OF HIGHER MEDICATION COPAYMENTS AMONGVETERANS WITH SCHIZOPHRENIA
|
Zeber, JE
|
|
2008
|
11 |
3 |
p. A129-A130
nvt p.
|
artikel
|
| 637 |
PMH81 EXAMINING THE PERCEIVED BURDEN OF PRIOR AUTHORIZATION OF PSYCHOTHERAPEUTICS AMONG TEXAS MEDICAID PRESCRIBERS
|
Brown, C
|
|
2008
|
11 |
3 |
p. A134-
1 p.
|
artikel
|
| 638 |
PMH38 GENERALIZED ANXIETY DISORDER: A COMPREHENSIVE LITERATURE REVIEW OF THE BURDEN OF ILLNESS IN NORTH AMERICA
|
Wyrwich, K
|
|
2008
|
11 |
3 |
p. A120-
1 p.
|
artikel
|
| 639 |
PMH44 HEALTH CARE RESOURCE UTILIZATION AND COSTS COMPARISON FOR MDD PATIENTS ON 10 MG ESCITALOPRAMWHO INCREASED TO 20 MG DOSE VS. THOSEWHOWERE SWITCHED TO SNRI
|
Wu, E
|
|
2008
|
11 |
3 |
p. A122-
1 p.
|
artikel
|
| 640 |
PMH25 HEALTH CARE USE AND COSTS OF PATIENTS WITH “PURE OBSESSIVE-COMPULSIVE DISORDER” VERSUS “PURE DEPRESSION”: 9-YEAR (1997-2006), LARGE-SCALE, RETROSPECTIVE CLAIMS ANALYSIS OF FLORIDA MEDICAID ADULT ENROLLEES
|
Hankin, C
|
|
2008
|
11 |
3 |
p. A116-
1 p.
|
artikel
|
| 641 |
PMH59 HEALTH RELATED QUALITY OF LIFE IN PATIENTS TREATED WITH ANTIPSYCHOTIC DRUGS: RESULTS AT BASELINE FROM THE COMETA STUDY
|
Scalone, L
|
|
2008
|
11 |
3 |
p. A127-
1 p.
|
artikel
|
| 642 |
PMH60 HEALTH STATUS ANDWORK-RELATED OUTCOMES OF PATIENTS WITH ANXIETY DISORDERS AND DEPRESSION
|
Erickson, S
|
|
2008
|
11 |
3 |
p. A127-A128
nvt p.
|
artikel
|
| 643 |
PMH53 IMPACT OF ALTERNATIVE TREATMENTS ON DURATION OF DRUGTHERAPY BY PATIENTS WITH BIPOLAR DISORDER
|
Ganapathy, V
|
|
2008
|
11 |
3 |
p. A125-
1 p.
|
artikel
|
| 644 |
PMH54 IMPACT OF ALTERNATIVE TREATMENTS ON DURATION OF DRUGTHERAPY BY PATIENTS WITH SCHIZOPHRENIA
|
Zolfaghari, S
|
|
2008
|
11 |
3 |
p. A125-A126
nvt p.
|
artikel
|
| 645 |
PMH74 IMPACT OF ALTERNATIVE TREATMENTS ON POST TREATMENT COSTS FOR PATIENTS WITH BIPOLAR DISORDER
|
Ganapathy, V
|
|
2008
|
11 |
3 |
p. A132-
1 p.
|
artikel
|
| 646 |
PMH75 IMPACT OF ALTERNATIVE TREATMENTS ON POST-TREATMENT COSTS FOR PATIENTS WITH SCHIZOPHRENIA
|
Zolfaghari, S
|
|
2008
|
11 |
3 |
p. A132-
1 p.
|
artikel
|
| 647 |
PMH42 IMPACT OF RISPERIDONE LONG-ACTING INJECTION VERSUS ORAL ANTIPSYCHOTIC TREATMENTS ON HOSPITALIZATION IN SCHIZOPHRENIA
|
Olivares, JM
|
|
2008
|
11 |
3 |
p. A121-A122
nvt p.
|
artikel
|
| 648 |
PMH26 IMPROVED WORK PRODUCTIVITY IN THE UNITED STATES (US) FOR PATIENTS TREATED WITH ESCITALOPRAM COMPARED TO DULOXETINE
|
François, C
|
|
2008
|
11 |
3 |
p. A117-
1 p.
|
artikel
|
| 649 |
PMH58 IMPROVEMENT IN PERSONAL AND SOCIAL FUNCTIONING IN SCHIZOPHRENIA PATIENTS TREATED WITH RISPERIDONE LONG ACTING INJECTION): 6-MONTH RESULTS FROM E-STAR
|
Pecenak, J
|
|
2008
|
11 |
3 |
p. A127-
1 p.
|
artikel
|
| 650 |
PMH24 INITIATING TREATMENT ON GENERIC ANTIDEPRESSANTS MAY NOT SAVE HEALTH CARE COSTS
|
Esposito, D
|
|
2008
|
11 |
3 |
p. A116-
1 p.
|
artikel
|
| 651 |
PMH73 INITIATION OF ATOMOXETINE VS. STIMULANTS FOR CHILDREN WITH ADHD IN MEDICAID SETTINGS
|
Van Brunt, D
|
|
2008
|
11 |
3 |
p. A131-
1 p.
|
artikel
|
| 652 |
PMH64 MAJOR DEPRESSIVE DISORDER: A COMPREHENSIVE LITERATURE REVIEW OFTHE BURDEN OF ILLNESS IN NORTH AMERICA
|
Van Hanswijck de Jonge, P
|
|
2008
|
11 |
3 |
p. A129-
1 p.
|
artikel
|
| 653 |
PMH50 MEDICATION ADHERENCE, ETHNICITY, ANDTHE INFLUENCE OF MULTIPLE PSYCHOSOCIAL AND FINANCIAL BARRIERS IN VETERANS WITH BIPOLAR DISORDER
|
Zeber, JE
|
|
2008
|
11 |
3 |
p. A124-
1 p.
|
artikel
|
| 654 |
PMH55 MEDICATION COMPLIANCE IN THOSE WITH SCHIZOPHRENIA RECEIVING PSYCHIATRIC SERVICES FROM AVETERANS HOSPITAL INTAIWAN
|
Cheng, JS
|
|
2008
|
11 |
3 |
p. A126-
1 p.
|
artikel
|
| 655 |
PMH57 MEDICATION PERSISTENCE AND ASSOCIATED HEALTH CARE COSTS IN AN OLDER POPULATION WITH DEMENTIA: A LONGITUDINAL COHORT STUDY
|
Balkrishnan, R
|
|
2008
|
11 |
3 |
p. A126-A127
nvt p.
|
artikel
|
| 656 |
PMH43 MENTAL HEALTH CARE RESOURCE USE BEFORE AND AFTER INITIATION OF PALIPERIDONE ER IN PATIENTS WITH SCHIZOPHRENIA
|
Wu, JH
|
|
2008
|
11 |
3 |
p. A122-
1 p.
|
artikel
|
| 657 |
PMH17 METABOLIC MONITORING AMONG SCHIZOPHRENIA PATIENTS INITIATED ON ATYPICAL ANTIPSYCHOTICS IN THE VETERAN HEALTH ADMINISTRATION
|
Shi, L
|
|
2008
|
11 |
3 |
p. A114-
1 p.
|
artikel
|
| 658 |
PMH16 METABOLIC SAFETY AND TOLERABILITY OF ZIPRASIDONE VS. OLANZAPINE IN SCHIZOPHRENIA PATIENTS: SYSTEMATIC REVIEW AND META-ANALYSIS
|
Campbell, RS
|
|
2008
|
11 |
3 |
p. A113-
1 p.
|
artikel
|
| 659 |
PMH19 MONOTHERAPYWITH ATYPICAL ANTIPSYCHOTICS FOR SCHIZOPHRENIAS CLINICAL REVIEW AND ECONOMIC EVALUATION OF FIRST TWELVE MONTHS OF TREATMENT
|
Farahati, F
|
|
2008
|
11 |
3 |
p. A114-
1 p.
|
artikel
|
| 660 |
PMH72 OFF-LABEL USE OF SECOND-GENERATION ANTIPSYCHOTICS AMONG ADULT PATIENTS WITH BIPOLAR DISORDER IN A LARGE MANAGED CARE POPULATION
|
Demland, JA
|
|
2008
|
11 |
3 |
p. A131-
1 p.
|
artikel
|
| 661 |
PMH6 OPTIMAL THRESHOLDS OF EARLY NON-RESPONSE TO ATYPICAL ANTIPSYCHOTICS: APPLICATION OF SIGNAL DETECTION ANALYSIS
|
Ascher-Svanum, H
|
|
2008
|
11 |
3 |
p. A110-A111
nvt p.
|
artikel
|
| 662 |
PMH61 PATIENT PREFERENCES IN THE THERAPY OF ADHD—A DISCRETE CHOICE EXPERIMENT
|
Mühlbacher, AC
|
|
2008
|
11 |
3 |
p. A128-
1 p.
|
artikel
|
| 663 |
PMH63 PATIENT REPORTED MEASURES AS QUALITY ASSURANCE TOOLS IN CNS CLINICAL TRIALS
|
Daniel, DG
|
|
2008
|
11 |
3 |
p. A128-A129
nvt p.
|
artikel
|
| 664 |
PMH21 PHARMACY COST IMPACT OF GUIDELINE-RECOMMENDED DOSING OF SECOND GERNERATION ANTIPSYCHOTICS IN SCHIZOPHRENIA
|
Chen, CC
|
|
2008
|
11 |
3 |
p. A115-
1 p.
|
artikel
|
| 665 |
PMH79 PHYSICAL MORBIDITY AMONG PATIENTS WITH SCHIZOPHRENIA: ANALYSIS OFTHE NATIONAL HOSPITAL DISCHARGE REGISTRY
|
Bouza, C
|
|
2008
|
11 |
3 |
p. A133-
1 p.
|
artikel
|
| 666 |
PMH46 PREDICTORS OF MEDICATION ADHERENCE AMONG SCHIZOPHRENIA PATIENTS TREATED WITH CONVENTIONAL AND ATYPICAL ANTIPSYCHOTICS IN A LARGE STATE MEDICAID PROGRAM
|
Lee, SP
|
|
2008
|
11 |
3 |
p. A123-
1 p.
|
artikel
|
| 667 |
PMH84 PREDICTORS OFTREATMENT INITIATION OF DULOXETINE VS. VENLAFAXINE XR FOR PATIENTS WITH MAJOR DEPRESSION DISORDER IN MANAGED CARE SETTINGS
|
Ye, W
|
|
2008
|
11 |
3 |
p. A135-
1 p.
|
artikel
|
| 668 |
PMH82 PREVALENCE AND PATTERNS OF NEWER ANTIDEPRSSANTS USED IN CHILDREN AND ADOLESCENTS IN A STATE MEDICAID PROGRAM OVER SEVENYEARS
|
Helm, ME
|
|
2008
|
11 |
3 |
p. A134-
1 p.
|
artikel
|
| 669 |
PMH71 PREVALENCE OF CONCOMITANT USE OF ANTICHOLINERGIC MEDICATIONS AND CHOLINESTERASE INHIBITORS IN A MEDICAID NURSING HOME POPULATION
|
Modi, A
|
|
2008
|
11 |
3 |
p. A131-
1 p.
|
artikel
|
| 670 |
PMH85 PSYCHOTHERAPY AND MEDICATION USE AMONG DEPRESSION PATIENTS
|
Rhee, Y
|
|
2008
|
11 |
3 |
p. A135-
1 p.
|
artikel
|
| 671 |
PMH5 REHOSPITALIZATION AFTER DISCONTINUATION OF PALIPERIDONE ER IN PATIENTS WITH SCHIZOPHRENIA
|
Wu, JH
|
|
2008
|
11 |
3 |
p. A110-
1 p.
|
artikel
|
| 672 |
PMH9 RETENTION RATES FOR ORAL AND DEPOT ANTIPSYCHOTIC MEDICATIONS OVER ONE YEAR IN ONTARIO, CANADA
|
Glass, JR
|
|
2008
|
11 |
3 |
p. A111-A112
nvt p.
|
artikel
|
| 673 |
PMH18 RISK OF NEUROLEPTIC MALIGNANT SYNDROME ASSOCIATED WITH ANTIPSYCHOTICS USE IN PATIENTS WITH BIPOLAR DISORDERS RETROSPECTIVE POPULATION-BASED CASE-CONTROL STUDY
|
Chen, Y
|
|
2008
|
11 |
3 |
p. A114-
1 p.
|
artikel
|
| 674 |
PMH3 STATISTICAL ANALYSIS OF SIGNIFICANT VARIABLES IN DEALING WITH DRUG ABUSE INPATIENTS
|
Cerrito, PB
|
|
2008
|
11 |
3 |
p. A109-A110
nvt p.
|
artikel
|
| 675 |
PMH87 SUPPORTING PRODUCT CLAIMS IN DRUG DEVELOPMENT: A FRAMEWORK FOR INTEGRATING PATIENT REPORTED OUTCOMES AND HEALTH ECONOMICS CONCEPTS AND ENDPOINTS
|
Donatti, C
|
|
2008
|
11 |
3 |
p. A136-
1 p.
|
artikel
|
| 676 |
PMH80 THE CHANGE OF PRICES AND EXPENDITURES OFTHE ORIGINAL AND GENERIC DRUGS OF FLUOXETINE—A LONGITUDINAL ANALYSIS ON REIMBURSEMENT DATABASE OFTHE NATIONAL HEALTH INSURANCE
|
Lee, CF
|
|
2008
|
11 |
3 |
p. A133-A134
nvt p.
|
artikel
|
| 677 |
PMH56 THE IMPACT OF DULOXETINE, VENLAFAXINE AND ESCITALOPRAM USE AND PRESCRIPTION COPAYS ON MEDICATION PERSISTENCE, HEDIS MEASURES AND EXPENDITURES
|
Nair, K
|
|
2008
|
11 |
3 |
p. A126-
1 p.
|
artikel
|
| 678 |
PMH39 THE PREVALENCE AND COSTS OF METABOLIC CONDITIONS AMONG PATIENTS WITH BIPOLAR DISORDERS AS COMPARED TO MATCHED CONTROLS
|
Mark, TL
|
|
2008
|
11 |
3 |
p. A120-A121
nvt p.
|
artikel
|
| 679 |
PMH47 THE RELATIONSHIP BETWEENTHE ANTIPSYCHOTIC MEDICATION ADHERENCE AND PATIENT OUTCOMES AMONG BIPOLAR DISORDER PATIENTS
|
Lage, MJ
|
|
2008
|
11 |
3 |
p. A123-
1 p.
|
artikel
|
| 680 |
PMH86 THE STANDARDS FOR BIPOLAR EXCELLENCE (STABLE) PROJECT: A BIPOLAR DISORDER QUALITY IMPROVEMENT INITIATIVE TO DEVELOP ANDVALIDATE EVIDENCE-BASED PERFORMANCE MEASURES FOR ENDORSEMENT BY THE NATIONAL QUALITY FORUM (NQF)
|
Jewell, M
|
|
2008
|
11 |
3 |
p. A135-A136
nvt p.
|
artikel
|
| 681 |
PMH40 TREATMENT COST AND COMORBIDITIES ASSOCIATED WITH OBESITY AMONG MEDICAID PATIENTS WITH BIPOLAR DISORDER
|
Guo, JJ
|
|
2008
|
11 |
3 |
p. A121-
1 p.
|
artikel
|
| 682 |
PMH8 TREATMENT DURATION FOLLOWING INITIATION ON ATYPICAL ANTIPSYCHOTICS AMONG SCHIZOPHRENIA PATIENTS WITH VERSUS WITHOUT A METABOLIC SYNDROME
|
Shi, L
|
|
2008
|
11 |
3 |
p. A111-
1 p.
|
artikel
|
| 683 |
PMH34 TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD): ESTIMATING THE MAXIMUM ALLOWABLE COST OF PSYCHOSOCIAL INTERVENTIONS IN THE UNITED STATES, GERMANY. THE NETHERLANDS, SWEDEN, AND THE UNITED KINGDOM
|
Schlander, M
|
|
2008
|
11 |
3 |
p. A119-
1 p.
|
artikel
|
| 684 |
PMH12 TREATMENT OUTCOMES OF RISPERIDONE LONG ACTING INJECTION (RLAI) IN SCHIZOPHRENIA: 18-MONTH RESULTS FROM THE ELECTRONIC SCHIZOPHRENIA TREATMENT ADHERENCE REGISTRY (E-STAR) IN CZECH REPUBLIC AND SLOVAKIA
|
Tuma, I
|
|
2008
|
11 |
3 |
p. A112-A113
nvt p.
|
artikel
|
| 685 |
PMH10 TREATMENT PATTERNS PRIORTO INITIATING DEPOT TYPICAL ANTIPSYCHOTICS FOR NON-ADHERENT SCHIZOPHRENIA PATIENTS
|
Peng, X
|
|
2008
|
11 |
3 |
p. A112-
1 p.
|
artikel
|
| 686 |
PMH37 UNITED KINGDOM COST-CONSEQUENCE ANALYSIS OF ARIPIPRAZOLE IN SCHIZOPHRENIA: DIABETES AND CORONARY HEART DISEASE RISK PROJECTIONS (STAR STUDY)
|
Barnett, AH
|
|
2008
|
11 |
3 |
p. A120-
1 p.
|
artikel
|
| 687 |
PMH83 USING RETAIL PHARMACY PRESCRIPTION DATATO INVESTIGATE THE SEASONALITY OF ADHDTREATMENT: JANUARY 2003-OCTOBER 2007
|
Lenderts, SE
|
|
2008
|
11 |
3 |
p. A134-A135
nvt p.
|
artikel
|
| 688 |
PM1 RASCH RATING SCALE ANALYSIS OF THE EQ-5D USING THE 2003 MEDICAL EXPENDITURE PANEL SURVEY (MEPS)
|
Gu, NY
|
|
2008
|
11 |
3 |
p. A13-
1 p.
|
artikel
|
| 689 |
PMS42 A COMPARISON OF PROVINCIAL PRESCRIPTION-ONLY PHARMACEUTICAL DATABASE WITH SELF-REPORTED USAGE OF ACETAMINOPHEN AND NSAIDS ACCORDING TO OSTEOARTHRITIS STAGE IN BRITISH COLUMBIA
|
Sayre, EC
|
|
2008
|
11 |
3 |
p. A267-A268
nvt p.
|
artikel
|
| 690 |
PMS14 A COST-EFFECTIVENESS ANALYSIS OF BIOLOGICAL AGENTS FOR PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS FOLLOWING INADEQAUTE RESPONSE TO METHOTREXATE
|
Gandhi, PK
|
|
2008
|
11 |
3 |
p. A258-A259
nvt p.
|
artikel
|
| 691 |
PMS37 ASSESSING THE VALIDITY AND RELIABILITY OF A SIMPLE ACTIVITY PARTICIPATION MEASURE FOR RHEUMATOID ARTHRITIS CLINICAL TRIALS
|
Li, T
|
|
2008
|
11 |
3 |
p. A266-
1 p.
|
artikel
|
| 692 |
PMS25 ASSOCIATION BETWEEN OUT-OF-POCKET EXPENSES AND CLINICAL OUTCOMES. AND QUALITY OF LIFE IN PATIENTS WITH RHEUMATOID ARTHRITIS
|
Tang, B
|
|
2008
|
11 |
3 |
p. A262-
1 p.
|
artikel
|
| 693 |
PMS34 ATWO-YEAR EVALUATION OF HEALTH OUTCOMES IN OSTEOARTHRITIS PATIENTS AFTERTOTAL KNEE REPLACEMENT
|
Xie, F
|
|
2008
|
11 |
3 |
p. A265-
1 p.
|
artikel
|
| 694 |
PMS45 A TWO-YEAR LONGITUDINAL STUDY OF SWITCHING PATTERNS AMONG ANTI-TUMOR NECROSIS FACTORS IN THE TREATMENT OF RHEUMATOID ARTHRITIS
|
Tang, B
|
|
2008
|
11 |
3 |
p. A268-
1 p.
|
artikel
|
| 695 |
PMS29 BAYESIAN COST-EFFECTIVENESS ANALYSIS OF TREATMENT OF ANKYLOSING SPONDYLITIS
|
Jansen, JP
|
|
2008
|
11 |
3 |
p. A263-
1 p.
|
artikel
|
| 696 |
PMS6 BUDGET IMPACT ANALYSIS OFABATACEPT INCLUSION FOR MODERATE TO SEVERE RHEUMATOID ARTHRITIS IN THE BRAZILIAN PUBLIC SYSTEM
|
Alves, MR
|
|
2008
|
11 |
3 |
p. A256-
1 p.
|
artikel
|
| 697 |
PMS43 CHARACTERISTICS OF PHARMACEUTICS HAVING NO ALTERNATIVES
|
Yim, EY
|
|
2008
|
11 |
3 |
p. A268-
1 p.
|
artikel
|
| 698 |
PMS2 COMPARATIVE EFFICACY OF BIOLOGICAL TREATMENTS IN PATIENTS WITH PSORIATIC ARTHRITIS; SYSTEMATIC LITERATURE REVIEW AND META-ANALYSIS
|
Brodszky, V
|
|
2008
|
11 |
3 |
p. A254-A255
nvt p.
|
artikel
|
| 699 |
PMS11 COST-EFFECTIVENESS ANALYSIS OF RITUXIMAB FOR RHEUMATOID ARTHRITIS IN TAIWAN
|
Lou, SF
|
|
2008
|
11 |
3 |
p. A257-A258
nvt p.
|
artikel
|
| 700 |
PMS12 COST-EFFECTIVENESS ANALYSIS OF ZOLEDRONIC ACID VERSUS RISEDRONATE FOR THE PREVENTION OF OSTEOPOROTIC HIP FRACTURE IN THE PRIVATE HEALTH CARE SYSTEM IN BRAZIL
|
Araujo, D
|
|
2008
|
11 |
3 |
p. A258-
1 p.
|
artikel
|
| 701 |
PMS9 COST-EFFECTIVENESS OF ABATACEPT IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS (RA)AND INADEQUATE RESPONSE TO METHOTREXATE (MTX) ORTUMOR NECROSIS FACTOR-ALPHA INHIBITORS (ANTI-TNFS):A CANADIAN PERSPECTIVE
|
Maier-Moldovan, M
|
|
2008
|
11 |
3 |
p. A257-
1 p.
|
artikel
|
| 702 |
PMS18 COST-EFFECTIVENESS OFABATACEPT IN PATIENTS WITH MODERATELYTO SEVERELY ACTIVE RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO METHOTREXATE IN BRAZIL
|
Alves, MR
|
|
2008
|
11 |
3 |
p. A260-
1 p.
|
artikel
|
| 703 |
PMS13 COST EFFECTIVENESS OF BIOLOGICS FOR RHEUMATOID ARTHRITIS: A SYSTEMATIC REVIEW
|
Pham, B
|
|
2008
|
11 |
3 |
p. A258-
1 p.
|
artikel
|
| 704 |
PMS15 COST-EFFECTIVENESS OF THE TREATMENT FOR EARLY RHEUMATOID ARTHRITIS IN MEXICO: INFLIXIMAB VS. ADALIMUMAB
|
Mucino, E
|
|
2008
|
11 |
3 |
p. A259-
1 p.
|
artikel
|
| 705 |
PMS19 COST MINIMIZATION AND BUDGET IMPACT ANALYSIS OF RITUXIMAB VERSUS INFLIXIMAB, ADALIMUMAB, ETANERCEPT AND ABATACEPT IN RHEUMATOID ARTHRITIS FROM A PAYER PERSPECTIVE IN BRAZIL
|
Saggia, MG
|
|
2008
|
11 |
3 |
p. A260-
1 p.
|
artikel
|
| 706 |
PMS27 DOES THE FUNDING SOURCE INFLUENCE THE RESULTS IN ECONOMIC EVALUATIONS? A CASE- STUDY IN BISPHOSPHONATES FORTHETREATMENT OF OSTEOPOROSIS
|
Fleurence, RL
|
|
2008
|
11 |
3 |
p. A262-A263
nvt p.
|
artikel
|
| 707 |
PMS16 ECONOMIC EVALUATION OF MONTHLY IBANDRONATE VS WEEKLY ALENDRONATE TO PREVENT OSTEOPOROTIC HIP FRACTURES IN MEXICAN WOMEN AGED FIFTY AND OLDER
|
Gasca-Pineda, R
|
|
2008
|
11 |
3 |
p. A259-
1 p.
|
artikel
|
| 708 |
PMS22 ECONOMIC IMPACT OF ALLOPURINOL HYPERSENSITIVITY SYNDROME
|
D'Souza, AO
|
|
2008
|
11 |
3 |
p. A261-
1 p.
|
artikel
|
| 709 |
PMS1 EFFECT OF BISPHOSPHONATES ON FRACTURES IN POSTMEOPAUSALWOMEN:A SYSTEMATIC LITERATURE REVIEW
|
Reddy, P
|
|
2008
|
11 |
3 |
p. A254-
1 p.
|
artikel
|
| 710 |
PMS30 EFFECTS OF 12-HOUR, EXTENDED-RELEASE HYDROCODONE/ACETAMINOPHEN ON PAIN-RELATED WORK PRODUCTIVITY: A SUBANALYSIS FROM A 56-WEEK OPEN-LABEL STUDY
|
Webster, D
|
|
2008
|
11 |
3 |
p. A263-A264
nvt p.
|
artikel
|
| 711 |
PMS3 EFFICACY OF COX-2 SELECTIVE NSAIDS, NON-SELECTIVE NSAIDS, AND ACETAMINOPHEN IN OSTEOARTHRITIS: A BAYESIAN MIXED TREATMENT COMPARISON
|
Jansen, JP
|
|
2008
|
11 |
3 |
p. A255-
1 p.
|
artikel
|
| 712 |
PMS38 ESTIMATING WORK PRODUCTIVITY: EFFECTS OFTRAMADOL EXTENDED-RELEASE TREATMENT
|
Benson, C
|
|
2008
|
11 |
3 |
p. A266-
1 p.
|
artikel
|
| 713 |
PMS8 HEALTH ECONOMICS MODEL FORTOTAL HIP ARTHROPLASTY: COST SAVINGS ACHIEVED BY NEWER TECHNOLOGY
|
Peoples, S
|
|
2008
|
11 |
3 |
p. A256-A257
nvt p.
|
artikel
|
| 714 |
PMS36 IMPROVEMENT IN SLEEP QUALITY FROM ABATACEPT TREATMENT IN RHEUMATOID ARTHRITIS PATIENTS
|
Li, T
|
|
2008
|
11 |
3 |
p. A265-A266
nvt p.
|
artikel
|
| 715 |
PMS17 LONGITUDINAL ESTIMATES AND COST-EFFECTIVENESS ANALYSIS OF ANTI-RESORPTIVE AGENTS FOR GLUCOCORTICOID-INDUCED OSTEOPOROSIS AND FRACTURES BASED ON US NATIONAL SURVEYS
|
Yeh, JY
|
|
2008
|
11 |
3 |
p. A259-A260
nvt p.
|
artikel
|
| 716 |
PMS39 LOSS OF EMPLOYABLE LIFE-YEARS IN PATIENTS WITH RHEUMATOID ARTHRITIS: A PRELIMINARY ANALYSIS USING MARKOV MODEL
|
Han, C
|
|
2008
|
11 |
3 |
p. A266-A267
nvt p.
|
artikel
|
| 717 |
PMS23 MODELLING OF BURDEN OF FEMORAL NECK FRACTURE IN 2007 FROM PURCHASER'S POINT OF VIEW
|
Sebestyén, A
|
|
2008
|
11 |
3 |
p. A261-
1 p.
|
artikel
|
| 718 |
PMS40 ORALVS INJECTABLE TREATMENTS: PATIENT PREFERENCE IN BRAZILIAN PATIENTS
|
Boscatti, FHG
|
|
2008
|
11 |
3 |
p. A267-
1 p.
|
artikel
|
| 719 |
PMS44 PRESCRIPTION TREATMENT PATTERNS IN PATIENTS WITH CHRONIC OSTEOARTHRITIS PAIN
|
Ng, DB
|
|
2008
|
11 |
3 |
p. A268-
1 p.
|
artikel
|
| 720 |
PMS35 QUALITY OF LIFE AMONG OUTPATIENTS WITH RHEUMATOID ARTHRITIS IN A REAL-LIFE SETTING IN GERMANY
|
Deeg, M
|
|
2008
|
11 |
3 |
p. A265-
1 p.
|
artikel
|
| 721 |
PMS28 REAL WORLD COSTS AND DOSING PATTERNS OF ABATACEPT AND INFLIXIMAB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
|
Trivedi, DN
|
|
2008
|
11 |
3 |
p. A263-
1 p.
|
artikel
|
| 722 |
PMS33 RELATIONSHIP BETWEEN PATIENTS' COMPLIANCE TO MS SPECIALTY MEDICATIONS AND TOTAL HEALTH CARE COSTS
|
Khandelwal, NG
|
|
2008
|
11 |
3 |
p. A264-A265
nvt p.
|
artikel
|
| 723 |
PMS32 RELATIONSHIP BETWEEN PATIENTS' COMPLIANCE TO RA SPECIALTY MEDICATIONS AND TOTAL HEALTH CARE COSTS
|
Jiang, JZ
|
|
2008
|
11 |
3 |
p. A264-
1 p.
|
artikel
|
| 724 |
PMS24 RESOURCE UTILIZATION AMONG INPATIENTS WITH RHEUMATOID ARTHRITIS-AN ANALYSIS OF 2004 HEALTH CARE COST AND UTILIZATION PROJECT DATA
|
Parekh, HH
|
|
2008
|
11 |
3 |
p. A262-
1 p.
|
artikel
|
| 725 |
PMS10 THE COST-EFFECTIVENESS OF ABATACEPT VERSUS RITUXIMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS: A PERSPECTIVE OF THE CANADIAN PUBLICLY FUNDED HEALTH CARE SYSTEM
|
Yuan, Y
|
|
2008
|
11 |
3 |
p. A257-
1 p.
|
artikel
|
| 726 |
PMS20 THE ECONOMIC CONSEQUENCES OF RHEUMATOID ARTHRITIS: AN ANALYSIS OF THE MEDICAL EXPENDITURE PANEL SURVEY (MEPS)
|
Simons, WR
|
|
2008
|
11 |
3 |
p. A260-A261
nvt p.
|
artikel
|
| 727 |
PMS4 THE EFFECT OF HOSPITAL VOLUME ON 30 DAYS MORTALITY FOLLOWING HIP FRACTURE
|
Sebestyén, A
|
|
2008
|
11 |
3 |
p. A255-
1 p.
|
artikel
|
| 728 |
PMS21 THE RELATIONSHIP BETWEEN COST OF ILLNESS AND DISEASE SEVERITY IN RHEUMATOID ARTHRITIS: RESULTS OF A SYSTEMATIC REVIEW
|
Richard, L
|
|
2008
|
11 |
3 |
p. A261-
1 p.
|
artikel
|
| 729 |
PMS7 TREATMENT OF DISPLACED FEMORAL NECK FRACTURES IN THE ELDERLYA COST BENEFIT ANALYSIS
|
Alolabi, B
|
|
2008
|
11 |
3 |
p. A256-
1 p.
|
artikel
|
| 730 |
PMS46 TREATMENTS FOR UPPER-LIMB POST-STROKE SPASTICITY: A CRITICAL EVALUATION
|
Olvey, EL
|
|
2008
|
11 |
3 |
p. A269-
1 p.
|
artikel
|
| 731 |
PMS26 TRENDS IN HOSPITALIZATIONS AMONG INPATIENTS WITH RHEUMATOID ARTHRITIS-AN ANALYSIS OF 2002-2004 HEALTH CARE COST AND UTILIZATION PROJECT DATA
|
Parekh, HH
|
|
2008
|
11 |
3 |
p. A262-
1 p.
|
artikel
|
| 732 |
PMS31 TWO-YEAR LONGITUDINAL STUDY OF PERSISTENCE TO ANTI-TUMOR NECROSIS FACTOR TREATMENT AMONG RHEUMATOID ARTHRITIS PATIENTS
|
Tang, B
|
|
2008
|
11 |
3 |
p. A264-
1 p.
|
artikel
|
| 733 |
PMS41 UTILIZATION AND COSTS OF DRUGS AND OFFICE SERVICES AMONG RECIPIENTS OF MEDICAID WITH RHEUMATOID ARTHRITIS WITH VERSUS WITHOUT COMORBID DEPRESSION
|
Khanna, R
|
|
2008
|
11 |
3 |
p. A267-
1 p.
|
artikel
|
| 734 |
PMS5 WHAT HAPPENED TO VIOXX USERS?
|
Huse, D
|
|
2008
|
11 |
3 |
p. A255-A256
nvt p.
|
artikel
|
| 735 |
PM3 THEVALIDITY AND RELIABILITY OF A PARENT-CHILD DYAD APPROACHTO UTILITY AND QUALITY-OF-LIFE ASSESSMENT IN CHILDREN
|
Ungar, WJ
|
|
2008
|
11 |
3 |
p. A14-
1 p.
|
artikel
|
| 736 |
PM2 WHAT PATIENTS SAYVS. WHAT PATIENTS MEAN: QUALITATIVE RESEARCH IN PRO DEVELOPMENT
|
Lasch, KE
|
|
2008
|
11 |
3 |
p. A13-A14
nvt p.
|
artikel
|
| 737 |
PND13 A COST-EFFECTIVENESS ANALYSIS OF NATALIZUMAB VS. INTERFERON-BETA AND GLATIRAMER ACETATE IN PATIENTS WITH ACTIVE RELAPSING-REMITTING MULTIPLE SCLEROSIS CURRENTLY FAILING ON EXISTING THERAPY
|
Gani, R
|
|
2008
|
11 |
3 |
p. A140-
1 p.
|
artikel
|
| 738 |
PND47 ARE THERE GENDER AND ETHNIC DISPARITIES IN THE USE OF INSOMNIA PRESCRIPTIONS?
|
Lai, L
|
|
2008
|
11 |
3 |
p. A151-
1 p.
|
artikel
|
| 739 |
PND34 ASSOCIATION BETWEEN CHANGE IN OVERALL QUALITY OF LIFE (QOL), DISEASE LEVEL AND FUNCTIONAL STATUS SINCE NATALIZUMAB INITIATION
|
Rajagopalan, K
|
|
2008
|
11 |
3 |
p. A147-
1 p.
|
artikel
|
| 740 |
PND7 BUDGET IMPACT OFTRANSDERMAL ADHESIVES OF RIVASTIGMINE IN BRAZILIAN PUBLIC HEALTH SYSTEM
|
Bueno, RLP
|
|
2008
|
11 |
3 |
p. A138-
1 p.
|
artikel
|
| 741 |
PND44 CANADIAN PATIENT SURVEY TO ASSESS PATIENTS' PLIGHT TO DYSTONIA DIAGNOSES AND BOTULINUM TOXIN TYPE A TREATMENT
|
Simonyi, S
|
|
2008
|
11 |
3 |
p. A150-
1 p.
|
artikel
|
| 742 |
PND31 CO-MORBID INSOMNIA IN PRIMARY CARE PATIENTS AFFECTS HEALTH-RELATED QUALITY OF LIFE (HRQL) INDEPENDENT OF OTHER FACTORS
|
Roy, AN
|
|
2008
|
11 |
3 |
p. A146-
1 p.
|
artikel
|
| 743 |
PND26 COMPARISON OF COMPLIANCE AND PERSISTENCE WITH IMMUNOMODULATING AGENTS FOR MULTIPLE SCLEROSIS IN A COMMERCIALLY INSURED POPULATION
|
Shea, T
|
|
2008
|
11 |
3 |
p. A144-A145
nvt p.
|
artikel
|
| 744 |
PND12 COST-EFFECTIVENESS ASSESSMENT OF ANTIEPILEPTIC DRUGS AS ADJUVANTTREATMENTS FOR THE MANAGEMENT OF REFRACTORY PARTIAL SEIZURES IN ADULT MEXICAN PATIENTS
|
Arreola-Ornelas, H
|
|
2008
|
11 |
3 |
p. A140-
1 p.
|
artikel
|
| 745 |
PND9 COST-EFFECTIVENESS OF PREGABALIN IN PATIENTS WITH FIBROMYALGIA: A US PERSPECTIVE
|
Vera-Llonch, M
|
|
2008
|
11 |
3 |
p. A139-
1 p.
|
artikel
|
| 746 |
PND15 COST-UTILITY OF INTERFERON BETA-1B IN THE TREATMENT OF PATIENTS WITH A CLINICALLY ISOLATED SYNDROME SUGGESTIVE OF MULTIPLE SCLEROSIS
|
Caloyeras, JP
|
|
2008
|
11 |
3 |
p. A141-
1 p.
|
artikel
|
| 747 |
PND21 COST-UTILITY OF PRAMIPEXOL COMPARED WITH L-DOPA/CARBIDOPA INTHE TREATMENT OF PARKINSON'S DISEASE IN MEXICO
|
Idrovo, J
|
|
2008
|
11 |
3 |
p. A143-
1 p.
|
artikel
|
| 748 |
PND32 DETERMINATION OFTHE LONGITUDINAL VALIDITY AND MINIMALLY IMPORTANT DIFFERENCE OFTHE 8-ITEM PARKINSON'S DISEASE QUESTIONNAIRE (PDQ-8)
|
Zhao, YJ
|
|
2008
|
11 |
3 |
p. A146-
1 p.
|
artikel
|
| 749 |
PND20 ECONOMIC CONSEQUENCES OF MULTIPLE SCLEROSIS: A POPULATION-BASED STUDY
|
Noyes, K
|
|
2008
|
11 |
3 |
p. A142-A143
nvt p.
|
artikel
|
| 750 |
PND14 ECONOMIC EVALUATION OF SATIVEX® FOR TREATMENT OF NEUROPATHIC PAIN IN PATIENTS WITH MULTIPLE SCLEROSIS
|
Mittmann, N
|
|
2008
|
11 |
3 |
p. A140-A141
nvt p.
|
artikel
|
| 751 |
PND38 EVALUATION OF INTERVIEWER TRAINING FOR AN INTERVIEWER ADMINISTERED PATIENT-REPORTED OUTCOME IN A GLOBAL CLINICAL TRIAL
|
Dries, J
|
|
2008
|
11 |
3 |
p. A148-
1 p.
|
artikel
|
| 752 |
PND25 EXPLORING THE RELATIONSHIP BETWEEN DIFFERENT DISPENSING SYSTEMS AND MEDICATION COMPLIANCE AND PERSISTENCY IN MULTIPLE SCLEROSIS PATIENTS USING PHARMACY CLAIMS DATA
|
Tang, J
|
|
2008
|
11 |
3 |
p. A144-
1 p.
|
artikel
|
| 753 |
PND18 HIGHER INPATIENT COSTS AMONG PATIENTS WITH SUBARACHNOID HEMORRHAGE COMPLICATED BY VASOSPASM
|
Chou, CH
|
|
2008
|
11 |
3 |
p. A142-
1 p.
|
artikel
|
| 754 |
PND35 IMPACT OF NATALIZUMAB ON PATIENT OUTCOMES IN MULTIPLE SCLEROSIS: A CROSS-SECTIONAL SURVEY
|
Stephenson, JJ
|
|
2008
|
11 |
3 |
p. A147-
1 p.
|
artikel
|
| 755 |
PND24 IMPACT OF NON-ADHERENCE TO ANTIEPILEPTIC DRUGS ON MORBIDITY
|
Weiner, JR
|
|
2008
|
11 |
3 |
p. A144-
1 p.
|
artikel
|
| 756 |
PND33 IMPROVED QUALITY OF LIFE AMONG RELAPSINGREMITTING MULTIPLE SCLEROSIS PATIENTS TREATED LONG-TERM WITH GLATIRAMER ACETATE
|
Oleen-Burkey, M
|
|
2008
|
11 |
3 |
p. A147-
1 p.
|
artikel
|
| 757 |
PND28 IMPROVEMENTS IN QUALITY OF LIFE FOLLOWING TREATMENT WITH BOTULINUM TOXIN TYPE A FOR CERVICAL DYSTONIA
|
Carlton, R
|
|
2008
|
11 |
3 |
p. A145-
1 p.
|
artikel
|
| 758 |
PND43 LEVEL OF SATISFACTION OF SPANISH MULTIPLE SCLEROSIS PATIENTS TREATED WITH A NEW FORMULATION OF AVONEX® (INTERFERON BETA-1A 30 MCG INTRAMUSCULAR, ONCE WEEKLY, SOLUTION FOR INJECTION READY TO USE)
|
Sánchez-Soliño, O
|
|
2008
|
11 |
3 |
p. A150-
1 p.
|
artikel
|
| 759 |
PND8 MEDICAL COSTS ASSOCIATED WITHTREATMENT CHANGE IN MULTIPLE SCLEROSIS
|
Nordstrom, B
|
|
2008
|
11 |
3 |
p. A138-A139
nvt p.
|
artikel
|
| 760 |
PND23 MIGRAINE SUFFERERS SHOW SIGNIFICANT HEALTH CARE UTILIZATION AND EXPENDITURES
|
Iyer, RG
|
|
2008
|
11 |
3 |
p. A143-A144
nvt p.
|
artikel
|
| 761 |
PND6 MODELING THE IMPACT OF A FIXED-DOSE COMBINATION OF SUMATRIPTAN AND NAPROXEN SODIUM ONTRIPTAN CONSUMPTION IN A US MANAGED CARE POPULATION
|
Smith, TW
|
|
2008
|
11 |
3 |
p. A138-
1 p.
|
artikel
|
| 762 |
PND36 OBSERVED DIFFERENCES BETWEEN DAILY DIARY AND WEEKLY REPORT OF CYSTIC FIBROSIS SYMPTOMS
|
Bennett, AV
|
|
2008
|
11 |
3 |
p. A148-
1 p.
|
artikel
|
| 763 |
PND39 PATIENT- AND PHYSICIAN-ASSESSED FUNCTIONAL DISABILITY IN PATIENTS TREATED WITH BOTULINUM TOXIN TYPE A FOR CERVICAL DYSTONIA
|
Bramley, T
|
|
2008
|
11 |
3 |
p. A148-A149
nvt p.
|
artikel
|
| 764 |
PND30 PERFORMANCE OFTHE EURO QOL 5D (EQ-5D) IN PRIMARY CARE PATIENTS WITH CO-MORBID INSOMNIA
|
Roy, AN
|
|
2008
|
11 |
3 |
p. A146-
1 p.
|
artikel
|
| 765 |
PND40 PHYSICAL AND PATIENT REPORTED OUTCOMES IN MULTIPLE SCLEROSIS
|
Kirzinger, S
|
|
2008
|
11 |
3 |
p. A149-
1 p.
|
artikel
|
| 766 |
PND41 PHYSICIAN AND PATIENT REPORTED OUTCOMES REVEAL RAPID ONSET OF IMPROVEMENT AND OVERALL CONVENIENCE, TOLERABILITY AND EASE-OF-USE WITH RASAGILINE IN PARKINSON'S DISEASE (PD) IN LEGATO
|
Castelli-Haley, J
|
|
2008
|
11 |
3 |
p. A149-
1 p.
|
artikel
|
| 767 |
PND1 PREVALENCE AND COSTS OF COMORBIDITIES AMONG PERSONS WITH AND WITHOUT MULTIPLE SCLEROSIS: AN ANALYSIS OFTHE AHRQ MAJOR AND SPECIFIC DIAGNOSTIC CATEGORIES
|
Brook, RA
|
|
2008
|
11 |
3 |
p. A136-
1 p.
|
artikel
|
| 768 |
PND37 REDUCTIONS IN FREQUENCY AND INTENSITY OF PAIN WITH BOTULINUM TOXIN TYPE A FOR THE TREATMENT OF CERVICAL DYSTONIA
|
Shah, MV
|
|
2008
|
11 |
3 |
p. A148-
1 p.
|
artikel
|
| 769 |
PND27 RELATIONSHIP BETWEEN GAPS IN DRUGTREATMENT FOR MULTIPLE SCLEROSIS AND INCIDENCE OF EXACERBATIONS: FINDINGS FROM A NATIONAL MANAGED CARE DATABASE
|
Okuda, DT
|
|
2008
|
11 |
3 |
p. A145-
1 p.
|
artikel
|
| 770 |
PND29 REVIEW OF QUALITY OF LIFE INSTRUMENTS IN MIGRAINE
|
Shah, N
|
|
2008
|
11 |
3 |
p. A145-A146
nvt p.
|
artikel
|
| 771 |
PND17 SEVERITY OF ILLNESS AMONG PERSONS WITH AND WITHOUT MULTIPLE SCLEROSIS: AN ANALYSIS OF COST QUINTILES
|
Kleinman, NL
|
|
2008
|
11 |
3 |
p. A141-A142
nvt p.
|
artikel
|
| 772 |
PND5 SUBSTANCE ABUSE AMONG PATIENTS DIAGNOSED WITH INSOMNIA
|
Boulanger, L
|
|
2008
|
11 |
3 |
p. A137-A138
nvt p.
|
artikel
|
| 773 |
PND10 SWITCHING TO HIGH-DOSE HIGH-FREQUENCY INTERFERONS OR NATALIZUMAB IN PATIENTS WITH MULTIPLE SCLEROSIS: A COST-EFFECTIVENESS ANALYSIS
|
Fincher, C
|
|
2008
|
11 |
3 |
p. A139-
1 p.
|
artikel
|
| 774 |
PND16 THE CONCENTRATION AND PERSISTENCE OF HEALTH CARE EXPENDITURES AND PRESCRIPTION DRUG EXPENDITURES IN PATIENTS WITH ALZHEIMER'S DISEASE
|
Lin, PJ
|
|
2008
|
11 |
3 |
p. A141-
1 p.
|
artikel
|
| 775 |
PND22 THE COST OF DISABILITY AND MEDICALLY-RELATED ABSENTEEISM AMONG EMPLOYEES WITH MULTIPLE SCLEROSIS
|
Birnbaum, HG
|
|
2008
|
11 |
3 |
p. A143-
1 p.
|
artikel
|
| 776 |
PND42 THE DEVELOPMENT OF A PATIENT SATISFACTION INSTRUMENT FOR INSOMNIA:A PSYCHOMETRIC APPROACH
|
Vander Wal, G
|
|
2008
|
11 |
3 |
p. A149-A150
nvt p.
|
artikel
|
| 777 |
PND19 THE ECONOMIC IMPACT OF ACUTE MEDICATION OVERUSE AMONG PATIENTS WITH MIGRAINE OR HEADACHE: A MANAGED CARE PERSPECTIVE
|
Pesa, JA
|
|
2008
|
11 |
3 |
p. A142-
1 p.
|
artikel
|
| 778 |
PND2 THE FABRY OUTCOME SURVEY (FOS): A DATABASE OF PROSPECTIVE OBSERVATIONS ONTHE NATURAL HISTORY AND MANAGEMENT OF A RARE DISEASE
|
Clarke, J
|
|
2008
|
11 |
3 |
p. A136-A137
nvt p.
|
artikel
|
| 779 |
PND46 THE RISKS OF MULTIPLE GENERIC SUBSTITUTION OF ANTIEPILEPTIC DRUGS: THE CASE OFTOPIRAMATE
|
Lelorier, J
|
|
2008
|
11 |
3 |
p. A151-
1 p.
|
artikel
|
| 780 |
PND48 THE USE OF BOTULINUM TOXIN TYPE A FOR MIGRAINE OR HEADACHE IN THE USA
|
Cyhaniuk, A
|
|
2008
|
11 |
3 |
p. A151-A152
nvt p.
|
artikel
|
| 781 |
PND4 TRENDS AMONG HOSPITALIZED CYSTIC FIBROSIS PATIENTS
|
Stevenson, HM
|
|
2008
|
11 |
3 |
p. A137-
1 p.
|
artikel
|
| 782 |
PND3 TRENDS IN THE PREVALENCE OF AUTISM SPECTRUM DISORDERS AND RELATED HEALTH CARE UTILIZATION AND COSTS IN A STATE MEDICAID PROGRAM
|
Khanna, R
|
|
2008
|
11 |
3 |
p. A137-
1 p.
|
artikel
|
| 783 |
PND11 TRIPTANS FOR ACUTE MIGRAINE: A SYSTEMATIC REVIEW OF COST-EFFECTIVENESS STUDIES
|
Membe, S
|
|
2008
|
11 |
3 |
p. A139-A140
nvt p.
|
artikel
|
| 784 |
PND45 USE OF DISEASE-MODIFYING DRUGS IN MULTIPLE SCLEROSIS: A POPULATION BASED STUDY
|
Noyes, K
|
|
2008
|
11 |
3 |
p. A150-A151
nvt p.
|
artikel
|
| 785 |
PR4 EVALUATION OF IMPACT OF ORALTOPOTECAN ON HEALTH-RELATED QUALITY OF LIFE IN RELAPSED SMALL CELL LUNG CANCER
|
Duh, MS
|
|
2008
|
11 |
3 |
p. A26-
1 p.
|
artikel
|
| 786 |
PR3 IMPACT OF UNCONTROLLED PEDIATRIC ASTHMA ON HEALTH-RELATED QUALITY OF LIFE (HRQOL)
|
Dean, BB
|
|
2008
|
11 |
3 |
p. A26-
1 p.
|
artikel
|
| 787 |
PRS40 ABSENCE OF CONTROLLER DRUG USE AMONG ASTHMATIC PATIENTS AT RISK OF ASTHMA ATTACK
|
Vaidya, V
|
|
2008
|
11 |
3 |
p. A281-A282
nvt p.
|
artikel
|
| 788 |
PRS6 A COST-EFFECTIVENESS MODEL FOR SMOKING CESSATION THERAPY USING VARENICLINE
|
Viswanathan, S
|
|
2008
|
11 |
3 |
p. A270-A271
nvt p.
|
artikel
|
| 789 |
PRS28 ADHERENCE TO INHALED CORTICOSTEROID USE AND LOCAL ADVERSE EVENTS IN PERSISTENT ASTHMA
|
Ivanova, J
|
|
2008
|
11 |
3 |
p. A278-
1 p.
|
artikel
|
| 790 |
PRS20 A LONG TERM COST-EFFECTIVENESS ANALYSIS MODEL FOR SMOKING CESSATION IN KOREA
|
Bae, JY
|
|
2008
|
11 |
3 |
p. A275-
1 p.
|
artikel
|
| 791 |
PRS2 A MIXED TREATMENT COMPARISON META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS OF PHARMACOLOGIC TREATMENTS FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE
|
Baker, WL
|
|
2008
|
11 |
3 |
p. A269-
1 p.
|
artikel
|
| 792 |
PRS44 ANALYSIS OF THE COSTS RELATED TO SMOKING HABITS OF BENEFICIARIES OF A BRAZILIAN HEALTH PLAN, WITH THE PURPOSE TO DEFINE TREATMENT STRATEGIES TO REIMBURSE FIRST LINE MEDICATIONS
|
Reis Neto, JP
|
|
2008
|
11 |
3 |
p. A283-
1 p.
|
artikel
|
| 793 |
PRS35 A STATISTICAL LOOK AT COPD
|
Cerrito, PB
|
|
2008
|
11 |
3 |
p. A280-
1 p.
|
artikel
|
| 794 |
PRS42 ASTHMA DISEASE BURDEN, EVIDENTIARY REQUIREMENTS, AND FORMULARY CONSIDERATIONS AMONG MANAGED CARE AND EMPLOYER DECISION MAKERS REGARDING INHALED CORTICOSTEROIDS (ICS)
|
O'Day, K
|
|
2008
|
11 |
3 |
p. A282-
1 p.
|
artikel
|
| 795 |
PRS47 ASTHMA PHARMACOTHERAPYAND AT RISK NON-AFRICAN AMERICAN MINORITY POPULATIONS: EVIDENCE OF SUB-OPTIMAL CARE FROM THE NATIONAL AMBULATORY MEDICAL SURVEY 1998-2004
|
Navaratnam, P
|
|
2008
|
11 |
3 |
p. A284-
1 p.
|
artikel
|
| 796 |
PRS41 AVAILABILITY AND PRICE OF TWO INHALATION MEDICINES FOR TREATMENT OF ASTHMA IN DIFFERENT STATES OF INDIA
|
Kotwani, A
|
|
2008
|
11 |
3 |
p. A282-
1 p.
|
artikel
|
| 797 |
PRS3 AVALIDATION STUDY ON USING MORTALITY RISK STRATIFICATION TOOL TO STRATIFY ECONOMIC RISK IN PATIENTS WITH ACUTE EXACERBATION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (AECOPD)
|
Tabak, YP
|
|
2008
|
11 |
3 |
p. A270-
1 p.
|
artikel
|
| 798 |
PRS14 BENEFITS FROM IMPROVED ASTHMA CARE IN FINLAND 1987-2005 ASSESSED WITH ANALYSIS OF COMPREHENSIVE SOCIETAL COST AND BEHAVIOUR OF COST DRIVERS
|
Reissell, E
|
|
2008
|
11 |
3 |
p. A273-
1 p.
|
artikel
|
| 799 |
PRS24 CEILING EFFECTS AND DISCRIMINATION OF TREATMENT BENEFIT FOR PATIENTS WITH LOWER SYMPTOM SEVERITY: MEASUREMENT OF HEALTH UTILITIES IN ALLERGIC RHINITIS
|
Stull, D
|
|
2008
|
11 |
3 |
p. A276-
1 p.
|
artikel
|
| 800 |
PRS1 COMPARISON OF THE EFFECTIVENESS OF ONE VERSUS TWO ANTIBIOTICS IN THE TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA (CAP). AN ANALISYS USING PROPENSITY SCORE.
|
Espinoza, MA
|
|
2008
|
11 |
3 |
p. A269-
1 p.
|
artikel
|
| 801 |
PRS37 CONCURRENT ASTHMA CONTROLLER MEDICATION POSSESSION PROFILES IN AN ADULT MANAGED CARE POPULATION
|
Wagner, S
|
|
2008
|
11 |
3 |
p. A280-A281
nvt p.
|
artikel
|
| 802 |
PRS7 COST-EFFECTIVENESS OF CICLESONIDE VERSUS FLUTICASONE IN THE TREATMENT OF PATIENTS WITH MILD, MODERATE, AND SEVERE ASTHMA
|
Taylor, DC
|
|
2008
|
11 |
3 |
p. A271-
1 p.
|
artikel
|
| 803 |
PRS18 COST-UTILITY ANALYSIS OF VARENICLINE, AN ORAL SMOKING CESSATION DRUG, IN JAPAN
|
Igarashi, A
|
|
2008
|
11 |
3 |
p. A274-
1 p.
|
artikel
|
| 804 |
PRS10 ECONOMIC AND CLINICAL OUTCOMES OF OMALIZUMAB USE FORTREATING ASTHMA IN A MANAGED CARE POPULATION
|
Prescott, J
|
|
2008
|
11 |
3 |
p. A272-
1 p.
|
artikel
|
| 805 |
PRS43 ECONOMIC BURDEN OF ASTHMA AMONG CHILDREN IN THE UNITED STATES
|
Bharmal, M
|
|
2008
|
11 |
3 |
p. A282-A283
nvt p.
|
artikel
|
| 806 |
PRS17 ECONOMIC OUTCOMES IN PATIENTS WITH CYSTIC FIBROSIS: A REVIEW OF THE LITERATURE
|
Toy, EL
|
|
2008
|
11 |
3 |
p. A274-
1 p.
|
artikel
|
| 807 |
PRS22 EFFECT OF PATIENTS' OUT-OF-POCKET COST ON ADHERENCE AND PERSISTENCE WITH OMALIZUMAB (XOLAIR) THERAPY FOR ALLERGIC ASTHMA
|
Yu, HT
|
|
2008
|
11 |
3 |
p. A276-
1 p.
|
artikel
|
| 808 |
PRS36 FACTORS ASSOCIATED WITH ANTIHISTAMINE PRESCRIBING IN ASTHMA IN THE UNITED STATES IN 2005
|
Parikh, K
|
|
2008
|
11 |
3 |
p. A280-
1 p.
|
artikel
|
| 809 |
PRS38 HEALTH CARE UTILIZATION CORRELATED WITH CONTROLLER DURATION DURING THE FIRST YEAR AFTER DIAGNOSIS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
|
Blanchette, CM
|
|
2008
|
11 |
3 |
p. A281-
1 p.
|
artikel
|
| 810 |
PRS8 HEALTH ECONOMICS OF ASTHMAASSESSING THE VALUE OF ASTHMA INTERVENTIONS
|
Spackman, DE
|
|
2008
|
11 |
3 |
p. A271-
1 p.
|
artikel
|
| 811 |
PRS46 HOW PROCESS INFLUENCES SCIENTIFIC EVIDENCE FOR HEALTH CARE POLICYMAKERS. THE CASE OF ECONOMICS AND MEDICAL DECISION-MAKING PROCESSES
|
Huttin, CCH
|
|
2008
|
11 |
3 |
p. A283-A284
nvt p.
|
artikel
|
| 812 |
PRS5 IMPACT OF TOBACCO SMOKE EXPOSURE ON EXACERBATION FREQUENCY, SEVERITY, AND INHALER USE IN ASTHMATIC CHILDREN
|
Everett, BL
|
|
2008
|
11 |
3 |
p. A270-
1 p.
|
artikel
|
| 813 |
PRS32 IMPACT OF UNCONTROLLED ASTHMA ON PRODUCTIVITY AND ACTIVITY IMPAIRMENT
|
Williams, S
|
|
2008
|
11 |
3 |
p. A279-
1 p.
|
artikel
|
| 814 |
PRS31 IMPACT OF UNCONTROLLED PEDIATRIC ASTHMA ON CHILD AND CAREGIVER PRODUCTIVITY
|
Dean, BB
|
|
2008
|
11 |
3 |
p. A279-
1 p.
|
artikel
|
| 815 |
PRS12 INCREMENTAL COST-EFFECTIVENESS OF COMBINATION INHALERTHERAPY IN MODERATE TO SEVERE COPD
|
Oba, Y
|
|
2008
|
11 |
3 |
p. A272-A273
nvt p.
|
artikel
|
| 816 |
PRS16 INCREMENTAL DIRECT MEDICAL EXPENDITURES ASSOCIATED WITH ADULT ASTHMA IN THE UNITED STATES
|
Kamble, S
|
|
2008
|
11 |
3 |
p. A274-
1 p.
|
artikel
|
| 817 |
PRS27 INTERPRETING CLINICAL TRIALS RESULTS FOR THE ONSET OF EFFECT QUESTIONNAIRE: METHODS AND RESULTS OF A DELPHI PANEL
|
Harding, G
|
|
2008
|
11 |
3 |
p. A277-
1 p.
|
artikel
|
| 818 |
PRS11 LONG TERM COST-EFFECTIVENESS AND COST-UTILITY ANALYSIS FOR SMOKING CESSATION IN CZECH REPUBLIC
|
Skoupá, J
|
|
2008
|
11 |
3 |
p. A272-
1 p.
|
artikel
|
| 819 |
PRS21 MEDICATION ADHERENCE AND PERSISTENCE IN THE LAST YEAR OF LIFE IN COPD PATIENTS
|
Jung, E
|
|
2008
|
11 |
3 |
p. A275-
1 p.
|
artikel
|
| 820 |
PRS34 NICOTINE REPLACEMENT THERAPY AND THE MAINE TOBACCO HELPLINE: KNOWLEDGE, UTILIZATION PATTERNS, SHORT-TERM OUTCOMES. AND SATISFACTION AMONG SMOKERS
|
Tworek, C
|
|
2008
|
11 |
3 |
p. A280-
1 p.
|
artikel
|
| 821 |
PRS23 PARTICIPANTS' EXPERIENCE OF ASTHMA: RESULTS FROM A FOCUS GROUP STUDY
|
Turner-Bowker, DM
|
|
2008
|
11 |
3 |
p. A276-
1 p.
|
artikel
|
| 822 |
PRS29 PATIENT, CAREGIVER, AND PHYSICIAN PERCEPTIONS OF MANAGEMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE: FINDINGS FROM QUALITATIVE RESEARCH
|
Bentkover, JD
|
|
2008
|
11 |
3 |
p. A278-
1 p.
|
artikel
|
| 823 |
PRS13 PEDIATRIC ASTHMA: AN EMPLOYER PERSPECTIVE ON ANNUAL EMPLOYEE AND DEPENDENT COSTS FOR MEDICAL CARE AND PRESCRIPTION DRUGS
|
Kleinman, N
|
|
2008
|
11 |
3 |
p. A273-
1 p.
|
artikel
|
| 824 |
PRS26 PREFERENCES FOR ONSET OF EFFECT OF COMBINATION MAINTENANCE MEDICATION AMONG ASTHMA PATIENTS
|
Mohamed, AF
|
|
2008
|
11 |
3 |
p. A277-
1 p.
|
artikel
|
| 825 |
PRS4 PROGNOSTIC FACTORS OF PATIENTS TRANSFERRED TO CHRONIC RESPIRATORY CARE WARD
|
Hung, MC
|
|
2008
|
11 |
3 |
p. A270-
1 p.
|
artikel
|
| 826 |
PRS19 SMOKING-CESSATION THERAPY USING VARENICLINE- THE COST-UTILITY OF AN ADDITIONAL 12-WEEK COURSE OF VARENICLINE FOR THE MAINTENANCE OF SMOKING ABSTINENCE
|
Bolin, K
|
|
2008
|
11 |
3 |
p. A275-
1 p.
|
artikel
|
| 827 |
PRS15 THE BURDEN OF NASAL CONGESTION IN THE UNITED STATES
|
Stull, D
|
|
2008
|
11 |
3 |
p. A273-A274
nvt p.
|
artikel
|
| 828 |
PRS9 THE COST-EFFECTIVENESS OF TARGETED PRESCRIBING OF ANTIMICROBIALS IN CANADA FOR COMMUNITY-ACQUIRED PNEUMONIA IN AN ERA OF ANTIMICROBIAL RESISTANCE
|
Moore, L
|
|
2008
|
11 |
3 |
p. A271-A272
nvt p.
|
artikel
|
| 829 |
PRS45 THE DEVELOPMENT AND VALIDATION OF A CONTEMPORARY ASTHMA POLICY MODEL
|
Campbell, JD
|
|
2008
|
11 |
3 |
p. A283-
1 p.
|
artikel
|
| 830 |
PRS39 THE IMPACT OF FORMULARY POLICIES ON THE USE OF MEDICATION FOR RESPIRATORY DISEASE: A COMPARISON OF DRUG UTILIZATION IN THE PROVINCES OF ONTARIO AND ALBERTA
|
Pilla, J
|
|
2008
|
11 |
3 |
p. A281-
1 p.
|
artikel
|
| 831 |
PRS33 TREATMENT SATISFACTION QUESTIONNAIRES IN ASTHMA AND OTHER CHRONIC DISEASES
|
Staniek, V
|
|
2008
|
11 |
3 |
p. A279-
1 p.
|
artikel
|
| 832 |
PRS30 USE OF INTERACTIVE VOICE RESPONSE (IVR)TO COLLECT DAILY PATIENT DIARY DATA IN A CLINICAL TRIAL OF SEASONAL RHINITIS
|
Tiplady, B
|
|
2008
|
11 |
3 |
p. A278-
1 p.
|
artikel
|
| 833 |
PRS25 VALIDATION OF CLAIMS-BASED PERSISTENT ASTHMA SEVERITY CLASSIFICATION
|
Yu, AP
|
|
2008
|
11 |
3 |
p. A277-
1 p.
|
artikel
|
| 834 |
PR2 VALIDATION OF THE PATIENT HEALTH QUESTIONNAIRE IN BRFSS—APPLICATION OF CROSS-VALIDATION METHOD
|
Yeh, Y
|
|
2008
|
11 |
3 |
p. A25-A26
nvt p.
|
artikel
|
| 835 |
PR1 VARIABILITY OF HEALTH UTILITIES INDEX MARK 3 (HUI3) MEASUREMENTS DURINGTREATMENT FOR ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDHOOD
|
Rae, CS
|
|
2008
|
11 |
3 |
p. A25-
1 p.
|
artikel
|
| 836 |
PSS11 A COST-EFFECTIVENESS ANALYSIS OF BRIMONIDINE/TIMOLOL
|
Higginbotham, E
|
|
2008
|
11 |
3 |
p. A287-
1 p.
|
artikel
|
| 837 |
PSS9 A COST-EFFECTIVENESS ANALYSIS OFTNF-ALPHA INHIBITORS IN COMPARISON TO OTHER STRATEGIES IN THE TREATMENT OF MODERATE-TO-SEVERE PSORIASIS: A DECISION ANALYSIS MODEL
|
Viswanathan, S
|
|
2008
|
11 |
3 |
p. A287-
1 p.
|
artikel
|
| 838 |
PSS16 A COST-EFFECTIVENESS ANALYSIS OF TWO TOPICAL OPHTHALMIC ANTIBIOTIC SOLUTIONS INDICATED FOR THE TREATMENT OF BACTERIAL CONJUNCTIVITIS
|
Waycaster, C
|
|
2008
|
11 |
3 |
p. A289-
1 p.
|
artikel
|
| 839 |
PSS47 AN OBSERVATIONAL DATABASE ANALYSIS OF TREATMENT PATTERNS OF PATIENTS WITH PSORIASIS
|
Mehra, M
|
|
2008
|
11 |
3 |
p. A299-
1 p.
|
artikel
|
| 840 |
PSS19 A PHARMACOECONOMIC EVALUATION OF PEGAPTANIB FOR THE MANAGEMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) IN MEXICO
|
Vega-Hernández, GY
|
|
2008
|
11 |
3 |
p. A290-
1 p.
|
artikel
|
| 841 |
PSS41 APPLES AND ORANGES? ASSESSING THE RELATIONSHIP BETWEEN HEALTH AND VISION RELATED QUALITY OF LIFE
|
Kymes, SM
|
|
2008
|
11 |
3 |
p. A297-
1 p.
|
artikel
|
| 842 |
PSS31 ASSESSMENT OF QUALITY OF LIFE IN DAILY CLINICAL DERMATOLOGICAL ROUTINE: QUESTIONNAIRES AND CHECKLIST
|
Tabolli, S
|
|
2008
|
11 |
3 |
p. A294-
1 p.
|
artikel
|
| 843 |
PSS1 CO-MORBIDITIES INCREASE IN THE YEAR FOLLOWING A DIAGNOSIS OF PSORIASIS
|
Rahman, M
|
|
2008
|
11 |
3 |
p. A284-
1 p.
|
artikel
|
| 844 |
PSS3 COMPARING THE EFFECTIVENESS OF CORTISPORIN VS. CIPRODEX FOR ACUTE OTITIS EXTERNA IN THE LOUISIANA MEDICAID POPULATION
|
Jain, G
|
|
2008
|
11 |
3 |
p. A285-
1 p.
|
artikel
|
| 845 |
PSS36 COMPARISON OF THE QUALITY OF LIFE IMPACT OF PERIPHERAL VISION LOSS VERSUS CENTRAL VISION LOSS
|
Walt, JG
|
|
2008
|
11 |
3 |
p. A295-
1 p.
|
artikel
|
| 846 |
PSS13 COST-EFFECTIVE ANALYSIS OF PEGAPTANIB (MACUGEN®) AS COMPARED WITH RANIBIZUMAB (LUCENTIS®) FOR TREATING IN AGE-RELATED MACULAR DEGENERATION (AMD)
|
Lu, LY
|
|
2008
|
11 |
3 |
p. A288-
1 p.
|
artikel
|
| 847 |
PSS12 COST-EFFECTIVENESS ANALYSIS OF BEVACIZUMAB AND RANIBIZUMAB IN NEOVASCULARAGE-RELATED MACULAR DEGENERATION (AMD): A CLINICAL AND ECONOMIC COMPARISON OF TWO VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITOR TREATMENTS
|
Patel, JJ
|
|
2008
|
11 |
3 |
p. A288-
1 p.
|
artikel
|
| 848 |
PSS10 COST-EFFECTIVENESS OF ANTIVEGF THERAPIES FOR WET AGE-RELATED MACULAR DEGENERATION—AMD IN BRAZIL: THE PRIVATE PAYER PERSPECTIVE
|
Bueno, RLP
|
|
2008
|
11 |
3 |
p. A287-
1 p.
|
artikel
|
| 849 |
PSS6 COST-EFFECTIVENESS OF INTERMITTENT VS. CONTINUOUS ANTI-TNF ALPHA THERAPY IN PLAQUE PSORIASIS
|
Lloyd, AC
|
|
2008
|
11 |
3 |
p. A286-
1 p.
|
artikel
|
| 850 |
PSS18 COST-EFFECTIVENESS OF THE BIOLOGIC AGENTS UTILIZED IN THE TREATMENT OF CHRONIC PLAQUE PSORIASIS: A MARKOV MODEL
|
Goldberg, LD
|
|
2008
|
11 |
3 |
p. A289-A290
nvt p.
|
artikel
|
| 851 |
PSS14 COST-EFFECTIVENESS OF THE TREATMENT FOR MODERATE TO SEVERE PSORIASIS IN MEXICO: INFLIXIMAB, ETANERCEPT AND EFALIZUMAB
|
Muciño, E
|
|
2008
|
11 |
3 |
p. A288-
1 p.
|
artikel
|
| 852 |
PSS20 COST-EFFECTIVENESS OF TOBRADEX VERSUS ZYLET FOR THE TREATMENT OF BLEPHAROKERATOCONJUNCTIVITIS
|
Rahman, A
|
|
2008
|
11 |
3 |
p. A290-
1 p.
|
artikel
|
| 853 |
PSS21 COST OF ILLNESS OF WORK-RELATED CHRONIC HAND ECZEMA IN GERMANY
|
Diepgen, T
|
|
2008
|
11 |
3 |
p. A290-A291
nvt p.
|
artikel
|
| 854 |
PSS28 DISTANCE VISUAL ACUITY AS A MEASURE OF VISION FUNCTION-INSIGHT INTO THE ASSOCIATION OF ETDRS LETTERS AND SELF-REPORT IN SUBJECTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NV-AMD)
|
Pleil, A
|
|
2008
|
11 |
3 |
p. A293-
1 p.
|
artikel
|
| 855 |
PSS17 ECONOMIC EVALUATION OF MELOXICAM SOLUTION 0.030% RESPECT AN OPHTHALMIC SODIUM DICLOFENAC SOLUTION 0.1% ON THE EYES OF PATIENTS WHO UNDERWENT TO LASIK LASER EYE SURGERY AT THE IMMEDIATELY POST-OPERATIVE TIME
|
Baiza, L
|
|
2008
|
11 |
3 |
p. A289-
1 p.
|
artikel
|
| 856 |
PSS2 EFFICACY OF BIOLOGICAL TREATMENT IN PATIENTS WITH PSORIASIS; META-ANALYSIS
|
Brodszky, V
|
|
2008
|
11 |
3 |
p. A284-A285
nvt p.
|
artikel
|
| 857 |
PSS8 ESTIMATING COST-EFFECTIVENESS OF TOPICAL OCULAR HYPOTENSIVES FOR MAINTAINING PERSISTENT THERAPY USING AREA UNDERTHE SURVIVAL CURVE
|
Reardon, G
|
|
2008
|
11 |
3 |
p. A286-A287
nvt p.
|
artikel
|
| 858 |
PSS39 ESTIMATING HEALTH RELATED UTILITY FROM SYMPTOM SEVERITY IN ATOPIC DERMATITIS (ECZEMA)
|
Poole, CD
|
|
2008
|
11 |
3 |
p. A296-
1 p.
|
artikel
|
| 859 |
PSS48 HEALTH CARE COSTS INCREASE IN THE YEAR FOLLOWING A DIAGNOSIS OF PSORIASIS
|
Rahman, M
|
|
2008
|
11 |
3 |
p. A299-
1 p.
|
artikel
|
| 860 |
PSS49 HEALTH CARE UTILIZATION INCREASES IN THE YEAR FOLLOWING A DIAGNOSIS OF PSORIASIS
|
Rahman, M
|
|
2008
|
11 |
3 |
p. A299-
1 p.
|
artikel
|
| 861 |
PSS33 INTERNATIONAL DEVELOPMENT OF THE FIRST QUALITY OF LIFE INSTRUMENT SPECIFIC TO COSMETOLOGY AND PHYSICAL APPEARANCE:THE BEAUTYQOL INITIATIVE
|
Beresniak, A
|
|
2008
|
11 |
3 |
p. A294-A295
nvt p.
|
artikel
|
| 862 |
PSS37 MAPPING THE DERMATOLOGY QUALITY OF LIFE INDEX (DLQI)TO HEALTH-RELATED UTILITYVIATHE SF-12 IN SUBJECTS WITH ECZEMA
|
Currie, CJ
|
|
2008
|
11 |
3 |
p. A295-A296
nvt p.
|
artikel
|
| 863 |
PSS42 MAPPING THE NATIONAL EYE INSTITUTE VISUAL FUNCTION QUESTIONNAIRE (NEI-VFQ 25) TO THE INDEX VALUES FOR THE EQ-5D:A COMPARISON OF MODELS
|
Payakachat, N
|
|
2008
|
11 |
3 |
p. A297-
1 p.
|
artikel
|
| 864 |
PSS5 MEDICAL COST OF GLAUCOMA IN SWEDEN
|
Strom, O
|
|
2008
|
11 |
3 |
p. A285-A286
nvt p.
|
artikel
|
| 865 |
PSS38 PATIENTS' PERCEPTION OF LIFE FREE OF GLASSES AFTER CATARACT SURGERY: DEVELOPMENT OF THE FREEDOM FROM GLASSES VALUE SCALE (FGVS®)
|
Arnould, B
|
|
2008
|
11 |
3 |
p. A296-
1 p.
|
artikel
|
| 866 |
PSS25 PHARMACOECONOMIC STUDY OF WET AGE-RELATED MACULAR DEGENERATION (AND)TREATMENT IN MEXICO
|
Soria-Cedillo, IF
|
|
2008
|
11 |
3 |
p. A292-
1 p.
|
artikel
|
| 867 |
PSS23 PROACTIVE USE OFTACROLIMUS 0.03% OINTMENT IN CHILDREN WITH MODERATE OR SEVERE ATOPIC DERMATITIS-OUTCOMES AND COST
|
Thaçi, D
|
|
2008
|
11 |
3 |
p. A291-
1 p.
|
artikel
|
| 868 |
PSS46 PROSTAGLANDIN ANALOG USE WITH AND WITHOUT ADJUNCTIVE THERAPY FOR THE TREATMENT OF GLAUCOMAA NETHERLANDS POPULATION BASED ANALYSIS
|
Iskedjian, M
|
|
2008
|
11 |
3 |
p. A298-A299
nvt p.
|
artikel
|
| 869 |
PSS40 QUALITY OF LIFE AND PSYCHOLOGICAL PROBLEMS IN PATIENTS WITH ORAL MUCOSAL DISEASES
|
Tabolli, S
|
|
2008
|
11 |
3 |
p. A296-A297
nvt p.
|
artikel
|
| 870 |
PSS32 QUALITY OF LIFE AND PSYCOLOGICAL DISTRESS IN PATIENT WITH CUTANEUOS LYMPHOMA
|
Sampogna, F
|
|
2008
|
11 |
3 |
p. A294-
1 p.
|
artikel
|
| 871 |
PSS34 QUALITY OF LIFE IN PATIENTS WITH VITILIGO. USE OF SINGLE ITEM ANALYSIS
|
Sampogna, F
|
|
2008
|
11 |
3 |
p. A295-
1 p.
|
artikel
|
| 872 |
PSS22 THE ANNUAL COST OF BACTERIAL CONJUNCTIVITIS IN THE UNITED STATES: EVIDENCE FROM AN ECONOMIC MODELLING APPROACH
|
Smith, AF
|
|
2008
|
11 |
3 |
p. A291-
1 p.
|
artikel
|
| 873 |
PSS7 THE COST-EFFECTIVENESS OF RANIBIZUMAB COMPARED TO PDT-VAND BSC FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION IN CANADA
|
Lozano-Ortega, G
|
|
2008
|
11 |
3 |
p. A286-
1 p.
|
artikel
|
| 874 |
PSS15 THE COST-EFFECTIVENESS OF RANIBIZUMAB (LUCENTIS®) IN TREATING PATIENTS WITH PREDOMINANTLY CLASSIC, MINIMALLY CLASSIC, AND OCCULT NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (AMD)
|
Turpcu, A
|
|
2008
|
11 |
3 |
p. A288-A289
nvt p.
|
artikel
|
| 875 |
PSS35 THE IMPACT OF GLAUCOMA ON QUALITY OF LIFE: COMPARISON WITH THE CHRONIC DISEASES OSTEOPOROSIS. TYPE 2 DIABETES MELLITUS, AND DEMENTIA
|
Walt, JG
|
|
2008
|
11 |
3 |
p. A295-
1 p.
|
artikel
|
| 876 |
PSS4 THE RCT EVIDENCE OF COMPARATIVE EFFECTIVENESS AND SAFETY OF TOPICAL GLAUCOMA MEDICATION
|
Lee, CW
|
|
2008
|
11 |
3 |
p. A285-
1 p.
|
artikel
|
| 877 |
PSS24 TRENDS IN EPISODE OF TREATMENT COSTS OF ACNE ACROSS THE UNITED STATES
|
Balkrishnan, R
|
|
2008
|
11 |
3 |
p. A291-A292
nvt p.
|
artikel
|
| 878 |
PSS50 TRENDS IN MEDICATION PRESCRIBING FOR ACNE IN THE UNITED STATES ACCORDING TO PATIENT AGE
|
Uhas, AA
|
|
2008
|
11 |
3 |
p. A300-
1 p.
|
artikel
|
| 879 |
PSS26 USING COST-UTILITY ANALYSIS TO ASSESS THE BUDGET IMPACT OF BIOLOGICS FOR THE TREATMENT OF PSORIASIS (PSO)
|
Spiegel, BM
|
|
2008
|
11 |
3 |
p. A292-
1 p.
|
artikel
|
| 880 |
PSS27 USING MEDICATION POSSESSION AND DAYS OF COVERAGE ON THERAPYTO ASSESS PERSISTENCE WITH PROSTAGLANDIN OCULAR HYPOTENSIVE THERAPY
|
Kotak, S
|
|
2008
|
11 |
3 |
p. A292-A293
nvt p.
|
artikel
|
| 881 |
PSS29 USTEKINUMAB IMPROVES DISEASE SPECIFIC HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MODERATE TO SEVERE PSORIASIS: RESULTS WITH THE DERMATOLOGY LIFE QUALITY INDEX
|
Lebwohl, M
|
|
2008
|
11 |
3 |
p. A293-
1 p.
|
artikel
|
| 882 |
PSS44 USTEKINUMAB IMPROVES WORK PRODUCTIVITY AND DECREASES WORKDAYS MISSED DUE TO PSORIASIS IN PATIENTS WITH MODERATE TO SEVERE PSORIASIS
|
Reich, K
|
|
2008
|
11 |
3 |
p. A298-
1 p.
|
artikel
|
| 883 |
PSS30 USTEKINUMAB SIGNIFICANTLY IMPROVES QUALITY OF LIFE IN PATIENTS WITH PSORIASIS: RESULTS FROM A PHASE III STUDY
|
Langley, R
|
|
2008
|
11 |
3 |
p. A293-A294
nvt p.
|
artikel
|
| 884 |
PSS45 VALUE OF DRIVING FOR PATIENTS WITH GLAUCOMA: WILLINGNESS TO PAY
|
Walt, JG
|
|
2008
|
11 |
3 |
p. A298-
1 p.
|
artikel
|
| 885 |
PSS43 WORK RELATED LOST PRODUCTIVITY AND ITS ECONOMIC IMPACT IN CANADIAN PATIENTS WITH MODERATE TO SEVERE PSORIASIS
|
Chan, BCF
|
|
2008
|
11 |
3 |
p. A297-A298
nvt p.
|
artikel
|
| 886 |
PSY18 A COMPARATIVE COST-EFFECTIVENESS ANALYSIS ONTHE USE OF FLECTOR(r) PATCH (DICLOFENAC EPOLAMINE TOPICAL PATCH) 1.3% VERSUS LIDODERM® (LIDOCAINE PATCH 5%) FOR THE TREATMENT OF ACUTE PAIN FOLLOWING INJURY
|
Carter, CA
|
|
2008
|
11 |
3 |
p. A157-
1 p.
|
artikel
|
| 887 |
PSY3 A META-ANALYSIS OF RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIALS OFTHE EFFICACY OF BOTULINUM TOXIN A FOR THE PROPHYLAXIS OF CHRONIC MIGRAINE HEADACHES
|
Shuhendler, AJ
|
|
2008
|
11 |
3 |
p. A152-A153
nvt p.
|
artikel
|
| 888 |
PSY10 A NOVEL APPROACHTO ADJUST FOR THE IMPACT ON SURVIVAL RESULTING FROM PATIENT CROSS-OVER FROM CONTROLTO EXPERIMENTAL TREATMENT IN CLINICAL TRIALS
|
Ishak, KJ
|
|
2008
|
11 |
3 |
p. A155-
1 p.
|
artikel
|
| 889 |
PSY28 A SYSTEMATIC REVIEW OF LOW BACK PAIN COST OF ILLNESS STUDIES IN THE UNITED STATES AND INTERNATIONALLY
|
Dagenais, S
|
|
2008
|
11 |
3 |
p. A160-A161
nvt p.
|
artikel
|
| 890 |
PSY27 BURDEN OF OBESITY: 10-YEAR REVIEW OF PUBLISHED LITERATURE ON DIRECT AND INDIRECT COSTS IN NINE COUNTRIES
|
Barrett, AM
|
|
2008
|
11 |
3 |
p. A160-
1 p.
|
artikel
|
| 891 |
PSY7 BURDEN OF OBESITY: 10-YEAR REVIEW OF PUBLISHED LITERATURE ON OBESITY PREVALENCE IN NINE COUNTRIES
|
Barrett, AM
|
|
2008
|
11 |
3 |
p. A154-
1 p.
|
artikel
|
| 892 |
PSY36 COMPLEMENTARY AND ALTERNATIVE MEDICINE AND HEALTH CARE UTILIZATION IN PATIENTS WITH NON-CANCER CHRONIC PAIN
|
Liao, D
|
|
2008
|
11 |
3 |
p. A163-
1 p.
|
artikel
|
| 893 |
PSY20 COST-EFFECTIVENESS ANALYSIS OF IMMUNOSUPPRESSIVE TREATMENTS FOR BONE MARROWTRANSPLANTATION IN PATIENTS WITH APLASTIC ANEMIA IN MEXICO
|
Mould-Quevedo, J
|
|
2008
|
11 |
3 |
p. A158-
1 p.
|
artikel
|
| 894 |
PSY15 COST-EFFECTIVENESS OF ERYTHROPOIESIS STIMULATING AGENTTHERAPY BY HEMOGLOBINTARGETS IN CHRONIC KIDNEY DISEASE
|
An, JJ
|
|
2008
|
11 |
3 |
p. A156-
1 p.
|
artikel
|
| 895 |
PSY23 COST-EFFECTIVENESS OF LAPAROSCOPIC ADJUSTABLE GASTRIC BANDING AND LAPAROSCOPIC ROUX-EN-Y GASTRIC BYPASS IN THE TREATMENT OF MORBID OBESITY
|
Campbell, J
|
|
2008
|
11 |
3 |
p. A159-
1 p.
|
artikel
|
| 896 |
PSY22 COST-EFFECTIVENESS OF PREGABALIN COMPARED TO GABAPENTIN INTREATMENT OF PATIENTS WITH POSTHERPETIC NEURALGIA
|
Ragnarson Tennvall, G
|
|
2008
|
11 |
3 |
p. A158-A159
nvt p.
|
artikel
|
| 897 |
PSY16 COST-EFFECTIVENESS OFTRANSDERMAL OPIOIDS REGARDING OPIOID-RELATED FRACTURES IN GERMANY— A MODEL APPROACH
|
Hass, B
|
|
2008
|
11 |
3 |
p. A157-
1 p.
|
artikel
|
| 898 |
PSY34 COST-UTILITY ANALYSIS OF SUBCUTANEOUSVERSUS INTRAVENOUS IMMUNOGLOBULIN
|
Membe, S
|
|
2008
|
11 |
3 |
p. A162-
1 p.
|
artikel
|
| 899 |
PSY32 COST-UTILITY STUDY OF RECOMBINANT FACTORVIII IN THE TREATMENT OF HEMOPHILIA A IN MEXICO
|
Soria-Cedillo, IF
|
|
2008
|
11 |
3 |
p. A162-
1 p.
|
artikel
|
| 900 |
PSY5 CROSS-CULTURAL COMPARISONS OFTHE OVERWEIGHT/OBESE POPULATION IN THE US AND EUROPE
|
Annunziata, K
|
|
2008
|
11 |
3 |
p. A153-
1 p.
|
artikel
|
| 901 |
PSY54 DEVELOPMENT OF AN OPIOID ROTATION MODEL
|
Magar, RS
|
|
2008
|
11 |
3 |
p. A169-
1 p.
|
artikel
|
| 902 |
PSY55 DIAGNOSIS ANDTREATMENT FLOWS FOR MORBIDLY OBESE PATIENTS VISITING PHYSICIAN OFFICES IN THE US
|
Pokras, S
|
|
2008
|
11 |
3 |
p. A169-
1 p.
|
artikel
|
| 903 |
PSY43 DISCOVERING THE STRUCTURE OFTHE POWER OF FOOD SCALE (PFS) IN OBESE PATIENTS
|
Cappelleri, JC
|
|
2008
|
11 |
3 |
p. A165-
1 p.
|
artikel
|
| 904 |
PSY14 ECONOMIC EVALUATION OF LENOLIDOMIDE USE FOR MULTIPLE MYELOMA IN SCOTLAND IN PATIENTSWHO HAVE RECEIVED ONE PRIOR THERAPY
|
Deniz, B
|
|
2008
|
11 |
3 |
p. A156-
1 p.
|
artikel
|
| 905 |
PSY25 ECONOMIC IMPACT AND CONSERVATION OF INTRAVENOUS IMMUNOGLOBULIN (IVIG)THROUGHTHERAPEUTIC SUBSTITUTION WITH ANTI-D IN PATIENTS WITH IDIOPATHICTHROMBOCYTOPENIA PURPURA (ITP) AT AN URBANTEACHING HOSPITAL IN STATEN ISLAND, NY
|
Coyne, M
|
|
2008
|
11 |
3 |
p. A159-A160
nvt p.
|
artikel
|
| 906 |
PSY42 EFFECTIVENESS OF ONCE-DAILY EXTENDED-RELEASE (ER) TRAMADOL IN ACHIEVING CLINICALLY MEANINGFUL IMPROVEMENT IN FUNCTIONING
|
Janagap, C
|
|
2008
|
11 |
3 |
p. A165-
1 p.
|
artikel
|
| 907 |
PSY11 EVALUATION OF ACETAMINOPHEN EXPOSURES REPORTED TO A REGIONAL POISON CONTROL CENTER FOR ADULT PATIENTS
|
Angalakuditi, MV
|
|
2008
|
11 |
3 |
p. A155-
1 p.
|
artikel
|
| 908 |
PSY30 EVALUATION OF COST AND OUTCOMES OF WEIGHT CONTROL PROGRAM IN A REGIONAL HOSPITAL AT SOUTHERNTAIWAN
|
Yen, JMC
|
|
2008
|
11 |
3 |
p. A161-
1 p.
|
artikel
|
| 909 |
PSY45 EVALUATION OF THE NEUROPATHIC PAIN SYMPTOM INVENTORY: CONCEPTUAL ADEQUACY IN SIX COUNTRIES
|
Crawford, B
|
|
2008
|
11 |
3 |
p. A166-
1 p.
|
artikel
|
| 910 |
PSY38 FACTORS ASSOCIATED WITH LOWER HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN ADULTS WITH FACTORVIII DEFICIENCY—THE HEMOPHILIA UTILIZATION GROUP STUDY-PART V (HUGS-V)
|
Zhou, ZY
|
|
2008
|
11 |
3 |
p. A163-A164
nvt p.
|
artikel
|
| 911 |
PSY31 GREATER SEVERITY OF ILLNESS, RISK OF MORTALITY, LENGTH-OF-STAY, AND HOSPITAL COSTS IN PATIENTS WITH HYPONATREMIA
|
Ernst, FR
|
|
2008
|
11 |
3 |
p. A161-A162
nvt p.
|
artikel
|
| 912 |
PSY39 HEALTH-RELATED QUALITY OF LIFE OF PATIENTS WITH HEMOPHILIA AND INHIBITORS
|
Lee, WC
|
|
2008
|
11 |
3 |
p. A164-
1 p.
|
artikel
|
| 913 |
PSY53 HOSPITAL CHARGES AND COMORBIDITIES AMONG OBESE AND MORBIDLY OBESE PATIENTS
|
Hlaing, WM
|
|
2008
|
11 |
3 |
p. A168-
1 p.
|
artikel
|
| 914 |
PSY48 IMPACT OF IMMUNETHROMBOCYTOPENIC PURPURA ON HEALTH CARE RESOURCE USE ANDWORKPLACE PRODUCTIVITY
|
Young, JW
|
|
2008
|
11 |
3 |
p. A167-
1 p.
|
artikel
|
| 915 |
PSY47 IMPACT OF NIGHTTIME PAIN ON SLEEP QUALITY IN PATIENTS WITH CHRONIC PAINFUL CONDITIONS
|
Chaudhari, PK
|
|
2008
|
11 |
3 |
p. A166-
1 p.
|
artikel
|
| 916 |
PSY52 INADEQUATE GASTROPROTECTION AMONG NEW CHRONIC USERS OFTRADITIONAL NSAIDS IN THE NETHERLANDS
|
Van der Linden, MW
|
|
2008
|
11 |
3 |
p. A168-
1 p.
|
artikel
|
| 917 |
PSY44 LINGUISTIC VALIDATION OF THE HAEMO-QOL AND HAEM-A-QOL FOR USE IN INTERNATIONAL STUDIES
|
Chevallet, L
|
|
2008
|
11 |
3 |
p. A165-
1 p.
|
artikel
|
| 918 |
PSY1 META-ANALYSIS OF ANTICONVULSANTS, SNRIS ANDTCAS IN TREATING NEUROPATHIC PAIN
|
Einarson, TR
|
|
2008
|
11 |
3 |
p. A152-
1 p.
|
artikel
|
| 919 |
PSY41 PATIENT- AND CAREGIVER-REPORTED PREFERENCES FOR CHARACTERISTICS OFTREATMENTS FOR HEMOPHILIA PATIENTS WITH INHIBITORS
|
Lee, WC
|
|
2008
|
11 |
3 |
p. A164-A165
nvt p.
|
artikel
|
| 920 |
PSY19 PHARMACOECONOMIC EVALUATION OF TREATMENT OF HAIRY CELL LEUKEMIA
|
Krysanov, I
|
|
2008
|
11 |
3 |
p. A158-
1 p.
|
artikel
|
| 921 |
PSY50 PHYSICIANS' INTENTIONS TO MEASURE BODY MASS INDEX IN CHILDREN AND ADOLESCENTS:ATHEORY OF REASONED ACTION MODEL
|
Khanna, R
|
|
2008
|
11 |
3 |
p. A167-
1 p.
|
artikel
|
| 922 |
PSY35 PREVALENCE OF METABOLIC SYNDROME AND ITS IMPACT ON HEALTH CARE RESOURCE UTILIZATION
|
Kannan, H
|
|
2008
|
11 |
3 |
p. A162-A163
nvt p.
|
artikel
|
| 923 |
PSY12 PROJECTED COST OF CARDIOMETABOLIC RISK FACTORS IN COMMERCIALLY INSURED NORMAL AND OVERWEIGHT PRIMARY CARE PATIENTS
|
Ghate, S
|
|
2008
|
11 |
3 |
p. A155-A156
nvt p.
|
artikel
|
| 924 |
PSY46 PSYCHOMETRIC ANALYSIS OFTHE THREE-FACTOR EATING QUESTIONNAIRE: RESULTS FROM A LARGE DIVERSE SAMPLE OF OBESE AND NON-OBESE SUBJECTS
|
Cappelleri, JC
|
|
2008
|
11 |
3 |
p. A166-
1 p.
|
artikel
|
| 925 |
PSY37 RESOURCE USE AND COSTS ASSOCIATED WITH BACK PAIN IN GERMANY
|
Greiner, W
|
|
2008
|
11 |
3 |
p. A163-
1 p.
|
artikel
|
| 926 |
PSY9 RISK FACTORS AND RISKS ASSOCIATED WITH HOSPITAL STAYS IN PATIENTS WITH MYALGIA
|
Justice, EE
|
|
2008
|
11 |
3 |
p. A154-
1 p.
|
artikel
|
| 927 |
PSY40 SYSTEMATIC REVIEW OFTHE PSYCHOMETRIC PROPERTIES OFTHE FUNCTIONAL ASSESSMENT OF CANCER THERAPY—ANEMIA (FACT-AN) FOR ANEMIC CANCER PATIENTS
|
An, JJ
|
|
2008
|
11 |
3 |
p. A164-
1 p.
|
artikel
|
| 928 |
PSY4 THE BALANCE BETWEEN SEVERE CARDIOVASCULAR AND GASTROINTESTINAL EVENTS AMONG USERS OF SELECTIVE AND NON-SELECTIVE NON STEROIDAL ANTI-INFLAMMATORY DRUGS
|
Van der Linden, MW
|
|
2008
|
11 |
3 |
p. A153-
1 p.
|
artikel
|
| 929 |
PSY17 THE COST AND COST EFFECTIVENESS OF DASATINIB (SPRYCEL) THERAPY FOR THE MANAGEMENT OF IMATINIB RESISTANT AND INTOLERANT PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) IN MEXICO
|
Juarez-Garcia, A
|
|
2008
|
11 |
3 |
p. A157-
1 p.
|
artikel
|
| 930 |
PSY21 THE COST-EFFECTIVENESS OF LYRICA (PREGABALIN) IN PATIENTS WITH CENTRAL NEUROPATHIC PAIN
|
Ramos, É
|
|
2008
|
11 |
3 |
p. A158-
1 p.
|
artikel
|
| 931 |
PSY2 THE DEVELOPMENT OF A STANDARDIZED CLINICAL ALGORYTHMIC PREDICTOR OF WEIGHT LOSS AFTER BARIATRIC SURGERY: DATABASE ANALYSIS ENABLES EMPIRICAL AND STATISTICAL PREDICTION OFTHRESHOLD WEIGHT LOSS BY END OFTHIRD POST-OPERATIVE PHYSICIAN VISIT
|
Hayward, A
|
|
2008
|
11 |
3 |
p. A152-
1 p.
|
artikel
|
| 932 |
PSY29 THE DIRECT AND INDIRECT COSTS OF OBESITY IN AN EMPLOYED POPULATION
|
Durden, ED
|
|
2008
|
11 |
3 |
p. A161-
1 p.
|
artikel
|
| 933 |
PSY26 THE DIRECT MEDICAL COSTS ASSOCIATED WITH SUSPECTED (CONFIRMED AND NEGATIVE) HEPARIN-INDUCEDTHROMBOCYTOPENIA
|
Nanwa, N
|
|
2008
|
11 |
3 |
p. A160-
1 p.
|
artikel
|
| 934 |
PSY8 THE ECONOMIC BURDEN OF SYSTEMIC LUPUS ERYTHEMATOSUS AMONG PATIENTS OFTHE CAROLINA LUPUS STUDY EARLY INTHE COURSE OF DISEASE
|
Campbell Jr, R
|
|
2008
|
11 |
3 |
p. A154-
1 p.
|
artikel
|
| 935 |
PSY24 THE ECONOMIC CONSEQUENCES OF POST OPERATING PAIN MANAGEMENT WITHTRANSDERMAL FENTANYL (IONSYS) VERSUS INTRAVENOUS PATIENT-CONTROLLED ANALGESIA
|
Liwing, J
|
|
2008
|
11 |
3 |
p. A159-
1 p.
|
artikel
|
| 936 |
PSY51 THE EFFECTS OF COMORBIDITY, PRESCRIPTION DRUG USE, AND MEDICAL UTILIZATION ON DULOXETINE INITIATION IN PATIENTS WITH FIBROMYALGIA
|
White, LA
|
|
2008
|
11 |
3 |
p. A168-
1 p.
|
artikel
|
| 937 |
PSY13 THE HEALTH CARE COST EFFECTS OF DIABETES AMONG OBESE AND MORBIDLY OBESE ADULTS IN THE UNITED STATES
|
Cawley, J
|
|
2008
|
11 |
3 |
p. A156-
1 p.
|
artikel
|
| 938 |
PSY6 THE PREVALENCE OF PAIN SYMPTOMS AMONG UNITED STATES ADULTS AGED 65 AND OLDER
|
McDonald, M
|
|
2008
|
11 |
3 |
p. A153-A154
nvt p.
|
artikel
|
| 939 |
PSY49 THE WILLINGNESS TO PAY TO MINIMIZE CHRONIC PAIN
|
Chuck, A
|
|
2008
|
11 |
3 |
p. A167-
1 p.
|
artikel
|
| 940 |
PUK13 A COST MINIMIZATION ANALYSIS OF EPOETIN ZETA FOR THE TREATMENT OF ANEMIA ASSOCIATED WITH CHRONIC KIDNEY DISEASE
|
Pearson, IV
|
|
2008
|
11 |
3 |
p. A304-
1 p.
|
artikel
|
| 941 |
PUK8 A REVIEW: DIFFERING COSTS AND EFFECTS IN ECONOMIC EVALUATIONS OF TOLTERODINE FOR THE TREATMENT OF OVERACTIVE BLADDER
|
Snedecor, SJ
|
|
2008
|
11 |
3 |
p. A302-
1 p.
|
artikel
|
| 942 |
PUK22 ASSESSING PATIENT DESCRIPTIONS OF LOWER URINARY TRACT SYMPTOMS (LUTS) AND PERSPECTIVES ON TREATMENT OUTCOMES FOR THE DEVELOPMENT OF A NEW LUTS PATIENT REPORTED OUTCOME TOOL
|
Coyne, KS
|
|
2008
|
11 |
3 |
p. A307-
1 p.
|
artikel
|
| 943 |
PUK1 CHRONIC KIDNEY DISEASE (CKD) AMONG INPATIENTS WITH REDUCED KIDNEY FUNCTION (RKF) ON HOSPITAL ADMISSION
|
Yu, HT
|
|
2008
|
11 |
3 |
p. A300-
1 p.
|
artikel
|
| 944 |
PUK16 COMPARATIVE ECONOMIC EVALUATION OF DUTASTERIDE VERSUS FINASTERIDE FOR MEDICARE-AGED MEN WITH BENIGN PROSTATIC HYPERPLASIA
|
Lin, PJ
|
|
2008
|
11 |
3 |
p. A305-
1 p.
|
artikel
|
| 945 |
PUK19 COMPARISON OF THE HEALTH-RELATED QUALITY OF LIFE BETWEEN PATIENTS UNDERGOING PERITONEAL DIALYSIS AND HAEMODIALYSIS
|
Cortés-Sanabria, L
|
|
2008
|
11 |
3 |
p. A306-
1 p.
|
artikel
|
| 946 |
PUK5 COST-EFFECTIVENESS OF CINECALCET IN THE TREATMENT OF SECONDARY HYPERPARATIROIDISM (SHPT)
|
Pinto, CG
|
|
2008
|
11 |
3 |
p. A301-
1 p.
|
artikel
|
| 947 |
PUK7 COST-EFFECTIVENESS OF IMMUNOSUPPRESSIVE REGIMENS IN RENAL TRANSPLANT RECIPIENTS IN GERMANY
|
Hass, B
|
|
2008
|
11 |
3 |
p. A302-
1 p.
|
artikel
|
| 948 |
PUK4 COST-EFFECTIVENESS OF SEVELAMER IN THE TREATMENT OF HYPERPHOSPHATEMIA ASSOCIATED WITH CHRONIC KIDNEY DISEASE IN MEXICO
|
Idrovo, J
|
|
2008
|
11 |
3 |
p. A301-
1 p.
|
artikel
|
| 949 |
PUK15 COST IMPLICATIONS OF INTRAVENOUS (IV) BEVACIZUMAB TREATMENT IN PATIENTS WITH RENAL CELL CARCINOMA (RCC)
|
Fournier, AA
|
|
2008
|
11 |
3 |
p. A304-A305
nvt p.
|
artikel
|
| 950 |
PUK12 COST-MINIMIZATION ANALYSIS OF EVEROLIMUS FOR KIDNEY TRANSPLANTATION IN BRAZIL
|
Bueno, RLP
|
|
2008
|
11 |
3 |
p. A304-
1 p.
|
artikel
|
| 951 |
PUK25 DIALYSIS FACILITY CHARACTERISTICS INFLUENCE THE USE OF HOME DIALYSIS IN THE U.S.
|
Walker, DR
|
|
2008
|
11 |
3 |
p. A308-
1 p.
|
artikel
|
| 952 |
PUK10 ECONOMIC EVALUATION OF POLYCLONAL ANTIBODIES FOR THE MANAGEMENT OF HIGH RISK PATIENTS WITH ACUTE REJECTION IN RENAL TRANSPLANTATION AT THE SOCIAL SECURITY MEXICAN INSTITUTE (IMSS)
|
Salinas-Escudero, G
|
|
2008
|
11 |
3 |
p. A303-
1 p.
|
artikel
|
| 953 |
PUK17 ECONOMIC EVALUATION OF SEVELAMER VERSUS CALCIUM-BASED PHOSPHATE BINDERS IN PATIENTS ON DIALYSIS IN THE UNITED KINGDOM SETTING
|
Wex, J
|
|
2008
|
11 |
3 |
p. A305-
1 p.
|
artikel
|
| 954 |
PUK3 EPIDEMIOLOGY AND OUTCOMES OF PATIENTS WITH CHANGES IN RENAL FUNCTION DURING HOSPITALIZATION THAT MAY REQUIRE DRUG DOSAGE ADJUSTMENT
|
Gupta, V
|
|
2008
|
11 |
3 |
p. A301-
1 p.
|
artikel
|
| 955 |
PUK23 EVALUATION OF FACE AND CONTENT VALIDITY OF NOCTURIA QUALITY OF LIFE QUESTIONNAIRE (N-QOL)
|
Nixon, A
|
|
2008
|
11 |
3 |
p. A307-
1 p.
|
artikel
|
| 956 |
PUK6 FESOTERODINE FOR THE TREATMENT OF OVERACTIVE BLADDER—A COST-EFFECTIVENESS CASE STUDY OF SWEDEN
|
Prütz, C
|
|
2008
|
11 |
3 |
p. A302-
1 p.
|
artikel
|
| 957 |
PUK9 HEALTH ECONOMIC EVALUATION OF PARICALCITOL COMPARED TO NON-SELECTIVE VITAMIN D RECEPTOR ACTIVATOR FORTHETREATMENT OF SECONDARY HYPERPARATHYROIDISM IN CHRONIC KIDNEY DISEASE PATIENTS: US PERSPECTIVE
|
Nuijten, MJ
|
|
2008
|
11 |
3 |
p. A303-
1 p.
|
artikel
|
| 958 |
PUK20 IMPROVEMENTS IN HEALTH-RELATED QUALITY OF LIFE WITH FESOTERODINE: KING'S HEALTH QUESTIONNAIRE ITEM ANALYSIS
|
Khullar, V
|
|
2008
|
11 |
3 |
p. A306-
1 p.
|
artikel
|
| 959 |
PUK14 INPATIENT COSTS AND CLINICAL OUTCOMES OF S. AUREUS BLOODSTREAM AND NON-BLOODSTREAM INFECTION IN PATIENTS WITH END-STAGE RENAL DISEASE: FINDINGS FROM A MULTI-CENTER TRIAL
|
Li, Y
|
|
2008
|
11 |
3 |
p. A304-
1 p.
|
artikel
|
| 960 |
PUK2 LONGITUDINAL DECLINE OF RENAL FUNCTION IN HYPERTENSIVE VETERANS
|
Smith, KL
|
|
2008
|
11 |
3 |
p. A300-A301
nvt p.
|
artikel
|
| 961 |
PUK24 POLYPHARMACYTREND IN WOMEN WITH CHRONIC KIDNEY DISEASE IN UNITED STATES OUTPATIENT SETTINGS
|
Rasu, R
|
|
2008
|
11 |
3 |
p. A308-
1 p.
|
artikel
|
| 962 |
PUK18 STAFF TIME AND COSTS FOR ANEMIA MANAGEMENT WITH ERYTHROPOIETIC STIMULATING AGENTS IN PATIENTS ON HEMODIALYSIS: CASE STUDY OF A BRAZILIAN DIALYSIS CENTER
|
Canziani, MEF
|
|
2008
|
11 |
3 |
p. A305-A306
nvt p.
|
artikel
|
| 963 |
PUK21 THE PSYCHOMETRIC VALIDATION OF AN US ENGLISH SATISFACTION MEASURE IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA
|
Black, L
|
|
2008
|
11 |
3 |
p. A306-A307
nvt p.
|
artikel
|
| 964 |
PUK11 URETEROSCOPYAND SHOCKWAVE LITHOTRIPSY FOR TREATMENT OF URETERAL STONES IN TAIWAN: ECONOMIC EVALUATION
|
Lin, CW
|
|
2008
|
11 |
3 |
p. A303-
1 p.
|
artikel
|
| 965 |
Reliability of Two Instruments for Critical Assessment of Economic Evaluations
|
Au, Flora
|
|
2008
|
11 |
3 |
p. 435-439
5 p.
|
artikel
|
| 966 |
The Burden of Ankylosing Spondylitis in Spain
|
Kobelt, Gisela
|
|
2008
|
11 |
3 |
p. 408-415
8 p.
|
artikel
|
| 967 |
The Impact of Body Weight on Patient Utilities with or without Type 2 Diabetes: A Review of the Medical Literature
|
Dennett, Susan L.
|
|
2008
|
11 |
3 |
p. 478-486
9 p.
|
artikel
|
| 968 |
The Impact of Chronic Hepatitis B on Quality of Life: A Multinational Study of Utilities from Infected and Uninfected Persons
|
Levy, Adrian R.
|
|
2008
|
11 |
3 |
p. 527-538
12 p.
|
artikel
|
| 969 |
Time and Expected Value of Sample Information Wait for No Patient
|
Eckermann, Simon
|
|
2008
|
11 |
3 |
p. 522-526
5 p.
|
artikel
|
| 970 |
Treatment Costs and Health Care Utilization for Patients with Bipolar Disorder in a Large Managed Care Population
|
Guo, Jeff J.
|
|
2008
|
11 |
3 |
p. 416-423
8 p.
|
artikel
|
| 971 |
Uncertainty in Decision-Making: Value of Additional Information in the Cost-Effectiveness of Lifestyle Intervention in Overweight and Obese People
|
Galani, Carmen
|
|
2008
|
11 |
3 |
p. 424-434
11 p.
|
artikel
|
| 972 |
Validation of a Prediction Model to Estimate Health Utilities Index Mark 3 Utility Scores from WOMAC Index Scores in Patients with Osteoarthritis of the Hip
|
Marshall, Deborah
|
|
2008
|
11 |
3 |
p. 470-477
8 p.
|
artikel
|
| 973 |
Validity of the Health Profile-Types of the Spanish Child Health and Illness Profile-Adolescent Edition (CHIP-AE)
|
Alonso, Jordi
|
|
2008
|
11 |
3 |
p. 440-449
10 p.
|
artikel
|
| 974 |
WH3 CLINICAL AND ECONOMIC OUTCOMESAMONGWOMEN USING LEVONORGESTREL-RELEASING INTRAUTERINE SYSTEM (LNG-IUS)
|
Yu, AP
|
|
2008
|
11 |
3 |
p. A27-
1 p.
|
artikel
|
| 975 |
WH2 DISABILITY AND ASSOCIATED COSTS AMONGWOMEN WITH EMPLOYER-SPONSORED INSURANCE AND NEWLY DIAGNOSED BREAST CANCER
|
Meadows, E
|
|
2008
|
11 |
3 |
p. A27-
1 p.
|
artikel
|
| 976 |
WH1 EXPOSURETO CONTRAINDICATEDAND OTHER POTENTIALLY DANGEROUS MEDICATIONS DURING PREGNANCY:A POPULATION BASED STUDY IN ITALY
|
Gagne, JJ
|
|
2008
|
11 |
3 |
p. A26-A27
nvt p.
|
artikel
|
| 977 |
WH4 PROBIOTICS IN PREGNANCY:A SYSTEMATIC REVIEWAND META-ANALYSIS OF THE SAFETY OF LACTOBACILLUS, BIFIDOBACTERIUM AND SACCHAROMYCES
|
Dugoua, JJ
|
|
2008
|
11 |
3 |
p. A27-A28
nvt p.
|
artikel
|
Tijdschrift beschrijving